2025-12-15T19:36:38.972564 - --- START REPLACEMENT on Page 78 ---
2025-12-15T19:36:38.973494 - Input Start Anchor (200 chars): Assessment report 
EMA/464842/2024 
Page 78/195 

PD results of phase 2 Study B7841003 (extension of...
2025-12-15T19:36:39.041045 - Found 3 blocks on page.
2025-12-15T19:36:39.041697 - Block 0: ...
2025-12-15T19:36:39.042871 - Block 1: ...
2025-12-15T19:36:39.043555 - Block 2: ...
2025-12-15T19:36:39.044404 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T19:36:39.045158 - Scanning Page 78...
2025-12-15T19:36:39.047737 - Scanning Page 77...
2025-12-15T19:36:39.055667 - Scanning Page 79...
2025-12-15T19:36:39.058998 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T19:36:39.060120 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T19:47:31.825266 - --- START REPLACEMENT on Page 78 ---
2025-12-15T19:47:31.826110 - Input Start Anchor (200 chars): Assessment report 
EMA/464842/2024 
Page 78/195 

PD results of phase 2 Study B7841003 (extension of...
2025-12-15T19:47:31.884802 - Found 3 blocks on page.
2025-12-15T19:47:31.885512 - Block 0: ...
2025-12-15T19:47:31.886029 - Block 1: ...
2025-12-15T19:47:31.886743 - Block 2: ...
2025-12-15T19:47:31.887573 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T19:47:31.888135 - Scanning Page 78...
2025-12-15T19:47:31.889705 - Scanning Page 77...
2025-12-15T19:47:31.898577 - Scanning Page 79...
2025-12-15T19:47:31.902087 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T19:47:31.902686 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:01:53.358753 - --- START REPLACEMENT on Page 78 ---
2025-12-15T20:01:53.359846 - Input Start Anchor (200 chars): Assessment report 
EMA/464842/2024 
Page 78/195 

PD results of phase 2 Study B7841003 (extension of...
2025-12-15T20:01:53.378101 - Found 3 blocks on page.
2025-12-15T20:01:53.378820 - Block 0: ...
2025-12-15T20:01:53.379321 - Block 1: ...
2025-12-15T20:01:53.379819 - Block 2: ...
2025-12-15T20:01:53.380361 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T20:01:53.380785 - Scanning Page 78...
2025-12-15T20:01:53.382208 - Sanitized Start Anchor: pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T20:01:53.382696 - Scanning Page 77...
2025-12-15T20:01:53.390108 - Sanitized Start Anchor: pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T20:01:53.391643 - Scanning Page 79...
2025-12-15T20:01:53.394710 - Sanitized Start Anchor: pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T20:01:53.395687 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:01:53.396184 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:09:34.279874 - --- START REPLACEMENT on Page 78 ---
2025-12-15T20:09:34.281007 - Input Start Anchor (200 chars): Assessment report 
EMA/464842/2024 
Page 78/195 

PD results of phase 2 Study B7841003 (extension of...
2025-12-15T20:09:34.296437 - Found 3 blocks on page.
2025-12-15T20:09:34.296938 - Block 0: ...
2025-12-15T20:09:34.297539 - Block 1: ...
2025-12-15T20:09:34.297943 - Block 2: ...
2025-12-15T20:09:34.298355 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T20:09:34.298798 - Scanning Page 78...
2025-12-15T20:09:34.299949 - Sanitized Start Anchor: pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T20:09:34.300475 - Scanning Page 77...
2025-12-15T20:09:34.307395 - Sanitized Start Anchor: pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T20:09:34.309719 - Scanning Page 79...
2025-12-15T20:09:34.313627 - Sanitized Start Anchor: pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T20:09:34.315120 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:09:34.316023 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:14:46.227965 - --- START REPLACEMENT on Page 78 ---
2025-12-15T20:14:46.229112 - Input Start Anchor (200 chars): Assessment report 
EMA/464842/2024 
Page 78/195 

PD results of phase 2 Study B7841003 (extension of...
2025-12-15T20:14:46.253003 - Found 3 blocks on page.
2025-12-15T20:14:46.253625 - Block 0: ...
2025-12-15T20:14:46.254480 - Block 1: ...
2025-12-15T20:14:46.255154 - Block 2: ...
2025-12-15T20:14:46.256157 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T20:14:46.257051 - Scanning Page 78...
2025-12-15T20:14:46.258703 - Sanitized Start Anchor: pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T20:14:46.259411 - Scanning Page 77...
2025-12-15T20:14:46.266857 - Sanitized Start Anchor: pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T20:14:46.269505 - Scanning Page 79...
2025-12-15T20:14:46.272183 - Sanitized Start Anchor: pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T20:14:46.272804 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:14:46.273149 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:28:03.919062 - --- START REPLACEMENT on Page 78 ---
2025-12-15T20:28:03.920284 - Input Start Anchor (200 chars): Assessment report 
EMA/464842/2024 
Page 78/195 

PD results of phase 2 Study B7841003 (extension of...
2025-12-15T20:28:03.940630 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T20:28:03.942342 - Scanning Page 78...
2025-12-15T20:28:03.950359 - Found 3 blocks on page.
2025-12-15T20:28:03.952084 - Block 0: ...
2025-12-15T20:28:03.952812 - Block 1: ...
2025-12-15T20:28:03.953554 - Block 2: ...
2025-12-15T20:28:03.954506 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T20:28:03.955450 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-15T20:28:03.956414 - Scanning Page 77...
2025-12-15T20:28:03.968299 - Found 14 blocks on page.
2025-12-15T20:28:03.969370 - Block 0: ...
2025-12-15T20:28:03.970770 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-15T20:28:03.971893 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-15T20:28:03.972827 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-15T20:28:03.973879 - Block 4: pd in phase 2 and 3 studies...
2025-12-15T20:28:03.974791 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-15T20:28:03.975715 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-15T20:28:03.976476 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-15T20:28:03.977007 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-15T20:28:03.977668 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-15T20:28:03.978176 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-15T20:28:03.978733 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-15T20:28:03.979480 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-15T20:28:03.979970 - Block 13: ...
2025-12-15T20:28:03.980509 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T20:28:03.980960 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-15T20:28:03.981536 - Scanning Page 79...
2025-12-15T20:28:03.984580 - Found 12 blocks on page.
2025-12-15T20:28:03.985261 - Block 0: ...
2025-12-15T20:28:03.985950 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-15T20:28:03.986481 - Block 2: b) pf 1+2:...
2025-12-15T20:28:03.987018 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-15T20:28:03.987398 - Block 4: group (b7841005)...
2025-12-15T20:28:03.987893 - Block 5: ...
2025-12-15T20:28:03.988294 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-15T20:28:03.988650 - Block 7: adolescents (150 mg sc)....
2025-12-15T20:28:03.988988 - Block 8: c) d-dimer:...
2025-12-15T20:28:03.989408 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (µg/ml) by dose group and age...
2025-12-15T20:28:03.989765 - Block 10: group (b7841005)...
2025-12-15T20:28:03.990176 - Block 11: ...
2025-12-15T20:28:03.990787 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T20:28:03.991472 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-15T20:28:03.992122 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:28:03.992553 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:34:57.408521 - --- START REPLACEMENT on Page 78 ---
2025-12-15T20:34:57.409628 - Input Start Anchor (200 chars): Assessment report 
EMA/464842/2024 
Page 78/195 

PD results of phase 2 Study B7841003 (extension of...
2025-12-15T20:34:57.430065 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T20:34:57.430965 - Scanning Page 78...
2025-12-15T20:34:57.440774 - Found 3 blocks on page.
2025-12-15T20:34:57.441871 - Block 0: ...
2025-12-15T20:34:57.443030 - Block 1: ...
2025-12-15T20:34:57.444063 - Block 2: ...
2025-12-15T20:34:57.445328 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T20:34:57.446084 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-15T20:34:57.447134 - Scanning Page 77...
2025-12-15T20:34:57.474590 - Found 14 blocks on page.
2025-12-15T20:34:57.475643 - Block 0: ...
2025-12-15T20:34:57.476364 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-15T20:34:57.477015 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-15T20:34:57.477505 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-15T20:34:57.478165 - Block 4: pd in phase 2 and 3 studies...
2025-12-15T20:34:57.478905 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-15T20:34:57.479597 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-15T20:34:57.480471 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-15T20:34:57.482276 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-15T20:34:57.483677 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-15T20:34:57.484783 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-15T20:34:57.485934 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-15T20:34:57.486795 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-15T20:34:57.487463 - Block 13: ...
2025-12-15T20:34:57.488213 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T20:34:57.488736 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-15T20:34:57.489575 - Scanning Page 79...
2025-12-15T20:34:57.493609 - Found 12 blocks on page.
2025-12-15T20:34:57.494566 - Block 0: ...
2025-12-15T20:34:57.495174 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-15T20:34:57.495755 - Block 2: b) pf 1+2:...
2025-12-15T20:34:57.496262 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-15T20:34:57.496987 - Block 4: group (b7841005)...
2025-12-15T20:34:57.497515 - Block 5: ...
2025-12-15T20:34:57.498003 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-15T20:34:57.498764 - Block 7: adolescents (150 mg sc)....
2025-12-15T20:34:57.499297 - Block 8: c) d-dimer:...
2025-12-15T20:34:57.499950 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (µg/ml) by dose group and age...
2025-12-15T20:34:57.500586 - Block 10: group (b7841005)...
2025-12-15T20:34:57.501090 - Block 11: ...
2025-12-15T20:34:57.501657 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T20:34:57.502432 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-15T20:34:57.502960 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:34:57.503376 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:41:47.487788 - --- START REPLACEMENT on Page 78 ---
2025-12-15T20:41:47.488691 - Input Start Anchor (149 chars): PD results of phase 2 Study B7841003 (extension of Study B7841002) Consistent with the PD results se...
2025-12-15T20:41:47.506398 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T20:41:47.507073 - Scanning Page 78...
2025-12-15T20:41:47.516776 - Found 3 blocks on page.
2025-12-15T20:41:47.517866 - Block 0: ...
2025-12-15T20:41:47.519107 - Block 1: ...
2025-12-15T20:41:47.520092 - Block 2: ...
2025-12-15T20:41:47.521767 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T20:41:47.523196 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-15T20:41:47.524689 - Scanning Page 77...
2025-12-15T20:41:47.535718 - Found 14 blocks on page.
2025-12-15T20:41:47.536503 - Block 0: ...
2025-12-15T20:41:47.537944 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-15T20:41:47.539110 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-15T20:41:47.539928 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-15T20:41:47.540949 - Block 4: pd in phase 2 and 3 studies...
2025-12-15T20:41:47.541670 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-15T20:41:47.542226 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-15T20:41:47.542816 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-15T20:41:47.544109 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-15T20:41:47.544893 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-15T20:41:47.545483 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-15T20:41:47.545972 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-15T20:41:47.546481 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-15T20:41:47.546880 - Block 13: ...
2025-12-15T20:41:47.547400 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T20:41:47.548040 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-15T20:41:47.548800 - Scanning Page 79...
2025-12-15T20:41:47.553075 - Found 12 blocks on page.
2025-12-15T20:41:47.554095 - Block 0: ...
2025-12-15T20:41:47.554636 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-15T20:41:47.555130 - Block 2: b) pf 1+2:...
2025-12-15T20:41:47.555561 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-15T20:41:47.555989 - Block 4: group (b7841005)...
2025-12-15T20:41:47.556387 - Block 5: ...
2025-12-15T20:41:47.556830 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-15T20:41:47.557269 - Block 7: adolescents (150 mg sc)....
2025-12-15T20:41:47.557677 - Block 8: c) d-dimer:...
2025-12-15T20:41:47.558157 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (µg/ml) by dose group and age...
2025-12-15T20:41:47.558649 - Block 10: group (b7841005)...
2025-12-15T20:41:47.559149 - Block 11: ...
2025-12-15T20:41:47.559702 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T20:41:47.560053 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-15T20:41:47.561017 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:41:47.561503 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T20:45:34.640854 - --- START REPLACEMENT on Page 93 ---
2025-12-15T20:45:34.641986 - Input Start Anchor (200 chars): Assessment report 
EMA/464842/2024 
Page 93/195 
Twenty-seven (27) participants were enrolled at 8 s...
2025-12-15T20:45:34.660506 - Search Strategy: Checking pages [93, 92, 94]
2025-12-15T20:45:34.661749 - Scanning Page 93...
2025-12-15T20:45:34.711156 - Found 43 blocks on page.
2025-12-15T20:45:34.712148 - Block 0: ...
2025-12-15T20:45:34.712923 - Block 1: assessment report ema/464842/2024 page 93/195...
2025-12-15T20:45:34.713589 - Block 2: twenty-seven (27) participants were enrolled at 8 study sites. subcutaneous (sc) multiple dose cohor...
2025-12-15T20:45:34.714163 - Block 3: enrolled starting at the 300 mg sc dose. intravenous (iv) routes of administration were not evaluate...
2025-12-15T20:45:34.714816 - Block 4: study. participants were enrolled and assigned to the study treatments in four cohorts: cohort 1 (no...
2025-12-15T20:45:34.715520 - Block 5: inhibitor, n = 8) with 300 mg weekly s.c. dosing, cohort 2 (non-inhibitor, n = 6) with 300 mg loadin...
2025-12-15T20:45:34.716245 - Block 6: followed by 150 mg weekly s.c. dosing, cohort 3 (non-inhibitor, n = 6) with 450 mg weekly s.c. dosin...
2025-12-15T20:45:34.717023 - Block 7: inhibitor cohort (cohort 4) was treated with 300 mg weekly s.c. dosing, which was assessed as safe a...
2025-12-15T20:45:34.717785 - Block 8: tolerated in participants without inhibitors before treatment of inhibitor patients was initiated....
2025-12-15T20:45:34.718538 - Block 9: cohorts were followed for at least 29 days. if available safety, tolerability and pharmacokinetic (p...
2025-12-15T20:45:34.719188 - Block 10: through day 29 were permissive for dose escalation, a cohort at a higher dose level was to be opened...
2025-12-15T20:45:34.720217 - Block 11: enrollment. alternatively, a cohort at a lower dose level was to be opened if data were supportive. ...
2025-12-15T20:45:34.720891 - Block 12: addition, if the dose level under review was safe and well tolerated through day 29, treatment was t...
2025-12-15T20:45:34.721714 - Block 13: continue for the participants in that respective cohort during the subsequent 2 months (day 30 to da...
2025-12-15T20:45:34.722309 - Block 14: eligible participants were patients with severe haemophilia a or b (fviii or fix activity ≤1%) with ...
2025-12-15T20:45:34.723108 - Block 15: demand treatment regimen, including those with inhibitors to fviii or fix....
2025-12-15T20:45:34.724182 - Block 16: for efficacy evaluation, frequency and annualised rate of bleeding episodes from day 1 to day 85 wer...
2025-12-15T20:45:34.725033 - Block 17: investigated as the key secondary endpoint of the study. information on bleeding episodes over the 6...
2025-12-15T20:45:34.726044 - Block 18: prior to the study were collected at screening, information on new bleeding episodes after screening...
2025-12-15T20:45:34.726697 - Block 19: collected continuously to day 113 (fu/eos). additionally, a historical on-demand group was construct...
2025-12-15T20:45:34.727385 - Block 20: using data from the following internal pfizer studies: refacto af 3082b2-4432 (b1831004), benefix...
2025-12-15T20:45:34.728038 - Block 21: b1821010, and benefix 3090a1-400 (b1821004)....
2025-12-15T20:45:34.728530 - Block 22: ...
2025-12-15T20:45:34.729247 - Block 23: results...
2025-12-15T20:45:34.730227 - Block 24: subject disposition and demography:...
2025-12-15T20:45:34.730962 - Block 25: 38 individuals were screened, of which, 11 individuals failed at screening. among the 27 participant...
2025-12-15T20:45:34.731636 - Block 26: met the eligibility criteria and were assigned to the study treatment, 26 (96.3%) participants were ...
2025-12-15T20:45:34.732696 - Block 27: with pf-06741086, and 1 (3.7%) participant assigned to the pf-06741086 300 mg sc qw non-inhibitor...
2025-12-15T20:45:34.733398 - Block 28: dose cohort was not treated due to consent withdrawal prior to dosing on day 1....
2025-12-15T20:45:34.734421 - Block 29: among 26 participants treated with pf-06741086, 24 (92.3%) participants completed the study, and 2...
2025-12-15T20:45:34.735281 - Block 30: (7.7%) participants discontinued from study due to aes. one (1) participant from the pf-06741086 300...
2025-12-15T20:45:34.735913 - Block 31: sc loading + 150 mg sc qw non-inhibitor dose cohort discontinued from study due to a grade 2 non-...
2025-12-15T20:45:34.736709 - Block 32: serious ae of hypertension, which was determined to be treatment related by the investigator. 1 part...
2025-12-15T20:45:34.737286 - Block 33: from the pf-06741086 300 mg sc qw inhibitor dose cohort discontinued from study due to a grade 3 non...
2025-12-15T20:45:34.737884 - Block 34: serious ae of decreased blood fibrinogen, which was determined to be treatment related by the invest...
2025-12-15T20:45:34.738416 - Block 35: all 26 participants were male. the majority of participants (19/26, 73.1%) were in the 18-44 age ran...
2025-12-15T20:45:34.739070 - Block 36: all 26 participants were of white (14/26, 53.8%) or black/african american race (12/26, 46.2%). the...
2025-12-15T20:45:34.740077 - Block 37: median weight ranged from 61.60 kg (pf-06741086 300 mg sc loading + 150 mg sc qw non-inhibitor...
2025-12-15T20:45:34.740725 - Block 38: dose cohort) to 82.85 kg (pf-06741086 450 mg sc qw non-inhibitor dose cohort) and individual values...
2025-12-15T20:45:34.741233 - Block 39: ranged from 50.2 to 96.0 kg. the median body mass index (bmi) ranged from 21.26 kg/m2 (pf-...
2025-12-15T20:45:34.741960 - Block 40: 06741086 300 mg sc loading + 150 mg sc qw non-inhibitor dose cohort) to 26.30 kg/m2 (pf-...
2025-12-15T20:45:34.742607 - Block 41: 06741086 450 mg sc qw non-inhibitor dose cohort) and individual values ranged from 17.8 to 30.4...
2025-12-15T20:45:34.743235 - Block 42: kg/m2....
2025-12-15T20:45:34.743868 - Sanitized Start: twenty-seven (27) participants were enrolled at 8 ...
2025-12-15T20:45:34.744372 - Sanitized End: hs (day 30 to day 85). eligible participants were ...
2025-12-15T20:45:34.744766 - Found Start (Prefix) at block 2
2025-12-15T20:45:34.745538 - Found End (Suffix) at block 15
2025-12-15T20:45:34.746027 - MATCH FOUND on Page 93: 2-15
2025-12-15T20:45:34.754443 - Replacing blocks 2 to 15
2025-12-15T20:45:34.774471 - Detected Font Size: 9.0
2025-12-15T20:45:34.949127 - Failed size 9.0 (Justified)
2025-12-15T20:45:34.965258 - Inserted with size 8.5 (Justified)
2025-12-15T20:45:35.396355 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmp8nnale0h.pdf
2025-12-15T21:22:59.856433 - --- START REPLACEMENT on Page 78 ---
2025-12-15T21:22:59.875981 - Input Start Anchor (200 chars): pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T21:22:59.945825 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T21:22:59.946938 - Scanning Page 78...
2025-12-15T21:22:59.962265 - Found 3 blocks on page.
2025-12-15T21:22:59.963431 - Block 0: ...
2025-12-15T21:22:59.964363 - Block 1: ...
2025-12-15T21:22:59.965092 - Block 2: ...
2025-12-15T21:22:59.965937 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T21:22:59.966609 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-15T21:22:59.967891 - Scanning Page 77...
2025-12-15T21:22:59.984733 - Found 14 blocks on page.
2025-12-15T21:22:59.985739 - Block 0: ...
2025-12-15T21:22:59.986600 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-15T21:22:59.987518 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-15T21:22:59.988364 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-15T21:22:59.989682 - Block 4: pd in phase 2 and 3 studies...
2025-12-15T21:22:59.990811 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-15T21:22:59.991424 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-15T21:22:59.992056 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-15T21:22:59.992627 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-15T21:22:59.993315 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-15T21:22:59.993943 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-15T21:22:59.994962 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-15T21:22:59.995817 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-15T21:22:59.996437 - Block 13: ...
2025-12-15T21:22:59.997306 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T21:22:59.997872 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-15T21:22:59.998501 - Scanning Page 79...
2025-12-15T21:23:00.003329 - Found 12 blocks on page.
2025-12-15T21:23:00.004327 - Block 0: ...
2025-12-15T21:23:00.005369 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-15T21:23:00.006374 - Block 2: b) pf 1+2:...
2025-12-15T21:23:00.007414 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-15T21:23:00.008219 - Block 4: group (b7841005)...
2025-12-15T21:23:00.009189 - Block 5: ...
2025-12-15T21:23:00.010015 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-15T21:23:00.011017 - Block 7: adolescents (150 mg sc)....
2025-12-15T21:23:00.011821 - Block 8: c) d-dimer:...
2025-12-15T21:23:00.013800 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-15T21:23:00.014590 - Block 10: group (b7841005)...
2025-12-15T21:23:00.016386 - Block 11: ...
2025-12-15T21:23:00.019541 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T21:23:00.020647 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-15T21:23:00.021766 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T21:23:00.022843 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T21:28:46.456485 - --- START REPLACEMENT on Page 78 ---
2025-12-15T21:28:46.477863 - Input Start Anchor (200 chars): pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-15T21:28:46.496575 - Search Strategy: Checking pages [78, 77, 79]
2025-12-15T21:28:46.497230 - Scanning Page 78...
2025-12-15T21:28:46.508173 - Found 3 blocks on page.
2025-12-15T21:28:46.508841 - Block 0: ...
2025-12-15T21:28:46.509656 - Block 1: ...
2025-12-15T21:28:46.510140 - Block 2: ...
2025-12-15T21:28:46.510787 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T21:28:46.511507 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-15T21:28:46.512120 - Scanning Page 77...
2025-12-15T21:28:46.526144 - Found 14 blocks on page.
2025-12-15T21:28:46.527044 - Block 0: ...
2025-12-15T21:28:46.528345 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-15T21:28:46.529246 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-15T21:28:46.530271 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-15T21:28:46.531526 - Block 4: pd in phase 2 and 3 studies...
2025-12-15T21:28:46.532792 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-15T21:28:46.533779 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-15T21:28:46.534829 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-15T21:28:46.535871 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-15T21:28:46.536843 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-15T21:28:46.537871 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-15T21:28:46.538886 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-15T21:28:46.539789 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-15T21:28:46.540583 - Block 13: ...
2025-12-15T21:28:46.541564 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T21:28:46.542458 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-15T21:28:46.544674 - Scanning Page 79...
2025-12-15T21:28:46.550831 - Found 12 blocks on page.
2025-12-15T21:28:46.551774 - Block 0: ...
2025-12-15T21:28:46.552974 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-15T21:28:46.554166 - Block 2: b) pf 1+2:...
2025-12-15T21:28:46.555051 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-15T21:28:46.556210 - Block 4: group (b7841005)...
2025-12-15T21:28:46.557211 - Block 5: ...
2025-12-15T21:28:46.558403 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-15T21:28:46.559492 - Block 7: adolescents (150 mg sc)....
2025-12-15T21:28:46.561041 - Block 8: c) d-dimer:...
2025-12-15T21:28:46.563242 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-15T21:28:46.564200 - Block 10: group (b7841005)...
2025-12-15T21:28:46.564934 - Block 11: ...
2025-12-15T21:28:46.566199 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-15T21:28:46.566924 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-15T21:28:46.567725 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-15T21:28:46.568604 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T10:12:57.299971 - --- START REPLACEMENT on Page 78 ---
2025-12-16T10:12:57.300905 - Input Start Anchor (200 chars): pd results of phase 3 study b7841005 (multiple sc doses in adult and adolescent haemophilia patients...
2025-12-16T10:12:57.362909 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T10:12:57.363331 - Scanning Page 78...
2025-12-16T10:12:57.377264 - Found 3 blocks on page.
2025-12-16T10:12:57.377794 - Block 0: ...
2025-12-16T10:12:57.378272 - Block 1: ...
2025-12-16T10:12:57.378898 - Block 2: ...
2025-12-16T10:12:57.379602 - Sanitized Start: pd results of phase 3 study b7841005 (multiple sc ...
2025-12-16T10:12:57.380059 - Sanitized End: mg sc). the median peak thrombin values were lower...
2025-12-16T10:12:57.380723 - Scanning Page 77...
2025-12-16T10:12:57.388961 - Found 14 blocks on page.
2025-12-16T10:12:57.389450 - Block 0: ...
2025-12-16T10:12:57.390024 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T10:12:57.390400 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T10:12:57.390887 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T10:12:57.391539 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T10:12:57.391970 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T10:12:57.392372 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T10:12:57.392788 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T10:12:57.393208 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T10:12:57.393612 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T10:12:57.394152 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T10:12:57.394605 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T10:12:57.395019 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T10:12:57.395407 - Block 13: ...
2025-12-16T10:12:57.395827 - Sanitized Start: pd results of phase 3 study b7841005 (multiple sc ...
2025-12-16T10:12:57.396160 - Sanitized End: mg sc). the median peak thrombin values were lower...
2025-12-16T10:12:57.396695 - Scanning Page 79...
2025-12-16T10:12:57.399960 - Found 12 blocks on page.
2025-12-16T10:12:57.400537 - Block 0: ...
2025-12-16T10:12:57.401069 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T10:12:57.401838 - Block 2: b) pf 1+2:...
2025-12-16T10:12:57.402439 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T10:12:57.402844 - Block 4: group (b7841005)...
2025-12-16T10:12:57.403367 - Block 5: ...
2025-12-16T10:12:57.403864 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T10:12:57.404274 - Block 7: adolescents (150 mg sc)....
2025-12-16T10:12:57.404660 - Block 8: c) d-dimer:...
2025-12-16T10:12:57.406918 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T10:12:57.407386 - Block 10: group (b7841005)...
2025-12-16T10:12:57.407922 - Block 11: ...
2025-12-16T10:12:57.408385 - Sanitized Start: pd results of phase 3 study b7841005 (multiple sc ...
2025-12-16T10:12:57.408846 - Sanitized End: mg sc). the median peak thrombin values were lower...
2025-12-16T10:12:57.409414 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T10:12:57.410035 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T10:18:11.538937 - --- START REPLACEMENT on Page 81 ---
2025-12-16T10:18:11.539632 - Input Start Anchor (200 chars): 2.6.3. discussion on clinical pharmacology the submitted dossier includes pk/pd data from six clinic...
2025-12-16T10:18:11.547601 - Search Strategy: Checking pages [81, 80, 82]
2025-12-16T10:18:11.548110 - Scanning Page 81...
2025-12-16T10:18:11.564923 - Found 24 blocks on page.
2025-12-16T10:18:11.565725 - Block 0: ...
2025-12-16T10:18:11.566512 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-16T10:18:11.567110 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-16T10:18:11.567800 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-16T10:18:11.568680 - Block 4: ...
2025-12-16T10:18:11.569492 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-16T10:18:11.570226 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-16T10:18:11.571009 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-16T10:18:11.571598 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-16T10:18:11.572319 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-16T10:18:11.573002 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-16T10:18:11.573586 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-16T10:18:11.574276 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-16T10:18:11.574836 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-16T10:18:11.575491 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-16T10:18:11.575972 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-16T10:18:11.576426 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-16T10:18:11.577033 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-16T10:18:11.577504 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-16T10:18:11.577917 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-16T10:18:11.578314 - Block 20: parameters....
2025-12-16T10:18:11.578748 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-16T10:18:11.579140 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-16T10:18:11.579489 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-16T10:18:11.579860 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the sub...
2025-12-16T10:18:11.580443 - Sanitized End: participants completed at least 1 period and contr...
2025-12-16T10:18:11.581271 - Scanning Page 80...
2025-12-16T10:18:11.585586 - Found 24 blocks on page.
2025-12-16T10:18:11.586137 - Block 0: ...
2025-12-16T10:18:11.586671 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-16T10:18:11.587165 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-16T10:18:11.587768 - Block 3: adolescents (150 mg sc)....
2025-12-16T10:18:11.588539 - Block 4: ...
2025-12-16T10:18:11.589199 - Block 5: d) total tfpi:...
2025-12-16T10:18:11.589759 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-16T10:18:11.590296 - Block 7: dose group and age group (b7841005)...
2025-12-16T10:18:11.590753 - Block 8: ...
2025-12-16T10:18:11.591457 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-16T10:18:11.592095 - Block 10: (150 mg sc)....
2025-12-16T10:18:11.592529 - Block 11: ...
2025-12-16T10:18:11.592934 - Block 12: effect of ada and nab on pd data...
2025-12-16T10:18:11.593335 - Block 13: profiles of key pharmacodynamic endpoints ie, tfpi (total), tga peak, pf1+2, dpt and d-dimer followi...
2025-12-16T10:18:11.593797 - Block 14: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-16T10:18:11.594247 - Block 15: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-16T10:18:11.594828 - Block 16: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-16T10:18:11.595478 - Block 17: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-16T10:18:11.595961 - Block 18: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-16T10:18:11.596690 - Block 19: between ada positive and ada negative participants....
2025-12-16T10:18:11.597112 - Block 20: ...
2025-12-16T10:18:11.597586 - Block 21: ...
2025-12-16T10:18:11.597957 - Block 22: ...
2025-12-16T10:18:11.598708 - Block 23: ...
2025-12-16T10:18:11.599218 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the sub...
2025-12-16T10:18:11.599687 - Sanitized End: participants completed at least 1 period and contr...
2025-12-16T10:18:11.600231 - Scanning Page 82...
2025-12-16T10:18:11.607569 - Found 41 blocks on page.
2025-12-16T10:18:11.608112 - Block 0: ...
2025-12-16T10:18:11.608686 - Block 1: assessment report ema/464842/2024 page 82/195...
2025-12-16T10:18:11.609128 - Block 2: n=6; cohort 3: non-inhibitors, 450 mg sc qw, n=6; cohort 4: inhibitors, 300 mg sc qw, n=7). the...
2025-12-16T10:18:11.609726 - Block 3: participants received weekly doses until up to day 85, while blood samples were taken until day 113....
2025-12-16T10:18:11.610137 - Block 4: the extension study b7841003 was an open-label long-term study on the safety, tolerability and effic...
2025-12-16T10:18:11.610815 - Block 5: marstacimab during up to 365 days of treatment. the study included a total of 20 participants out of...
2025-12-16T10:18:11.611374 - Block 6: were rollovers from study b7841002 and 2 were newly enrolled. participants from cohorts 1 and 4 of s...
2025-12-16T10:18:11.612049 - Block 7: b7841002 kept their dose regimen of 300 mg sc qw, while all other participants (including the 2 newl...
2025-12-16T10:18:11.612609 - Block 8: participants and those who previously received 450 mg sc qw) received 150 mg sc qw with a loading do...
2025-12-16T10:18:11.612997 - Block 9: of 300 mg sc....
2025-12-16T10:18:11.613455 - Block 10: the phase 1 study b7841010 investigated the pk/pd of a single sc dose of 300 mg marstacimab in chine...
2025-12-16T10:18:11.614094 - Block 11: adults with severe haemophilia a or b, with or without inhibitors (n=6, 5 with haemophilia a, 1 with...
2025-12-16T10:18:11.614656 - Block 12: b)....
2025-12-16T10:18:11.615131 - Block 13: the phase 3 study b7841005 was a one-way, cross-over, open-label, multi-centre study in adolescent a...
2025-12-16T10:18:11.615569 - Block 14: adult participants between ages 12 to <75 years with severe haemophilia a or moderately severe to se...
2025-12-16T10:18:11.615997 - Block 15: haemophilia b (defined as fviii activity <1%, or fix activity ≤2%, respectively) with or without inh...
2025-12-16T10:18:11.616473 - Block 16: dossier only includes data from non-inhibitor patients (97 adult and 19 adolescent patients, 91 with...
2025-12-16T10:18:11.617048 - Block 17: a and 25 with haemophilia b). all participants started treatment with an initial loading dose of 300...
2025-12-16T10:18:11.617491 - Block 18: experiencing 2 or more breakthrough bleeds), an increase of the weekly dose to 300 mg was allowed at...
2025-12-16T10:18:11.617989 - Block 19: time after 6 months (d180 visit)....
2025-12-16T10:18:11.618554 - Block 20: in study b7841007 (=extension of the phase 3 trial), blood samples for pk and pd assessments are onl...
2025-12-16T10:18:11.619060 - Block 21: collected on a conditional basis as soon as possible for any participant who tested positive for bot...
2025-12-16T10:18:11.619437 - Block 22: nab during their participation in the study. this criterion was not met so far and therefore, no pk/...
2025-12-16T10:18:11.619889 - Block 23: available from the phase 3 extension study....
2025-12-16T10:18:11.620320 - Block 24: investigated pd parameters and pk/pd sampling schedule...
2025-12-16T10:18:11.621311 - Block 25: the main pd parameters investigated in the development program included plasma total tfpi, peak thro...
2025-12-16T10:18:11.621902 - Block 26: (via thrombin generation assay), prothrombin fragments 1+2 (pf 1+2), d-dimer, and dilute prothrombin...
2025-12-16T10:18:11.622536 - Block 27: (dpt)....
2025-12-16T10:18:11.623103 - Block 28: concentration of total tfpi in plasma (bound and free tfpi) is expected to increase after binding of...
2025-12-16T10:18:11.623595 - Block 29: due to the longer half-life of the monoclonal antibody leading to delayed clearance of the complex. ...
2025-12-16T10:18:11.623987 - Block 30: total plasma tfpi levels reflect target binding....
2025-12-16T10:18:11.624556 - Block 31: the generation of thrombin (by cleavage of prothrombin) is an important step of the coagulation casc...
2025-12-16T10:18:11.624924 - Block 32: thrombin is a serine protease that converts soluble fibrinogen into insoluble strands of fibrin, whi...
2025-12-16T10:18:11.625447 - Block 33: form fibrin-based blood clots. the thrombin generation assay is an established method and considered...
2025-12-16T10:18:11.625916 - Block 34: suitable biomarker to investigate the procoagulant effect of marstacimab....
2025-12-16T10:18:11.626574 - Block 35: the commonly used safety laboratory parameters d-dimer and pf 1+2 are both markers for activation of...
2025-12-16T10:18:11.626995 - Block 36: coagulation system and considered relevant additional pd endpoints. the dilute prothrombin time (dpt...
2025-12-16T10:18:11.627359 - Block 37: additional informative method to further characterise the effect of marstacimab on the coagulation s...
2025-12-16T10:18:11.627786 - Block 38: the investigated subjects....
2025-12-16T10:18:11.628222 - Block 39: overall, the choice of pd biomarkers is considered suitable to characterise the procoagulant effect ...
2025-12-16T10:18:11.628744 - Block 40: marstacimab. however, no data. on the effect of marstacimab on free tfpi are available....
2025-12-16T10:18:11.629413 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the sub...
2025-12-16T10:18:11.629846 - Sanitized End: participants completed at least 1 period and contr...
2025-12-16T10:18:11.630679 - ERROR: Start anchor not found on pages [81, 80, 82]
2025-12-16T10:18:11.631160 - CRITICAL ERROR: Start anchor not found on pages [81, 80, 82]
2025-12-16T10:22:48.557081 - --- START REPLACEMENT on Page 86 ---
2025-12-16T10:22:48.557863 - Input Start Anchor (200 chars): 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 365: 60930 ng/ml, n=4). of note, for non-inhibitor ...
2025-12-16T10:22:48.570410 - Search Strategy: Checking pages [86, 85, 87]
2025-12-16T10:22:48.571070 - Scanning Page 86...
2025-12-16T10:22:48.593227 - Found 46 blocks on page.
2025-12-16T10:22:48.594106 - Block 0: ...
2025-12-16T10:22:48.594759 - Block 1: assessment report ema/464842/2024 page 86/195...
2025-12-16T10:22:48.595371 - Block 2: thrombin, and tga endogenous thrombin generation potential, shortening of dpt and tga lag time) were...
2025-12-16T10:22:48.596148 - Block 3: maintained for more than a week. for most of these pd parameters, the maximum effect was observed wi...
2025-12-16T10:22:48.596954 - Block 4: the first week, except for total plasma tfpi and d-dimer, which peaked later (during week 2 or 3, re...
2025-12-16T10:22:48.597632 - Block 5: in the phase 1b/2 study b7841002, weekly administration of marstacimab led to an increasing plasma...
2025-12-16T10:22:48.598351 - Block 6: concentration up to the day 29 visit. the plasma concentrations at the following visits (day 57, day...
2025-12-16T10:22:48.599018 - Block 7: lower or comparable, suggesting that a steady state may have been reached. this should however be...
2025-12-16T10:22:48.599691 - Block 8: interpreted with caution due to the small sample size and reference is made to the discussion of the...
2025-12-16T10:22:48.600431 - Block 9: term data of the phase 3 trial b7841005 were accumulation of marstacimab was noted for the weekly do...
2025-12-16T10:22:48.601026 - Block 10: 300 mg. at day 29, pk parameters such as auctau, cmax, and cmin seemed to be dose-dependent, with th...
2025-12-16T10:22:48.601455 - Block 11: highest values observed for the 450 mg sc qw group and the lowest values for the 150 mg sc qw (+300 ...
2025-12-16T10:22:48.601907 - Block 12: sc loading dose) group. importantly, the more than proportional increase in pk parameters such as cm...
2025-12-16T10:22:48.602297 - Block 13: auc (as described for the first-in-human single dose study in healthy adults) was not observed durin...
2025-12-16T10:22:48.602731 - Block 14: multiple dose study in haemophilia patients, at least not to the same extent. it should however be n...
2025-12-16T10:22:48.603110 - Block 15: the lower dose levels of study b7841001 (30 mg sc, 100 mg sc) were not investigated during study b78...
2025-12-16T10:22:48.603609 - Block 16: and that the 150 mg sc qw cohort received a loading dose of 300 mg. a possible explanation for the r...
2025-12-16T10:22:48.604805 - Block 17: dose-dependent increase in pk parameters could be that the linear elimination likely dominates at th...
2025-12-16T10:22:48.605505 - Block 18: levels (and plasma concentrations) investigated during the multiple dose trials due to a saturated d...
2025-12-16T10:22:48.605946 - Block 19: (tmdd)....
2025-12-16T10:22:48.606671 - Block 20: while study b7841002 suggested that steady state concentration of marstacimab might have been reache...
2025-12-16T10:22:48.607267 - Block 21: until day 85, the pk data of the extension study b7841003 do not allow a clear conclusion on this as...
2025-12-16T10:22:48.607832 - Block 22: for the higher dose regimen (300 mg sc qw). among the participants who received weekly doses of 300 ...
2025-12-16T10:22:48.608238 - Block 23: (participants with or without inhibitors combined) throughout the study, the mean plasma concentrati...
2025-12-16T10:22:48.608606 - Block 24: marstacimab were higher at later time points compared to day 85 (day 85: 41720 ng/ml, n=10; day 169:...
2025-12-16T10:22:48.609424 - Block 25: 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 365: 60930 ng/ml, n=4). of note, for non-inhibitor...
2025-12-16T10:22:48.610080 - Block 26: patients, the plasma concentrations of marstacimab did continue to increase until d365, while the le...
2025-12-16T10:22:48.610614 - Block 27: stable or decreasing for inhibitor patients. the interpretability of these one-year pk data seems li...
2025-12-16T10:22:48.611207 - Block 28: the small number of participants in the different dose cohorts of this study....
2025-12-16T10:22:48.611685 - Block 29: during the multiple dose study b7841002 and its extension study b7841003, the effects on pd paramete...
2025-12-16T10:22:48.612106 - Block 30: tended to increase until either day 85 (increased pf1+2) or day 169 (total tfpi, increased peak thro...
2025-12-16T10:22:48.612502 - Block 31: shortened tga lag time, increased endogenous thrombin generation potential) and remained roughly...
2025-12-16T10:22:48.612882 - Block 32: comparable until the end of the extension study....
2025-12-16T10:22:48.613305 - Block 33: in the phase 3 study b7841005, 102 participants (85 adults, 17 adolescents) received a weekly dose o...
2025-12-16T10:22:48.613735 - Block 34: mg sc marstacimab (after an initial loading dose of 300 mg) throughout the whole study duration of o...
2025-12-16T10:22:48.614254 - Block 35: for 14 participants (12 adults, 2 adolescents), the weekly dose was escalated to 300 mg sc after the...
2025-12-16T10:22:48.614663 - Block 36: visit....
2025-12-16T10:22:48.615071 - Block 37: among the 102 participants who remained on the 150 mg sc wq dose regimen throughout the study, the...
2025-12-16T10:22:48.615565 - Block 38: marstacimab plasma concentration seemingly reached a steady state around day 60. adolescents reached...
2025-12-16T10:22:48.616083 - Block 39: higher mean plasma concentrations (roughly around 21000-27000 ng/ml, sd ~ 12000-18000) than adults...
2025-12-16T10:22:48.616575 - Block 40: (roughly around 12000-14000 ng/ml, sd ~ 10000-13000) throughout the visits at day 60, day 120, day 1...
2025-12-16T10:22:48.617045 - Block 41: day 240, day 300 and day 360. a higher plasma concentration in adolescents was predicted by the popu...
2025-12-16T10:22:48.617455 - Block 42: pk model. the variability of these pk measurements was high, as shown by the standard deviation valu...
2025-12-16T10:22:48.617826 - Block 43: the phase 3 study, the coefficients of variation were approximately between 40% - 85% in adolescents...
2025-12-16T10:22:48.618199 - Block 44: between 62% - 92% in adults. in the csr it is argued that the variability was likely caused by diffe...
2025-12-16T10:22:48.618533 - Block 45: sampling time points. in order to support this hypothesis, the applicant was asked to provide an ove...
2025-12-16T10:22:48.618861 - Sanitized Start: 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 3...
2025-12-16T10:22:48.619190 - Sanitized End: sma concentrations (roughly around 21000-27000 ng/...
2025-12-16T10:22:48.619689 - Found Start (Prefix) at block 25
2025-12-16T10:22:48.620735 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-16T10:22:48.621273 - MATCH FOUND on Page 86: 25-25
2025-12-16T10:22:48.627751 - Replacing blocks 25 to 25
2025-12-16T10:22:48.646407 - Detected Font Size: 9.0
2025-12-16T10:22:48.697072 - Failed size 9.0 (Justified)
2025-12-16T10:22:48.699413 - Failed size 8.5 (Justified)
2025-12-16T10:22:48.701562 - Failed size 8.0 (Justified)
2025-12-16T10:22:48.703704 - Failed size 7.5 (Justified)
2025-12-16T10:22:48.705846 - Failed size 7.0 (Justified)
2025-12-16T10:22:48.708299 - Failed size 6.5 (Justified)
2025-12-16T10:22:48.710703 - Failed size 6.0 (Justified)
2025-12-16T10:22:48.711247 - Fallback to Left Align
2025-12-16T10:22:48.903710 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpbb3jhnw_.pdf
2025-12-16T10:29:48.011993 - --- START REPLACEMENT on Page 47 ---
2025-12-16T10:29:48.012631 - Input Start Anchor (200 chars): an increase in thrombin generation in haemophilia a (with and without inhibitor) and haemophilia b p...
2025-12-16T10:29:48.023333 - Search Strategy: Checking pages [47, 46, 48]
2025-12-16T10:29:48.023984 - Scanning Page 47...
2025-12-16T10:29:48.044090 - Found 45 blocks on page.
2025-12-16T10:29:48.045049 - Block 0: ...
2025-12-16T10:29:48.045843 - Block 1: assessment report ema/464842/2024 page 47/195...
2025-12-16T10:29:48.046589 - Block 2: an increase in thrombin generation in haemophilia a (with and without inhibitor) and haemophilia b p...
2025-12-16T10:29:48.047324 - Block 3: with increasing doses of marstacimab with or without co-treatment of rfviia was observed in study pf...
2025-12-16T10:29:48.047848 - Block 4: 06741086_31mar16_122443 as well, overall, obtaining physiological peak thrombin values, similarly as...
2025-12-16T10:29:48.048534 - Block 5: measured in untreated non-haemophilic plasma, at 16μg/ml marstacimab. combined treatment of...
2025-12-16T10:29:48.048984 - Block 6: marstacimab with a plasma derived activated prothrombin complex concentrate (apcc), at systemic...
2025-12-16T10:29:48.049474 - Block 7: exposures expected to occur after clinical administration, was investigated in study pf-...
2025-12-16T10:29:48.049976 - Block 8: 06741086_26jul18_045123, showing an additive increase in thrombin generation, even exceeding non-...
2025-12-16T10:29:48.050439 - Block 9: haemophilic plasma control levels, but no additive decrease in lag time....
2025-12-16T10:29:48.050846 - Block 10: study pf-06741086_14oct22_103228 investigated the effect of a possible combined treatment of...
2025-12-16T10:29:48.051221 - Block 11: marstacimab and byclot (fviia/fx), which resulted in, including but not limited to, an additive incr...
2025-12-16T10:29:48.052143 - Block 12: peak thrombin, whereas a decrease in lag time was observed as well, but without any additive effect....
2025-12-16T10:29:48.052800 - Block 13: the concentration of 16μg/ml marstacimab used in various non-clinical in vitro assays was chosen to ...
2025-12-16T10:29:48.053282 - Block 14: expected cmax steady state concentrations following subcutaneous dosing of marstacimab at 2mg/kg, ba...
2025-12-16T10:29:48.054162 - Block 15: on modelling. a comparable cmax (18.5μg/ml) was observed in the cynomolgus monkey study (number...
2025-12-16T10:29:48.054696 - Block 16: 8299672) after sc administration of marstacimab at 3mg/kg. similar values were reported following si...
2025-12-16T10:29:48.055126 - Block 17: dose subcutaneous administrations of 300mg to healthy study participants (cmax 16490ng/ml and...
2025-12-16T10:29:48.055597 - Block 18: 12870ng/ml in study b7841001 and b7841009, respectively) and patients with haemophilia (17110ng/ml...
2025-12-16T10:29:48.056093 - Block 19: and 15610ng/ml in study b7841002 and b7841010, respectively)....
2025-12-16T10:29:48.056564 - Block 20: overall, the performed in vitro studies provided evidence for selective and high affinity binding of...
2025-12-16T10:29:48.057031 - Block 21: marstacimab to the k2 domain of tfpi with broad species cross reactivity and for the increased activ...
2025-12-16T10:29:48.057598 - Block 22: the extrinsic pathway in both non-haemophilic whole blood / plasma and haemophilia a and b plasmas...
2025-12-16T10:29:48.058097 - Block 23: without and with inhibitors. the combination of marstacimab and bypass agents in haemophilic plasmas...
2025-12-16T10:29:48.058570 - Block 24: and b) sometimes resulted in slight additivity in thrombin generation (peak thrombin level) but the...
2025-12-16T10:29:48.059090 - Block 25: concentration was within the range in studies reported for non-haemophilic normal plasmas. in this c...
2025-12-16T10:29:48.059570 - Block 26: is worth to note that the intended clinical indication of marstacimab is prophylaxis of bleeding epi...
2025-12-16T10:29:48.060199 - Block 27: patients with severe haemophilia a without factor viii inhibitors, or severe haemophilia without fac...
2025-12-16T10:29:48.060753 - Block 28: inhibitors....
2025-12-16T10:29:48.061400 - Block 29: pharmacodynamic...
2025-12-16T10:29:48.062061 - Block 30: pharmacodynamic in vivo studies to assess non-clinical efficacy of marstacimab were conducted in...
2025-12-16T10:29:48.062830 - Block 31: cynomolgus monkeys, haemophilia a and b mice and wistar han rats....
2025-12-16T10:29:48.063463 - Block 32: pharmacodynamics after repeated intravenous and/or subcutaneous dosing of marstacimab, observed as a...
2025-12-16T10:29:48.063928 - Block 33: decrease in dpt clotting time, and dose-dependent pharmacokinetics, correlating with target concentr...
2025-12-16T10:29:48.064435 - Block 34: (total tfpi) in plasma, were investigated in male cynomolgus monkeys in study 8299672. in group 1...
2025-12-16T10:29:48.064884 - Block 35: animals, plasma concentrations of marstacimab after iv administrations of 1mg/kg marstacimab at day ...
2025-12-16T10:29:48.065351 - Block 36: were not quantifiable at 144 hours post-dose and therefore, animals receiving their second dose iv o...
2025-12-16T10:29:48.065726 - Block 37: 3mg/kg on day 8 assumed to have no or negligible marstacimab concentrations prior to dosing. animals...
2025-12-16T10:29:48.066086 - Block 38: group 2, which received 10mg/kg iv marstacimab at day 1 still had high plasma concentrations of...
2025-12-16T10:29:48.066430 - Block 39: marstacimab at 168 hours post-dose and therefore prior to their second dose of 10mg/kg sc marstacima...
2025-12-16T10:29:48.066824 - Block 40: day 8. recalculations of the pk parameters of the 10mg/kg sc marstacimab treatment group at day 8 us...
2025-12-16T10:29:48.067283 - Block 41: the pre-dose sample values taken from the prior time course (ie 168 hour) as c0 instead of setting c...
2025-12-16T10:29:48.067800 - Block 42: ng/ml as done before, showed to have no impact on evaluated pk parameters when compared to each othe...
2025-12-16T10:29:48.068638 - Block 43: total tfpi concentrations in cynomolgus monkey plasma increased with increasing concentrations of...
2025-12-16T10:29:48.069144 - Block 44: marstacimab and decreased with elimination of marstacimab. because a strong correlation between free...
2025-12-16T10:29:48.069707 - Sanitized Start: an increase in thrombin generation in haemophilia ...
2025-12-16T10:29:48.070170 - Sanitized End: cmax (18.5μg/ml) was observed in the cynomolgus mo...
2025-12-16T10:29:48.070604 - Found Start (Prefix) at block 2
2025-12-16T10:29:48.071827 - Found End (Suffix) at block 17
2025-12-16T10:29:48.072195 - MATCH FOUND on Page 47: 2-17
2025-12-16T10:29:48.077539 - Replacing blocks 2 to 17
2025-12-16T10:29:48.086666 - Detected Font Size: 9.0
2025-12-16T10:29:48.191675 - Failed size 9.0 (Justified)
2025-12-16T10:29:48.207994 - Inserted with size 8.5 (Justified)
2025-12-16T10:29:48.364397 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpv6g2rfl1.pdf
2025-12-16T11:31:28.910486 - --- START REPLACEMENT on Page 46 ---
2025-12-16T11:31:28.916417 - Input Start Anchor (200 chars): cynomolgus monkey plasma, increasing thrombin generation with increasing doses in non-haemophilic hu...
2025-12-16T11:31:29.117171 - Search Strategy: Checking pages [46, 45, 47]
2025-12-16T11:31:29.118251 - Scanning Page 46...
2025-12-16T11:31:29.307478 - Found 43 blocks on page.
2025-12-16T11:31:29.308600 - Block 0: ...
2025-12-16T11:31:29.309751 - Block 1: assessment report ema/464842/2024 page 46/195...
2025-12-16T11:31:29.310689 - Block 2: cynomolgus monkey plasma, increasing thrombin generation with increasing doses in non-haemophilic...
2025-12-16T11:31:29.311755 - Block 3: human plasma and no effect on aptt clotting time, which is focused on the intrinsic pathway of the...
2025-12-16T11:31:29.313266 - Block 4: coagulation cascade. similar results were obtained in severe haemophilia a (with and without inhibit...
2025-12-16T11:31:29.314090 - Block 5: haemophilia b plasma samples (study pf-06741086_07apr15_135025), with ec50 values akin to the ones...
2025-12-16T11:31:29.315057 - Block 6: seen in non-haemophilic plasma of study 123404. combination of marstacimab with rfviia further incre...
2025-12-16T11:31:29.315941 - Block 7: thrombin generation compared to rfviia alone, reaching non-haemophilic plasma control levels or even...
2025-12-16T11:31:29.316698 - Block 8: above. in this study (135025), the thrombin generation assay was performed in haemophilia a plasma f...
2025-12-16T11:31:29.317519 - Block 9: four different donors with increasing concentrations of marstacimab. in a separate assay, thrombin...
2025-12-16T11:31:29.318518 - Block 10: generation was investigated after addition of increasing doses of rfvii to haemophilia a plasma from...
2025-12-16T11:31:29.319742 - Block 11: gk-897-3292, with and without addition of 16μg/ml marstacimab. untreated haemophilia a and normal...
2025-12-16T11:31:29.321126 - Block 12: plasma were used as control. no haemophilia a plasma with marstacimab alone was added for direct...
2025-12-16T11:31:29.322214 - Block 13: comparison with rfvii alone or combined treatment with marstacimab and rfvii in this assay, which wo...
2025-12-16T11:31:29.323061 - Block 14: have been of interest in this context. when the same plasma from the severe haemophilia a donor lot ...
2025-12-16T11:31:29.323874 - Block 15: 897-3292 was used to determine the dose-response relationship for marstacimab, rfviia, and the...
2025-12-16T11:31:29.324789 - Block 16: combination of rfviia with a fixed 16 ug/ml concentration of marstacimab, not only the measured abso...
2025-12-16T11:31:29.325646 - Block 17: values of lag time and peak thrombin were significantly different for the controls (lag time 23.08 m...
2025-12-16T11:31:29.326549 - Block 18: 5.68 min; peak thrombin 3.2 nm and 38.4 nm) during the two measurements but also the effect size of ...
2025-12-16T11:31:29.327368 - Block 19: μg/ml marstacimab: the lag time decrease was approximately 75% vs. 20%, and the peak thrombin...
2025-12-16T11:31:29.329122 - Block 20: increase was ~12-fold vs. ~4-fold. literature data provided showed substantial susceptibility of thr...
2025-12-16T11:31:29.330279 - Block 21: generation assay for preanalytical errors explaining the observed large interexperimental variabilit...
2025-12-16T11:31:29.331544 - Block 22: additionally, it was shown that the inherent limitations of the thrombin generation assay were reduc...
2025-12-16T11:31:29.332707 - Block 23: coherent results of multiple independent non-clinical studies....
2025-12-16T11:31:29.333868 - Block 24: table 2: thrombin generation parameters in severe haemophilia a plasma (gk-897-3292). data from appe...
2025-12-16T11:31:29.335151 - Block 25: lot no table no in report 135025...
2025-12-16T11:31:29.336813 - Block 26: marstacimab concentration (μg/ml)...
2025-12-16T11:31:29.337751 - Block 27: lag time (min) peak thrombin (nm)...
2025-12-16T11:31:29.338926 - Block 28: lot gk-897-3292 12.1 0 23.08 3.2 lot gk-897-3292 12.1 16 5.85 39.81 lot gk-897-3292 12.8 0 5.68 38.4...
2025-12-16T11:31:29.340031 - Block 29: however, further extensive in vitro assays were conducted investigating concomitant dosing of marsta...
2025-12-16T11:31:29.341029 - Block 30: and rfvii (see study 122443 below). as mentioned above, in study 123404, the dilute prothrombin time...
2025-12-16T11:31:29.342049 - Block 31: (dpt) assay was conducted in human non-haemophilic human, rabbit and cynomolgus monkey plasma, but...
2025-12-16T11:31:29.343032 - Block 32: not in rat plasma. thrombin generation was investigated in human haemophilic inhibitor plasmas in th...
2025-12-16T11:31:29.345073 - Block 33: combination study 045123 with apcc. within the scope of the scientific advice from 2019 (chmp protoc...
2025-12-16T11:31:29.346201 - Block 34: assistance, emea h sa 3363 3 20 18 pa iii, 31 january 2019), the conduct of an in vitro study with r...
2025-12-16T11:31:29.347308 - Block 35: plasma similar to that performed in human haemophilia plasma with activated prothrombin (study 04512...
2025-12-16T11:31:29.348485 - Block 36: was proposed, to further help with the translation of any or the lack of effects seen in vivo in rat...
2025-12-16T11:31:29.349535 - Block 37: the applicant was asked why haemophilic assays as dpt and tga were not conducted with rat plasma, si...
2025-12-16T11:31:29.351125 - Block 38: this animal species had been used in in vivo combination studies with byclot, feiba and novoseven. i...
2025-12-16T11:31:29.352815 - Block 39: then asserted that pharmacological activity of marstacimab in rats was sufficiently demonstrated in ...
2025-12-16T11:31:29.354468 - Block 40: assessing marstacimab’s binding affinity to recombinant rat tfpi k1k2 (by spr), as well as in vivo, ...
2025-12-16T11:31:29.355921 - Block 41: test-article related effects observed in the repeated dose toxicity study in rats pertained to the p...
2025-12-16T11:31:29.358193 - Block 42: mode of action of marstacimab....
2025-12-16T11:31:29.359664 - Sanitized Start: cynomolgus monkey plasma, increasing thrombin gene...
2025-12-16T11:31:29.360855 - Sanitized End: philia a donor lot gk897-3292 was used to determin...
2025-12-16T11:31:29.362171 - Found Start (Prefix) at block 2
2025-12-16T11:31:29.364866 - Found End (Suffix) at block 16
2025-12-16T11:31:29.366995 - MATCH FOUND on Page 46: 2-16
2025-12-16T11:31:29.387324 - Replacing blocks 2 to 16
2025-12-16T11:31:29.412428 - Detected Font Size: 9.0
2025-12-16T11:31:29.470260 - Error inserting 9.0: need font file or buffer
2025-12-16T11:31:29.473507 - Error inserting 8.5: need font file or buffer
2025-12-16T11:31:29.476541 - Error inserting 8.0: need font file or buffer
2025-12-16T11:31:29.480905 - Error inserting 7.5: need font file or buffer
2025-12-16T11:31:29.484577 - Error inserting 7.0: need font file or buffer
2025-12-16T11:31:29.488929 - Error inserting 6.5: need font file or buffer
2025-12-16T11:31:29.493399 - Error inserting 6.0: need font file or buffer
2025-12-16T11:31:29.494492 - Fallback to Left Align
2025-12-16T11:31:29.499646 - CRITICAL ERROR: need font file or buffer
2025-12-16T11:34:32.622816 - --- START REPLACEMENT on Page 37 ---
2025-12-16T11:34:32.625424 - Input Start Anchor (200 chars): 2.0 minutes in ha and 5.50 to 2.67 minutes in hb). after addition of 16μg/ml marstacimab to haemophi...
2025-12-16T11:34:32.657712 - Search Strategy: Checking pages [37, 36, 38]
2025-12-16T11:34:32.659015 - Scanning Page 37...
2025-12-16T11:34:32.716210 - Found 47 blocks on page.
2025-12-16T11:34:32.718468 - Block 0: ...
2025-12-16T11:34:32.720773 - Block 1: assessment report ema/464842/2024 page 37/195...
2025-12-16T11:34:32.722334 - Block 2: a plateau at marstacimab >0.5μg/ml. addition of 16μg/ml marstacimab to increasing doses of apcc led ...
2025-12-16T11:34:32.723949 - Block 3: dose-dependent increase in peak thrombin values. focusing on a combined treatment with apcc at 1 u/m...
2025-12-16T11:34:32.725997 - Block 4: and 16μg/ml marstacimab, each expected plasma levels which could be achieved after clinical...
2025-12-16T11:34:32.727296 - Block 5: administration, the latter corresponding to a cmax following a single sc dose of 300mg marstacimab, ...
2025-12-16T11:34:32.728456 - Block 6: additive increase in peak thrombin generation, but no additive decrease in lag time were observed, w...
2025-12-16T11:34:32.729582 - Block 7: each single treatment led to an increase in peak thrombin and decrease in lag time itself. reported ...
2025-12-16T11:34:32.731187 - Block 8: peak thrombin: (1) untreated haemophilic inhibitor plasma a (ha): 14.6-19.05nm, untreated haemophili...
2025-12-16T11:34:32.732990 - Block 9: inhibitor plasma b (hb): 30.51nm; (2) untreated non-haemophilic plasma: 89.62-135.23nm; (3) ha treat...
2025-12-16T11:34:32.734226 - Block 10: with 1 u/ml apcc: 74.73-110.08nm, hb treated with 1 u/ml apcc: 163.08nm; (4) non-haemophilic plasma...
2025-12-16T11:34:32.735234 - Block 11: with 16μg/ml marstacimab: 160.43-256.73nm; (5) ha with 16μg/ml marstacimab: 72.92-109.69nm, hb...
2025-12-16T11:34:32.737382 - Block 12: with 16μg/ml marstacimab: 70.14nm; (6) ha with combined treatment of 1 u/ml apcc and 16μg/ml...
2025-12-16T11:34:32.738531 - Block 13: marstacimab: 209.26-240.57nm, ha with combined treatment of 1 u/ml apcc and 16μg/ml marstacimab:...
2025-12-16T11:34:32.740248 - Block 14: 254.11nm....
2025-12-16T11:34:32.741764 - Block 15: study pf-06741086_14oct22_103228 investigated combined treatment of byclot at concentrations of...
2025-12-16T11:34:32.742999 - Block 16: fviia/fx at 2/20, 1/10, 0.5/5 μg/ml and marstacimab at 16μg/ml in haemophilia a and haemophilia b...
2025-12-16T11:34:32.743804 - Block 17: plasma with inhibitor (for the latter, haemophilia b plasma was spiked with a fix inhibitory monoclo...
2025-12-16T11:34:32.744596 - Block 18: antibody) by a thrombin generation assay. non-haemophilic plasma and haemophilia a and b plasma with...
2025-12-16T11:34:32.745442 - Block 19: inhibitor, each with and without 16μg/ml marstacimab, were used as controls for comparison. furtherm...
2025-12-16T11:34:32.746181 - Block 20: the dose-response relationship of increasing doses of byclot (0.25/2.5μg/ml to 8/80μg/ml) was examin...
2025-12-16T11:34:32.747028 - Block 21: haemophilia a and b plasma with inhibitor. a dose-response relationship for byclot at all concentrat...
2025-12-16T11:34:32.747986 - Block 22: tested was observed in haemophilia a and b plasma with inhibitor and mirrored by increases in peak...
2025-12-16T11:34:32.748899 - Block 23: thrombin (peak thrombin values ranging dose-dependently from 42.79 to 260.99 nm and 25.65 to 209.12...
2025-12-16T11:34:32.750281 - Block 24: nm, respectively), etp and velindex. byclot led to a similar shortening of lag time at all concentra...
2025-12-16T11:34:32.751248 - Block 25: both, haemophilia a and b plasmas with inhibitor (decrease from 4.17min in untreated haemophilic pla...
2025-12-16T11:34:32.752290 - Block 26: 2.0 minutes in ha and 5.50 to 2.67 minutes in hb). after addition of 16μg/ml marstacimab to haemophi...
2025-12-16T11:34:32.753763 - Block 27: and b plasma with inhibitor or non-haemophilic plasma, an increase in thrombin generation, reflected...
2025-12-16T11:34:32.754534 - Block 28: increase in peak thrombin (102.25nm in ha, 64.59nm in hb and 220.97/219.56nm in non-haemophilic...
2025-12-16T11:34:32.755261 - Block 29: plasma) and decrease in lag time (3.83min, 4.83min and 3.50min, respectively) was observed, when...
2025-12-16T11:34:32.756038 - Block 30: compared to corresponding plasmas without addition of marstacimab (haemophilia a and b: peak thrombi...
2025-12-16T11:34:32.756951 - Block 31: 15.20nm and 6.15nm, respectively; lag time of 4.17min and 5.50min, respectively; non-haemophilic pla...
2025-12-16T11:34:32.758080 - Block 32: peak thrombin of 99.13 and 91.36 nm, lag time of 4.50min). a dose-dependent increase in thrombin...
2025-12-16T11:34:32.759188 - Block 33: generation was observed as well for the combined treatment of byclot (2/20, 1/10, 0.5/5 μg/ml) and...
2025-12-16T11:34:32.760060 - Block 34: marstacimab (16μg/ml) in haemophilia a and b plasma with inhibitor, which showed an additive effect ...
2025-12-16T11:34:32.760905 - Block 35: peak thrombin (ranging from 209.85 to 291.22 nm in ha and from 156.22 to 228.61 nm in hb). a decreas...
2025-12-16T11:34:32.761681 - Block 36: lag time with the combined treatment in haemophilia a and b plasma with inhibitor was observed (rang...
2025-12-16T11:34:32.762466 - Block 37: from 1.83min to 2min and 2.17min to 2.33min, respectively)....
2025-12-16T11:34:32.763486 - Block 38: pharmacological activity of marstacimab was assessed in six in vivo studies conducted in male cynomo...
2025-12-16T11:34:32.764334 - Block 39: monkeys, male haemophilia a and b mice or male wistar han rats....
2025-12-16T11:34:32.765144 - Block 40: study 8299672 was conducted to investigate pharmacokinetics and pharmacodynamics of marstacimab in...
2025-12-16T11:34:32.765918 - Block 41: male cynomolgus monkeys. therefore, the animals (2/group) received either intravenous (iv) marstacim...
2025-12-16T11:34:32.766716 - Block 42: at 1mg/kg, 3mg/kg and 1mg/kg on day 1, day 8 and day 22, respectively (group 1), or iv marstacimab a...
2025-12-16T11:34:32.767599 - Block 43: 10mg/kg on day 1 and at 3mg/kg on day 22 but subcutaneous (sc) marstacimab at 10mg/kg on day 8...
2025-12-16T11:34:32.768385 - Block 44: (group 2), or iv marstacimab at 1mg/kg, at day 1 and day 22 but sc marstacimab at 3mg/kg on day 8...
2025-12-16T11:34:32.769389 - Block 45: (group 3). plasma concentrations for marstacimab and for total tfpi (by lc-ms) were determined pre a...
2025-12-16T11:34:32.770809 - Block 46: post dose [day 1: pre-dose, and at 0.083, 6, 24, 48, 72, 96, 120, 144, and 168 (just prior to the ne...
2025-12-16T11:34:32.771853 - Sanitized Start: 2.0 minutes in ha and 5.50 to 2.67 minutes in hb)....
2025-12-16T11:34:32.772626 - Sanitized End: lasma) and decrease in lag time (3.83min, 4.83min ...
2025-12-16T11:34:32.773974 - Found Start (Prefix) at block 26
2025-12-16T11:34:32.774912 - Found End (Suffix) at block 30
2025-12-16T11:34:32.776058 - MATCH FOUND on Page 37: 26-30
2025-12-16T11:34:32.785719 - Replacing blocks 26 to 30
2025-12-16T11:34:32.800917 - Detected Font Size: 9.0
2025-12-16T11:34:32.894458 - Failed size 9.0 (Justified)
2025-12-16T11:34:32.915800 - Inserted with size 8.5 (Justified)
2025-12-16T11:34:33.350161 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmp1gjbk90a.pdf
2025-12-16T11:35:15.332476 - --- START REPLACEMENT on Page 37 ---
2025-12-16T11:35:15.335421 - Input Start Anchor (200 chars): 2.0 minutes in ha and 5.50 to 2.67 minutes in hb). after addition of 16μg/ml marstacimab to haemophi...
2025-12-16T11:35:15.355330 - Search Strategy: Checking pages [37, 36, 38]
2025-12-16T11:35:15.356813 - Scanning Page 37...
2025-12-16T11:35:15.404910 - Found 43 blocks on page.
2025-12-16T11:35:15.407001 - Block 0: ...
2025-12-16T11:35:15.408961 - Block 1: assessment report ema/464842/2024 page 37/195...
2025-12-16T11:35:15.409917 - Block 2: a plateau at marstacimab >0.5μg/ml. addition of 16μg/ml marstacimab to increasing doses of apcc led ...
2025-12-16T11:35:15.411163 - Block 3: dose-dependent increase in peak thrombin values. focusing on a combined treatment with apcc at 1 u/m...
2025-12-16T11:35:15.412266 - Block 4: and 16μg/ml marstacimab, each expected plasma levels which could be achieved after clinical...
2025-12-16T11:35:15.413656 - Block 5: administration, the latter corresponding to a cmax following a single sc dose of 300mg marstacimab, ...
2025-12-16T11:35:15.414567 - Block 6: additive increase in peak thrombin generation, but no additive decrease in lag time were observed, w...
2025-12-16T11:35:15.415605 - Block 7: each single treatment led to an increase in peak thrombin and decrease in lag time itself. reported ...
2025-12-16T11:35:15.416679 - Block 8: peak thrombin: (1) untreated haemophilic inhibitor plasma a (ha): 14.6-19.05nm, untreated haemophili...
2025-12-16T11:35:15.417569 - Block 9: inhibitor plasma b (hb): 30.51nm; (2) untreated non-haemophilic plasma: 89.62-135.23nm; (3) ha treat...
2025-12-16T11:35:15.418468 - Block 10: with 1 u/ml apcc: 74.73-110.08nm, hb treated with 1 u/ml apcc: 163.08nm; (4) non-haemophilic plasma...
2025-12-16T11:35:15.421141 - Block 11: with 16μg/ml marstacimab: 160.43-256.73nm; (5) ha with 16μg/ml marstacimab: 72.92-109.69nm, hb...
2025-12-16T11:35:15.422085 - Block 12: with 16μg/ml marstacimab: 70.14nm; (6) ha with combined treatment of 1 u/ml apcc and 16μg/ml...
2025-12-16T11:35:15.423100 - Block 13: marstacimab: 209.26-240.57nm, ha with combined treatment of 1 u/ml apcc and 16μg/ml marstacimab:...
2025-12-16T11:35:15.425159 - Block 14: 254.11nm....
2025-12-16T11:35:15.427388 - Block 15: study pf-06741086_14oct22_103228 investigated combined treatment of byclot at concentrations of...
2025-12-16T11:35:15.447356 - Block 16: fviia/fx at 2/20, 1/10, 0.5/5 μg/ml and marstacimab at 16μg/ml in haemophilia a and haemophilia b...
2025-12-16T11:35:15.448139 - Block 17: plasma with inhibitor (for the latter, haemophilia b plasma was spiked with a fix inhibitory monoclo...
2025-12-16T11:35:15.448860 - Block 18: antibody) by a thrombin generation assay. non-haemophilic plasma and haemophilia a and b plasma with...
2025-12-16T11:35:15.450077 - Block 19: inhibitor, each with and without 16μg/ml marstacimab, were used as controls for comparison. furtherm...
2025-12-16T11:35:15.450983 - Block 20: the dose-response relationship of increasing doses of byclot (0.25/2.5μg/ml to 8/80μg/ml) was examin...
2025-12-16T11:35:15.451530 - Block 21: haemophilia a and b plasma with inhibitor. a dose-response relationship for byclot at all concentrat...
2025-12-16T11:35:15.452041 - Block 22: tested was observed in haemophilia a and b plasma with inhibitor and mirrored by increases in peak...
2025-12-16T11:35:15.452576 - Block 23: thrombin (peak thrombin values ranging dose-dependently from 42.79 to 260.99 nm and 25.65 to 209.12...
2025-12-16T11:35:15.453185 - Block 24: nm, respectively), etp and velindex. byclot led to a similar shortening of lag time at all concentra...
2025-12-16T11:35:15.453782 - Block 25: both, haemophilia a and b plasmas with inhibitor (decrease from 4.17min in untreated haemophilic pla...
2025-12-16T11:35:15.454502 - Block 26: 15.20nm and 6.15nm, respectively; lag time of 4.17min and 5.50min, respectively; non-haemophilic pla...
2025-12-16T11:35:15.455486 - Block 27: peak thrombin of 99.13 and 91.36 nm, lag time of 4.50min). a dose-dependent increase in thrombin...
2025-12-16T11:35:15.456183 - Block 28: generation was observed as well for the combined treatment of byclot (2/20, 1/10, 0.5/5 μg/ml) and...
2025-12-16T11:35:15.456893 - Block 29: marstacimab (16μg/ml) in haemophilia a and b plasma with inhibitor, which showed an additive effect ...
2025-12-16T11:35:15.457594 - Block 30: peak thrombin (ranging from 209.85 to 291.22 nm in ha and from 156.22 to 228.61 nm in hb). a decreas...
2025-12-16T11:35:15.458118 - Block 31: lag time with the combined treatment in haemophilia a and b plasma with inhibitor was observed (rang...
2025-12-16T11:35:15.458879 - Block 32: from 1.83min to 2min and 2.17min to 2.33min, respectively)....
2025-12-16T11:35:15.459694 - Block 33: pharmacological activity of marstacimab was assessed in six in vivo studies conducted in male cynomo...
2025-12-16T11:35:15.460220 - Block 34: monkeys, male haemophilia a and b mice or male wistar han rats....
2025-12-16T11:35:15.460710 - Block 35: study 8299672 was conducted to investigate pharmacokinetics and pharmacodynamics of marstacimab in...
2025-12-16T11:35:15.461235 - Block 36: male cynomolgus monkeys. therefore, the animals (2/group) received either intravenous (iv) marstacim...
2025-12-16T11:35:15.461780 - Block 37: at 1mg/kg, 3mg/kg and 1mg/kg on day 1, day 8 and day 22, respectively (group 1), or iv marstacimab a...
2025-12-16T11:35:15.462546 - Block 38: 10mg/kg on day 1 and at 3mg/kg on day 22 but subcutaneous (sc) marstacimab at 10mg/kg on day 8...
2025-12-16T11:35:15.463208 - Block 39: (group 2), or iv marstacimab at 1mg/kg, at day 1 and day 22 but sc marstacimab at 3mg/kg on day 8...
2025-12-16T11:35:15.463859 - Block 40: (group 3). plasma concentrations for marstacimab and for total tfpi (by lc-ms) were determined pre a...
2025-12-16T11:35:15.464532 - Block 41: post dose [day 1: pre-dose, and at 0.083, 6, 24, 48, 72, 96, 120, 144, and 168 (just prior to the ne...
2025-12-16T11:35:15.465262 - Block 42: non-clinical evidence identifies marstacimab?s mechanism of action in the well-defined extrinsic coa...
2025-12-16T11:35:15.466050 - Sanitized Start: 2.0 minutes in ha and 5.50 to 2.67 minutes in hb)....
2025-12-16T11:35:15.467162 - Sanitized End: lasma) and decrease in lag time (3.83min, 4.83min ...
2025-12-16T11:35:15.468742 - Scanning Page 36...
2025-12-16T11:35:15.481701 - Found 47 blocks on page.
2025-12-16T11:35:15.482486 - Block 0: ...
2025-12-16T11:35:15.483371 - Block 1: assessment report ema/464842/2024 page 36/195...
2025-12-16T11:35:15.485489 - Block 2: - 20 to 0.0002 g/ml when fviia was added to plasma of one haemophilia a donor in concentrations...
2025-12-16T11:35:15.486230 - Block 3: ranging, marstacimab was added at a final concentration of 16 g/ml (106.7 nm) and a tga was conduct...
2025-12-16T11:35:15.487023 - Block 4: again....
2025-12-16T11:35:15.487631 - Block 5: unexpectedly, slight decreases in aptt clotting times were observed in all haemophilic plasmas at th...
2025-12-16T11:35:15.488164 - Block 6: highest concentrations of marstacimab (56000 ng/ml, 16000 ng/ml and 8000 ng/ml) but were obviously f...
2025-12-16T11:35:15.488897 - Block 7: from the normal range of non-haemophilic, normal plasma. as observed in non-haemophilic human plasma...
2025-12-16T11:35:15.489666 - Block 8: (study 123404), dose-dependent shortening of the dpt clotting time was seen in all haemophilic plasm...
2025-12-16T11:35:15.490398 - Block 9: well, with similar ec values ranging from 380.5 to 471.4 ng/ml (2.3 to 3.1 nm). the thrombin generat...
2025-12-16T11:35:15.491102 - Block 10: assay revealed dose-dependent increases in thrombin generation with increasing doses of marstacimab ...
2025-12-16T11:35:15.492284 - Block 11: haemophilic plasma samples. the presence of increasing doses of rfviia, without marstacimab, led to ...
2025-12-16T11:35:15.493409 - Block 12: dose-dependent increase in thrombin generation. addition of marstacimab further increased thrombin...
2025-12-16T11:35:15.494564 - Block 13: generation, even to normal plasma levels or above and showed to be dose-dependent at lower rfviia...
2025-12-16T11:35:15.495664 - Block 14: concentrations (up to 0.02μg/ml)....
2025-12-16T11:35:15.496561 - Block 15: in study pf-06741086_31mar16_122443, the effect of marstacimab on thrombin generation with and witho...
2025-12-16T11:35:15.497181 - Block 16: the combination of rfviia (novosevenrt, eptacog alfa) was investigated in haemophilic plasma (from 6...
2025-12-16T11:35:15.497906 - Block 17: haemophilia a donors, 3 haemophilia a donors with an inhibitor and one haemophilia b donor) by a thr...
2025-12-16T11:35:15.498772 - Block 18: generation assay. following samples were analysed: vehicle-treated haemophilic plasma; 2μg/ml rfviia...
2025-12-16T11:35:15.499612 - Block 19: treated haemophilic plasma; 0.5, 1, 2, 4, 8 or 16μg/ml marstacimab-treated haemophilic plasma; 0.5, ...
2025-12-16T11:35:15.500426 - Block 20: 4, 8 or 16μg/ml marstacimab-treated haemophilic plasma in addition of 2μg/ml rfviia; untreated non-...
2025-12-16T11:35:15.501307 - Block 21: haemophilic plasma and non-haemophilic plasma dosed with 16 μg/ml marstacimab. increasing doses of...
2025-12-16T11:35:15.502012 - Block 22: marstacimab at 0.5, 1, 2, 4, 8 and 16μg/ml to haemophilic plasma increased peak thrombin levels and...
2025-12-16T11:35:15.502904 - Block 23: decreased lag time, when compared to vehicle control. addition of rfviia at 2μg/ml to marstacimab at...
2025-12-16T11:35:15.503577 - Block 24: 1, 2, 4 and 8μg/ml in haemophilic plasma led to similar peak thrombin levels as seen with marstacima...
2025-12-16T11:35:15.504313 - Block 25: alone, whereas a slight additive effect of rfviia at 2μg/ml and marstacimab at 16μg/ml was observed ...
2025-12-16T11:35:15.505209 - Block 26: co-treatment. overall, in haemophilic plasma, marstacimab at 16μg/ml with and without co-treatment o...
2025-12-16T11:35:15.505944 - Block 27: 2μg/ml rfviia reached comparable peak thrombin levels as observed in untreated non-haemophilic plasm...
2025-12-16T11:35:15.506653 - Block 28: addition of 16μg/ml marstacimab to non-haemophilic plasma led to the highest increase in thrombin...
2025-12-16T11:35:15.507399 - Block 29: generation. summary of observed peak thrombin levels: (1) vehicle control: 26-76nm in haemophilia a,...
2025-12-16T11:35:15.508088 - Block 30: 66nm in haemophilia a with inhibitor, 81nm in haemophilia b; (2) rfviia at 2μg/ml: 45-113nm in...
2025-12-16T11:35:15.508842 - Block 31: haemophilia a, 46-89nm in haemophilia a with inhibitor, 131nm in haemophilia b; (3) marstacimab at...
2025-12-16T11:35:15.509751 - Block 32: 16μg/ml: 82-172nm in haemophilia a, 88-166nm in haemophilia a with inhibitor, 174nm in haemophilia b...
2025-12-16T11:35:15.510595 - Block 33: (4) marstacimab at 16μg/ml and rfviia at 2μg/ml: 102-178nm in haemophilia a, 99-157nm in haemophilia...
2025-12-16T11:35:15.511680 - Block 34: a with inhibitor, 167nm in haemophilia b; (5) untreated non-haemophilic plasma: 128-143nm; (6) non-...
2025-12-16T11:35:15.512431 - Block 35: haemophilic plasma treated with marstacimab at 16μg/ml: 171-198nm....
2025-12-16T11:35:15.513249 - Block 36: a thrombin generation assay was performed in study pf-06741086_26jul18_045123 to evaluate individual...
2025-12-16T11:35:15.514341 - Block 37: and combined treatment of plasma derived activated prothrombin complex concentrate (apcc; feiba) and...
2025-12-16T11:35:15.515066 - Block 38: marstacimab in haemophilic inhibitor plasmas (from four haemophilia a donors and one factor ix immun...
2025-12-16T11:35:15.515765 - Block 39: depleted plasma with the addition of an inhibitory antibody as haemophilia b plasma). for individual...
2025-12-16T11:35:15.516663 - Block 40: treatments, apcc was dosed at 0.063, 0.125, 0.5 or 1 u/ml and marstacimab at 0.5, 1, 2, 4, 8, or 16...
2025-12-16T11:35:15.517579 - Block 41: μg/ml, whereas the highest dose of 1 u/ml apcc or 16μg/ml marstacimab was used in combination with...
2025-12-16T11:35:15.518650 - Block 42: increasing doses of marstacimab or apcc, respectively. human non-haemophilic plasma with and without...
2025-12-16T11:35:15.519588 - Block 43: addition of marstacimab at 16μg/ml was used for comparison. peak thrombin values increased dose-...
2025-12-16T11:35:15.520270 - Block 44: dependently in haemophilic plasmas with increasing doses of either apcc or marstacimab, the latter...
2025-12-16T11:35:15.520993 - Block 45: indicating to reach a plateau at >0.5μg/ml marstacimab. after addition of 1 u/ml apcc to increasing ...
2025-12-16T11:35:15.522171 - Block 46: of marstacimab in haemophilic plasma, an additional increase in thrombin generation was observed, re...
2025-12-16T11:35:15.523120 - Sanitized Start: 2.0 minutes in ha and 5.50 to 2.67 minutes in hb)....
2025-12-16T11:35:15.523890 - Sanitized End: lasma) and decrease in lag time (3.83min, 4.83min ...
2025-12-16T11:35:15.525450 - Scanning Page 38...
2025-12-16T11:35:15.532978 - Found 46 blocks on page.
2025-12-16T11:35:15.534472 - Block 0: ...
2025-12-16T11:35:15.535295 - Block 1: assessment report ema/464842/2024 page 38/195...
2025-12-16T11:35:15.535952 - Block 2: hours post-dose; day 8: 0.083, 6, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312 (just ...
2025-12-16T11:35:15.537110 - Block 3: the next dose) and 336 hours post-dose; day 22: 0.083 hours post-dose] and a dilute prothrombin time...
2025-12-16T11:35:15.538013 - Block 4: assay (dpt) was conducted pre-and post-dose at various time points for group 1 at 1mg/kg iv marstaci...
2025-12-16T11:35:15.539132 - Block 5: on day 1, for group 2 at 10mg/kg sc marstacimab on day 8 and group 3 at 3mg/kg sc marstacimab on day...
2025-12-16T11:35:15.539724 - Block 6: 8. a dose dependent increase in marstacimab plasma concentrations was observed. mean cmax (20400,...
2025-12-16T11:35:15.540593 - Block 7: 54600 and 289000ng/ml), auc168 (386000, 1950000 and 14100000ng*hrs/ml) and t1/2 (12.3, 35 and 118...
2025-12-16T11:35:15.541269 - Block 8: hours) increased with increasing doses of iv marstacimab at 1, 3 and 10mg/kg/dose, respectively. aft...
2025-12-16T11:35:15.542122 - Block 9: administration of marstacimab at 3 and 10mg/kg/dose, an increase in mean cmax (18500 and 148000ng/ml...
2025-12-16T11:35:15.542956 - Block 10: respectively), auc336 (2360000 and 28200000 ng*hrs/ml, respectively) and t1/2 (36.5 and 163 hours,...
2025-12-16T11:35:15.543704 - Block 11: respectively) was observed as well. systemic plasma clearance (cl, in ml/min/kg) decreased with incr...
2025-12-16T11:35:15.544414 - Block 12: doses after iv marstacimab administration. furthermore, increases in marstacimab plasma concentratio...
2025-12-16T11:35:15.545252 - Block 13: correlated with increases in total tfpi concentrations in plasma and the other way round, total tfpi...
2025-12-16T11:35:15.545996 - Block 14: decreased with elimination of marstacimab. the dpt assay revealed a decrease in dpt clotting time af...
2025-12-16T11:35:15.546666 - Block 15: or sc administration of marstacimab at the respective doses tested in all groups, compared to baseli...
2025-12-16T11:35:15.547407 - Block 16: dose values. at 3 mg/kg sc marstacimab, dpt clotting time decreased gradually up to 24 hours and the...
2025-12-16T11:35:15.548354 - Block 17: remained stable up to approximately 240 hours. in intravenously dosed animals at 1mg/kg marstacimab ...
2025-12-16T11:35:15.549199 - Block 18: more rapid decrease in dpt clotting time was noticed at 5 minutes post-dose, but with dpt values ret...
2025-12-16T11:35:15.550455 - Block 19: to baseline values approximately after 72-96 hours. at 10mg/kg sc marstacimab, mean baseline pre-dos...
2025-12-16T11:35:15.551237 - Block 20: values for both animals tested (animal 102447:107.7s and animal 102448: 106.8s) decreased as well,...
2025-12-16T11:35:15.552108 - Block 21: measured at 0.083, 24, 192 and 336 hours post dose (animal 102447: 90.8, 92.7, 91.1 and 92.5s,...
2025-12-16T11:35:15.552790 - Block 22: respectively and animal 102448: 88.5, 92.0, 90.1 and 89.9s, respectively)....
2025-12-16T11:35:15.553759 - Block 23: in study pf-06741086_07apr15_135244, male haemophilia a and b mice (5 animals/group) were used as...
2025-12-16T11:35:15.554450 - Block 24: acute tail clip injury model and the duration of marstacimab’s efficacy in the reduction of tail ble...
2025-12-16T11:35:15.555377 - Block 25: injury at certain time points (0.5 hours in hb; 0.5, 24, 96, 189 and 240 hours in ha mice) postdosin...
2025-12-16T11:35:15.556097 - Block 26: intravenous marstacimab (6 mg/kg) or vehicle was assessed. dose-response on tail bleeding obtained w...
2025-12-16T11:35:15.556875 - Block 27: increasing iv doses of marstacimab (0.5, 1, 2 or 6 mg/kg) administered to haemophilia a mice was...
2025-12-16T11:35:15.557555 - Block 28: investigated after 0.5 hours. blood was collected for 10 minutes after tail clip, then blood volume ...
2025-12-16T11:35:15.558556 - Block 29: haemoglobin content, which was then converted to total blood loss (μl), were determined for each mou...
2025-12-16T11:35:15.559199 - Block 30: additionally, male haemophilia a and non-haemophilic wt c57bl6/j mice were used in the laser induced...
2025-12-16T11:35:15.559992 - Block 31: injury model using intravital microscopy imaging, detecting platelet accumulation and fibrin deposit...
2025-12-16T11:35:15.560743 - Block 32: fluorescent labelled antibodies to platelet cd42c (dylight 649) and fibrin (alexa 488). haemophilia ...
2025-12-16T11:35:15.561620 - Block 33: were intravenously dosed with 6 mg/kg of marstacimab, pbs saline (as negative control) or 200 iu/kg ...
2025-12-16T11:35:15.562630 - Block 34: rfviii (as positive control) and 0.5 hours post-dose the cremaster arteriolar endothelium of the mic...
2025-12-16T11:35:15.563516 - Block 35: injured by laser (7 to 12 injuries/mouse, 3 mice/group). non-haemophilic wt c57bl6/j mice received s...
2025-12-16T11:35:15.564284 - Block 36: before injury and served as control. blood loss after tail clip injury showed to decrease dose-depen...
2025-12-16T11:35:15.564938 - Block 37: increasing doses of marstacimab in haemophilia a mice. at 0.5, 1, 2 or 6 mg/kg a decrease of 6.1%, 5...
2025-12-16T11:35:15.565682 - Block 38: 63.2% and 77.7% in bleeding was observed in haemophilia a mice. in haemophilia b mice, a decrease of...
2025-12-16T11:35:15.566498 - Block 39: 74% was noticed at 6 mg/kg marstacimab. furthermore, a high reduction in blood loss was observed at ...
2025-12-16T11:35:15.567862 - Block 40: hours, which finally returned to baseline and control values after 240 hours in haemophilia a mice t...
2025-12-16T11:35:15.568802 - Block 41: with 6mg/kg marstacimab (e.g. 77.9% reduction at 0.5 hours, 27.3% reduction at 189 hours). the laser...
2025-12-16T11:35:15.569503 - Block 42: induced injury model revealed a similar increase in platelet accumulation and fibrin deposition for...
2025-12-16T11:35:15.570437 - Block 43: haemophilia a mice treated with 6 mg/kg marstacimab or 200 iu/kg rfviii but were far from the maxima...
2025-12-16T11:35:15.571336 - Block 44: level observed in non-haemophilic control animals. the haemostatic effect of marstacimab persisted t...
2025-12-16T11:35:15.572127 - Block 45: hours....
2025-12-16T11:35:15.573266 - Sanitized Start: 2.0 minutes in ha and 5.50 to 2.67 minutes in hb)....
2025-12-16T11:35:15.573977 - Sanitized End: lasma) and decrease in lag time (3.83min, 4.83min ...
2025-12-16T11:35:15.575767 - ERROR: Start anchor not found on pages [37, 36, 38]
2025-12-16T11:35:15.576561 - CRITICAL ERROR: Start anchor not found on pages [37, 36, 38]
2025-12-16T11:38:01.931355 - --- START REPLACEMENT on Page 37 ---
2025-12-16T11:38:01.933060 - Input Start Anchor (200 chars): 2.0 minutes in ha and 5.50 to 2.67 minutes in hb). after addition of 16μg/ml marstacimab to haemophi...
2025-12-16T11:38:01.956008 - Search Strategy: Checking pages [37, 36, 38]
2025-12-16T11:38:01.958698 - Scanning Page 37...
2025-12-16T11:38:02.010638 - Found 43 blocks on page.
2025-12-16T11:38:02.013203 - Block 0: ...
2025-12-16T11:38:02.014782 - Block 1: assessment report ema/464842/2024 page 37/195...
2025-12-16T11:38:02.018300 - Block 2: a plateau at marstacimab >0.5μg/ml. addition of 16μg/ml marstacimab to increasing doses of apcc led ...
2025-12-16T11:38:02.021202 - Block 3: dose-dependent increase in peak thrombin values. focusing on a combined treatment with apcc at 1 u/m...
2025-12-16T11:38:02.024966 - Block 4: and 16μg/ml marstacimab, each expected plasma levels which could be achieved after clinical...
2025-12-16T11:38:02.026955 - Block 5: administration, the latter corresponding to a cmax following a single sc dose of 300mg marstacimab, ...
2025-12-16T11:38:02.029026 - Block 6: additive increase in peak thrombin generation, but no additive decrease in lag time were observed, w...
2025-12-16T11:38:02.031239 - Block 7: each single treatment led to an increase in peak thrombin and decrease in lag time itself. reported ...
2025-12-16T11:38:02.032785 - Block 8: peak thrombin: (1) untreated haemophilic inhibitor plasma a (ha): 14.6-19.05nm, untreated haemophili...
2025-12-16T11:38:02.033906 - Block 9: inhibitor plasma b (hb): 30.51nm; (2) untreated non-haemophilic plasma: 89.62-135.23nm; (3) ha treat...
2025-12-16T11:38:02.035402 - Block 10: with 1 u/ml apcc: 74.73-110.08nm, hb treated with 1 u/ml apcc: 163.08nm; (4) non-haemophilic plasma...
2025-12-16T11:38:02.036762 - Block 11: with 16μg/ml marstacimab: 160.43-256.73nm; (5) ha with 16μg/ml marstacimab: 72.92-109.69nm, hb...
2025-12-16T11:38:02.037816 - Block 12: with 16μg/ml marstacimab: 70.14nm; (6) ha with combined treatment of 1 u/ml apcc and 16μg/ml...
2025-12-16T11:38:02.038933 - Block 13: marstacimab: 209.26-240.57nm, ha with combined treatment of 1 u/ml apcc and 16μg/ml marstacimab:...
2025-12-16T11:38:02.039984 - Block 14: 254.11nm....
2025-12-16T11:38:02.040888 - Block 15: study pf-06741086_14oct22_103228 investigated combined treatment of byclot at concentrations of...
2025-12-16T11:38:02.041764 - Block 16: fviia/fx at 2/20, 1/10, 0.5/5 μg/ml and marstacimab at 16μg/ml in haemophilia a and haemophilia b...
2025-12-16T11:38:02.042631 - Block 17: plasma with inhibitor (for the latter, haemophilia b plasma was spiked with a fix inhibitory monoclo...
2025-12-16T11:38:02.043720 - Block 18: antibody) by a thrombin generation assay. non-haemophilic plasma and haemophilia a and b plasma with...
2025-12-16T11:38:02.044967 - Block 19: inhibitor, each with and without 16μg/ml marstacimab, were used as controls for comparison. furtherm...
2025-12-16T11:38:02.046474 - Block 20: the dose-response relationship of increasing doses of byclot (0.25/2.5μg/ml to 8/80μg/ml) was examin...
2025-12-16T11:38:02.047653 - Block 21: haemophilia a and b plasma with inhibitor. a dose-response relationship for byclot at all concentrat...
2025-12-16T11:38:02.048620 - Block 22: tested was observed in haemophilia a and b plasma with inhibitor and mirrored by increases in peak...
2025-12-16T11:38:02.049413 - Block 23: thrombin (peak thrombin values ranging dose-dependently from 42.79 to 260.99 nm and 25.65 to 209.12...
2025-12-16T11:38:02.050092 - Block 24: nm, respectively), etp and velindex. byclot led to a similar shortening of lag time at all concentra...
2025-12-16T11:38:02.050917 - Block 25: both, haemophilia a and b plasmas with inhibitor (decrease from 4.17min in untreated haemophilic pla...
2025-12-16T11:38:02.052002 - Block 26: 15.20nm and 6.15nm, respectively; lag time of 4.17min and 5.50min, respectively; non-haemophilic pla...
2025-12-16T11:38:02.053051 - Block 27: peak thrombin of 99.13 and 91.36 nm, lag time of 4.50min). a dose-dependent increase in thrombin...
2025-12-16T11:38:02.053999 - Block 28: generation was observed as well for the combined treatment of byclot (2/20, 1/10, 0.5/5 μg/ml) and...
2025-12-16T11:38:02.054821 - Block 29: marstacimab (16μg/ml) in haemophilia a and b plasma with inhibitor, which showed an additive effect ...
2025-12-16T11:38:02.055621 - Block 30: peak thrombin (ranging from 209.85 to 291.22 nm in ha and from 156.22 to 228.61 nm in hb). a decreas...
2025-12-16T11:38:02.056549 - Block 31: lag time with the combined treatment in haemophilia a and b plasma with inhibitor was observed (rang...
2025-12-16T11:38:02.057863 - Block 32: from 1.83min to 2min and 2.17min to 2.33min, respectively)....
2025-12-16T11:38:02.058709 - Block 33: pharmacological activity of marstacimab was assessed in six in vivo studies conducted in male cynomo...
2025-12-16T11:38:02.059510 - Block 34: monkeys, male haemophilia a and b mice or male wistar han rats....
2025-12-16T11:38:02.060417 - Block 35: study 8299672 was conducted to investigate pharmacokinetics and pharmacodynamics of marstacimab in...
2025-12-16T11:38:02.061762 - Block 36: male cynomolgus monkeys. therefore, the animals (2/group) received either intravenous (iv) marstacim...
2025-12-16T11:38:02.062944 - Block 37: at 1mg/kg, 3mg/kg and 1mg/kg on day 1, day 8 and day 22, respectively (group 1), or iv marstacimab a...
2025-12-16T11:38:02.064136 - Block 38: 10mg/kg on day 1 and at 3mg/kg on day 22 but subcutaneous (sc) marstacimab at 10mg/kg on day 8...
2025-12-16T11:38:02.065098 - Block 39: (group 2), or iv marstacimab at 1mg/kg, at day 1 and day 22 but sc marstacimab at 3mg/kg on day 8...
2025-12-16T11:38:02.066197 - Block 40: (group 3). plasma concentrations for marstacimab and for total tfpi (by lc-ms) were determined pre a...
2025-12-16T11:38:02.067112 - Block 41: post dose [day 1: pre-dose, and at 0.083, 6, 24, 48, 72, 96, 120, 144, and 168 (just prior to the ne...
2025-12-16T11:38:02.067963 - Block 42: non-clinical evidence identifies marstacimab?s mechanism of action in the well-defined extrinsic coa...
2025-12-16T11:38:02.068982 - Sanitized Start: 2.0 minutes in ha and 5.50 to 2.67 minutes in hb)....
2025-12-16T11:38:02.069898 - Sanitized End: lasma) and decrease in lag time (3.83min, 4.83min ...
2025-12-16T11:38:02.071752 - Scanning Page 36...
2025-12-16T11:38:02.086237 - Found 47 blocks on page.
2025-12-16T11:38:02.087293 - Block 0: ...
2025-12-16T11:38:02.088380 - Block 1: assessment report ema/464842/2024 page 36/195...
2025-12-16T11:38:02.089052 - Block 2: - 20 to 0.0002 g/ml when fviia was added to plasma of one haemophilia a donor in concentrations...
2025-12-16T11:38:02.089683 - Block 3: ranging, marstacimab was added at a final concentration of 16 g/ml (106.7 nm) and a tga was conduct...
2025-12-16T11:38:02.090569 - Block 4: again....
2025-12-16T11:38:02.091376 - Block 5: unexpectedly, slight decreases in aptt clotting times were observed in all haemophilic plasmas at th...
2025-12-16T11:38:02.092126 - Block 6: highest concentrations of marstacimab (56000 ng/ml, 16000 ng/ml and 8000 ng/ml) but were obviously f...
2025-12-16T11:38:02.092864 - Block 7: from the normal range of non-haemophilic, normal plasma. as observed in non-haemophilic human plasma...
2025-12-16T11:38:02.093715 - Block 8: (study 123404), dose-dependent shortening of the dpt clotting time was seen in all haemophilic plasm...
2025-12-16T11:38:02.094603 - Block 9: well, with similar ec values ranging from 380.5 to 471.4 ng/ml (2.3 to 3.1 nm). the thrombin generat...
2025-12-16T11:38:02.095450 - Block 10: assay revealed dose-dependent increases in thrombin generation with increasing doses of marstacimab ...
2025-12-16T11:38:02.096519 - Block 11: haemophilic plasma samples. the presence of increasing doses of rfviia, without marstacimab, led to ...
2025-12-16T11:38:02.097137 - Block 12: dose-dependent increase in thrombin generation. addition of marstacimab further increased thrombin...
2025-12-16T11:38:02.097844 - Block 13: generation, even to normal plasma levels or above and showed to be dose-dependent at lower rfviia...
2025-12-16T11:38:02.098479 - Block 14: concentrations (up to 0.02μg/ml)....
2025-12-16T11:38:02.099220 - Block 15: in study pf-06741086_31mar16_122443, the effect of marstacimab on thrombin generation with and witho...
2025-12-16T11:38:02.099860 - Block 16: the combination of rfviia (novosevenrt, eptacog alfa) was investigated in haemophilic plasma (from 6...
2025-12-16T11:38:02.100623 - Block 17: haemophilia a donors, 3 haemophilia a donors with an inhibitor and one haemophilia b donor) by a thr...
2025-12-16T11:38:02.101351 - Block 18: generation assay. following samples were analysed: vehicle-treated haemophilic plasma; 2μg/ml rfviia...
2025-12-16T11:38:02.102216 - Block 19: treated haemophilic plasma; 0.5, 1, 2, 4, 8 or 16μg/ml marstacimab-treated haemophilic plasma; 0.5, ...
2025-12-16T11:38:02.103144 - Block 20: 4, 8 or 16μg/ml marstacimab-treated haemophilic plasma in addition of 2μg/ml rfviia; untreated non-...
2025-12-16T11:38:02.103977 - Block 21: haemophilic plasma and non-haemophilic plasma dosed with 16 μg/ml marstacimab. increasing doses of...
2025-12-16T11:38:02.104809 - Block 22: marstacimab at 0.5, 1, 2, 4, 8 and 16μg/ml to haemophilic plasma increased peak thrombin levels and...
2025-12-16T11:38:02.105471 - Block 23: decreased lag time, when compared to vehicle control. addition of rfviia at 2μg/ml to marstacimab at...
2025-12-16T11:38:02.106055 - Block 24: 1, 2, 4 and 8μg/ml in haemophilic plasma led to similar peak thrombin levels as seen with marstacima...
2025-12-16T11:38:02.106960 - Block 25: alone, whereas a slight additive effect of rfviia at 2μg/ml and marstacimab at 16μg/ml was observed ...
2025-12-16T11:38:02.107737 - Block 26: co-treatment. overall, in haemophilic plasma, marstacimab at 16μg/ml with and without co-treatment o...
2025-12-16T11:38:02.108527 - Block 27: 2μg/ml rfviia reached comparable peak thrombin levels as observed in untreated non-haemophilic plasm...
2025-12-16T11:38:02.109205 - Block 28: addition of 16μg/ml marstacimab to non-haemophilic plasma led to the highest increase in thrombin...
2025-12-16T11:38:02.109981 - Block 29: generation. summary of observed peak thrombin levels: (1) vehicle control: 26-76nm in haemophilia a,...
2025-12-16T11:38:02.110581 - Block 30: 66nm in haemophilia a with inhibitor, 81nm in haemophilia b; (2) rfviia at 2μg/ml: 45-113nm in...
2025-12-16T11:38:02.111069 - Block 31: haemophilia a, 46-89nm in haemophilia a with inhibitor, 131nm in haemophilia b; (3) marstacimab at...
2025-12-16T11:38:02.111646 - Block 32: 16μg/ml: 82-172nm in haemophilia a, 88-166nm in haemophilia a with inhibitor, 174nm in haemophilia b...
2025-12-16T11:38:02.112143 - Block 33: (4) marstacimab at 16μg/ml and rfviia at 2μg/ml: 102-178nm in haemophilia a, 99-157nm in haemophilia...
2025-12-16T11:38:02.112720 - Block 34: a with inhibitor, 167nm in haemophilia b; (5) untreated non-haemophilic plasma: 128-143nm; (6) non-...
2025-12-16T11:38:02.113233 - Block 35: haemophilic plasma treated with marstacimab at 16μg/ml: 171-198nm....
2025-12-16T11:38:02.113845 - Block 36: a thrombin generation assay was performed in study pf-06741086_26jul18_045123 to evaluate individual...
2025-12-16T11:38:02.114356 - Block 37: and combined treatment of plasma derived activated prothrombin complex concentrate (apcc; feiba) and...
2025-12-16T11:38:02.114873 - Block 38: marstacimab in haemophilic inhibitor plasmas (from four haemophilia a donors and one factor ix immun...
2025-12-16T11:38:02.115352 - Block 39: depleted plasma with the addition of an inhibitory antibody as haemophilia b plasma). for individual...
2025-12-16T11:38:02.115947 - Block 40: treatments, apcc was dosed at 0.063, 0.125, 0.5 or 1 u/ml and marstacimab at 0.5, 1, 2, 4, 8, or 16...
2025-12-16T11:38:02.116530 - Block 41: μg/ml, whereas the highest dose of 1 u/ml apcc or 16μg/ml marstacimab was used in combination with...
2025-12-16T11:38:02.117301 - Block 42: increasing doses of marstacimab or apcc, respectively. human non-haemophilic plasma with and without...
2025-12-16T11:38:02.117998 - Block 43: addition of marstacimab at 16μg/ml was used for comparison. peak thrombin values increased dose-...
2025-12-16T11:38:02.118684 - Block 44: dependently in haemophilic plasmas with increasing doses of either apcc or marstacimab, the latter...
2025-12-16T11:38:02.119289 - Block 45: indicating to reach a plateau at >0.5μg/ml marstacimab. after addition of 1 u/ml apcc to increasing ...
2025-12-16T11:38:02.119972 - Block 46: of marstacimab in haemophilic plasma, an additional increase in thrombin generation was observed, re...
2025-12-16T11:38:02.120760 - Sanitized Start: 2.0 minutes in ha and 5.50 to 2.67 minutes in hb)....
2025-12-16T11:38:02.121434 - Sanitized End: lasma) and decrease in lag time (3.83min, 4.83min ...
2025-12-16T11:38:02.123199 - Scanning Page 38...
2025-12-16T11:38:02.133697 - Found 46 blocks on page.
2025-12-16T11:38:02.134516 - Block 0: ...
2025-12-16T11:38:02.135160 - Block 1: assessment report ema/464842/2024 page 38/195...
2025-12-16T11:38:02.136029 - Block 2: hours post-dose; day 8: 0.083, 6, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312 (just ...
2025-12-16T11:38:02.136731 - Block 3: the next dose) and 336 hours post-dose; day 22: 0.083 hours post-dose] and a dilute prothrombin time...
2025-12-16T11:38:02.137406 - Block 4: assay (dpt) was conducted pre-and post-dose at various time points for group 1 at 1mg/kg iv marstaci...
2025-12-16T11:38:02.138079 - Block 5: on day 1, for group 2 at 10mg/kg sc marstacimab on day 8 and group 3 at 3mg/kg sc marstacimab on day...
2025-12-16T11:38:02.138829 - Block 6: 8. a dose dependent increase in marstacimab plasma concentrations was observed. mean cmax (20400,...
2025-12-16T11:38:02.139516 - Block 7: 54600 and 289000ng/ml), auc168 (386000, 1950000 and 14100000ng*hrs/ml) and t1/2 (12.3, 35 and 118...
2025-12-16T11:38:02.140497 - Block 8: hours) increased with increasing doses of iv marstacimab at 1, 3 and 10mg/kg/dose, respectively. aft...
2025-12-16T11:38:02.141326 - Block 9: administration of marstacimab at 3 and 10mg/kg/dose, an increase in mean cmax (18500 and 148000ng/ml...
2025-12-16T11:38:02.142045 - Block 10: respectively), auc336 (2360000 and 28200000 ng*hrs/ml, respectively) and t1/2 (36.5 and 163 hours,...
2025-12-16T11:38:02.142939 - Block 11: respectively) was observed as well. systemic plasma clearance (cl, in ml/min/kg) decreased with incr...
2025-12-16T11:38:02.144016 - Block 12: doses after iv marstacimab administration. furthermore, increases in marstacimab plasma concentratio...
2025-12-16T11:38:02.144804 - Block 13: correlated with increases in total tfpi concentrations in plasma and the other way round, total tfpi...
2025-12-16T11:38:02.145671 - Block 14: decreased with elimination of marstacimab. the dpt assay revealed a decrease in dpt clotting time af...
2025-12-16T11:38:02.146661 - Block 15: or sc administration of marstacimab at the respective doses tested in all groups, compared to baseli...
2025-12-16T11:38:02.147898 - Block 16: dose values. at 3 mg/kg sc marstacimab, dpt clotting time decreased gradually up to 24 hours and the...
2025-12-16T11:38:02.149028 - Block 17: remained stable up to approximately 240 hours. in intravenously dosed animals at 1mg/kg marstacimab ...
2025-12-16T11:38:02.149876 - Block 18: more rapid decrease in dpt clotting time was noticed at 5 minutes post-dose, but with dpt values ret...
2025-12-16T11:38:02.150641 - Block 19: to baseline values approximately after 72-96 hours. at 10mg/kg sc marstacimab, mean baseline pre-dos...
2025-12-16T11:38:02.151783 - Block 20: values for both animals tested (animal 102447:107.7s and animal 102448: 106.8s) decreased as well,...
2025-12-16T11:38:02.152661 - Block 21: measured at 0.083, 24, 192 and 336 hours post dose (animal 102447: 90.8, 92.7, 91.1 and 92.5s,...
2025-12-16T11:38:02.153499 - Block 22: respectively and animal 102448: 88.5, 92.0, 90.1 and 89.9s, respectively)....
2025-12-16T11:38:02.154561 - Block 23: in study pf-06741086_07apr15_135244, male haemophilia a and b mice (5 animals/group) were used as...
2025-12-16T11:38:02.155949 - Block 24: acute tail clip injury model and the duration of marstacimab’s efficacy in the reduction of tail ble...
2025-12-16T11:38:02.157393 - Block 25: injury at certain time points (0.5 hours in hb; 0.5, 24, 96, 189 and 240 hours in ha mice) postdosin...
2025-12-16T11:38:02.158369 - Block 26: intravenous marstacimab (6 mg/kg) or vehicle was assessed. dose-response on tail bleeding obtained w...
2025-12-16T11:38:02.160151 - Block 27: increasing iv doses of marstacimab (0.5, 1, 2 or 6 mg/kg) administered to haemophilia a mice was...
2025-12-16T11:38:02.161432 - Block 28: investigated after 0.5 hours. blood was collected for 10 minutes after tail clip, then blood volume ...
2025-12-16T11:38:02.162309 - Block 29: haemoglobin content, which was then converted to total blood loss (μl), were determined for each mou...
2025-12-16T11:38:02.163531 - Block 30: additionally, male haemophilia a and non-haemophilic wt c57bl6/j mice were used in the laser induced...
2025-12-16T11:38:02.164328 - Block 31: injury model using intravital microscopy imaging, detecting platelet accumulation and fibrin deposit...
2025-12-16T11:38:02.165267 - Block 32: fluorescent labelled antibodies to platelet cd42c (dylight 649) and fibrin (alexa 488). haemophilia ...
2025-12-16T11:38:02.166394 - Block 33: were intravenously dosed with 6 mg/kg of marstacimab, pbs saline (as negative control) or 200 iu/kg ...
2025-12-16T11:38:02.167420 - Block 34: rfviii (as positive control) and 0.5 hours post-dose the cremaster arteriolar endothelium of the mic...
2025-12-16T11:38:02.168545 - Block 35: injured by laser (7 to 12 injuries/mouse, 3 mice/group). non-haemophilic wt c57bl6/j mice received s...
2025-12-16T11:38:02.169592 - Block 36: before injury and served as control. blood loss after tail clip injury showed to decrease dose-depen...
2025-12-16T11:38:02.170540 - Block 37: increasing doses of marstacimab in haemophilia a mice. at 0.5, 1, 2 or 6 mg/kg a decrease of 6.1%, 5...
2025-12-16T11:38:02.171567 - Block 38: 63.2% and 77.7% in bleeding was observed in haemophilia a mice. in haemophilia b mice, a decrease of...
2025-12-16T11:38:02.172322 - Block 39: 74% was noticed at 6 mg/kg marstacimab. furthermore, a high reduction in blood loss was observed at ...
2025-12-16T11:38:02.173094 - Block 40: hours, which finally returned to baseline and control values after 240 hours in haemophilia a mice t...
2025-12-16T11:38:02.173902 - Block 41: with 6mg/kg marstacimab (e.g. 77.9% reduction at 0.5 hours, 27.3% reduction at 189 hours). the laser...
2025-12-16T11:38:02.174695 - Block 42: induced injury model revealed a similar increase in platelet accumulation and fibrin deposition for...
2025-12-16T11:38:02.175761 - Block 43: haemophilia a mice treated with 6 mg/kg marstacimab or 200 iu/kg rfviii but were far from the maxima...
2025-12-16T11:38:02.176683 - Block 44: level observed in non-haemophilic control animals. the haemostatic effect of marstacimab persisted t...
2025-12-16T11:38:02.177529 - Block 45: hours....
2025-12-16T11:38:02.179156 - Sanitized Start: 2.0 minutes in ha and 5.50 to 2.67 minutes in hb)....
2025-12-16T11:38:02.180472 - Sanitized End: lasma) and decrease in lag time (3.83min, 4.83min ...
2025-12-16T11:38:02.182206 - ERROR: Start anchor not found on pages [37, 36, 38]
2025-12-16T11:38:02.183197 - CRITICAL ERROR: Start anchor not found on pages [37, 36, 38]
2025-12-16T11:41:16.691207 - --- START REPLACEMENT on Page 86 ---
2025-12-16T11:41:16.700875 - Input Start Anchor (200 chars): 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 365: 60930 ng/ml, n=4). of note, for non-inhibitor ...
2025-12-16T11:41:17.235152 - Search Strategy: Checking pages [86, 85, 87]
2025-12-16T11:41:17.236303 - Scanning Page 86...
2025-12-16T11:41:17.399990 - Found 45 blocks on page.
2025-12-16T11:41:17.401020 - Block 0: ...
2025-12-16T11:41:17.406101 - Block 1: assessment report ema/464842/2024 page 86/195...
2025-12-16T11:41:17.407069 - Block 2: thrombin, and tga endogenous thrombin generation potential, shortening of dpt and tga lag time) were...
2025-12-16T11:41:17.408132 - Block 3: maintained for more than a week. for most of these pd parameters, the maximum effect was observed wi...
2025-12-16T11:41:17.408878 - Block 4: the first week, except for total plasma tfpi and d-dimer, which peaked later (during week 2 or 3, re...
2025-12-16T11:41:17.413960 - Block 5: in the phase 1b/2 study b7841002, weekly administration of marstacimab led to an increasing plasma...
2025-12-16T11:41:17.414832 - Block 6: concentration up to the day 29 visit. the plasma concentrations at the following visits (day 57, day...
2025-12-16T11:41:17.415502 - Block 7: lower or comparable, suggesting that a steady state may have been reached. this should however be...
2025-12-16T11:41:17.416189 - Block 8: interpreted with caution due to the small sample size and reference is made to the discussion of the...
2025-12-16T11:41:17.416801 - Block 9: term data of the phase 3 trial b7841005 were accumulation of marstacimab was noted for the weekly do...
2025-12-16T11:41:17.417437 - Block 10: 300 mg. at day 29, pk parameters such as auctau, cmax, and cmin seemed to be dose-dependent, with th...
2025-12-16T11:41:17.426995 - Block 11: highest values observed for the 450 mg sc qw group and the lowest values for the 150 mg sc qw (+300 ...
2025-12-16T11:41:17.434721 - Block 12: sc loading dose) group. importantly, the more than proportional increase in pk parameters such as cm...
2025-12-16T11:41:17.435765 - Block 13: auc (as described for the first-in-human single dose study in healthy adults) was not observed durin...
2025-12-16T11:41:17.444291 - Block 14: multiple dose study in haemophilia patients, at least not to the same extent. it should however be n...
2025-12-16T11:41:17.448899 - Block 15: the lower dose levels of study b7841001 (30 mg sc, 100 mg sc) were not investigated during study b78...
2025-12-16T11:41:17.449974 - Block 16: and that the 150 mg sc qw cohort received a loading dose of 300 mg. a possible explanation for the r...
2025-12-16T11:41:17.466289 - Block 17: dose-dependent increase in pk parameters could be that the linear elimination likely dominates at th...
2025-12-16T11:41:17.467144 - Block 18: levels (and plasma concentrations) investigated during the multiple dose trials due to a saturated d...
2025-12-16T11:41:17.475600 - Block 19: (tmdd)....
2025-12-16T11:41:17.476794 - Block 20: while study b7841002 suggested that steady state concentration of marstacimab might have been reache...
2025-12-16T11:41:17.477771 - Block 21: until day 85, the pk data of the extension study b7841003 do not allow a clear conclusion on this as...
2025-12-16T11:41:17.478960 - Block 22: for the higher dose regimen (300 mg sc qw). among the participants who received weekly doses of 300 ...
2025-12-16T11:41:17.479691 - Block 23: (participants with or without inhibitors combined) throughout the study, the mean plasma concentrati...
2025-12-16T11:41:17.480614 - Block 24: marstacimab were higher at later time points compared to day 85 (day 85: 41720 ng/ml, n=10; day 169:...
2025-12-16T11:41:17.481434 - Block 25: patients, the plasma concentrations of marstacimab did continue to increase until d365, while the le...
2025-12-16T11:41:17.482355 - Block 26: stable or decreasing for inhibitor patients. the interpretability of these one-year pk data seems li...
2025-12-16T11:41:17.483866 - Block 27: the small number of participants in the different dose cohorts of this study....
2025-12-16T11:41:17.485051 - Block 28: during the multiple dose study b7841002 and its extension study b7841003, the effects on pd paramete...
2025-12-16T11:41:17.487039 - Block 29: tended to increase until either day 85 (increased pf1+2) or day 169 (total tfpi, increased peak thro...
2025-12-16T11:41:17.493462 - Block 30: shortened tga lag time, increased endogenous thrombin generation potential) and remained roughly...
2025-12-16T11:41:17.494241 - Block 31: comparable until the end of the extension study....
2025-12-16T11:41:17.500988 - Block 32: in the phase 3 study b7841005, 102 participants (85 adults, 17 adolescents) received a weekly dose o...
2025-12-16T11:41:17.501838 - Block 33: mg sc marstacimab (after an initial loading dose of 300 mg) throughout the whole study duration of o...
2025-12-16T11:41:17.502553 - Block 34: for 14 participants (12 adults, 2 adolescents), the weekly dose was escalated to 300 mg sc after the...
2025-12-16T11:41:17.503304 - Block 35: visit....
2025-12-16T11:41:17.504067 - Block 36: among the 102 participants who remained on the 150 mg sc wq dose regimen throughout the study, the...
2025-12-16T11:41:17.504742 - Block 37: marstacimab plasma concentration seemingly reached a steady state around day 60. adolescents reached...
2025-12-16T11:41:17.505488 - Block 38: higher mean plasma concentrations (roughly around 21000-27000 ng/ml, sd ~ 12000-18000) than adults...
2025-12-16T11:41:17.513352 - Block 39: (roughly around 12000-14000 ng/ml, sd ~ 10000-13000) throughout the visits at day 60, day 120, day 1...
2025-12-16T11:41:17.521017 - Block 40: day 240, day 300 and day 360. a higher plasma concentration in adolescents was predicted by the popu...
2025-12-16T11:41:17.523213 - Block 41: pk model. the variability of these pk measurements was high, as shown by the standard deviation valu...
2025-12-16T11:41:17.526843 - Block 42: the phase 3 study, the coefficients of variation were approximately between 40% - 85% in adolescents...
2025-12-16T11:41:17.527721 - Block 43: between 62% - 92% in adults. in the csr it is argued that the variability was likely caused by diffe...
2025-12-16T11:41:17.532972 - Block 44: sampling time points. in order to support this hypothesis, the applicant was asked to provide an ove...
2025-12-16T11:41:17.534105 - Sanitized Start: 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 3...
2025-12-16T11:41:17.534933 - Sanitized End: sma concentrations (roughly around 21000-27000 ng/...
2025-12-16T11:41:17.541516 - Scanning Page 85...
2025-12-16T11:41:17.608685 - Found 45 blocks on page.
2025-12-16T11:41:17.613371 - Block 0: ...
2025-12-16T11:41:17.614454 - Block 1: assessment report ema/464842/2024 page 85/195...
2025-12-16T11:41:17.615771 - Block 2: established. they were set up correctly and fully validated according to current ema guidelines. per...
2025-12-16T11:41:17.616598 - Block 3: of the assays during clinical studies is considered acceptable....
2025-12-16T11:41:17.621270 - Block 4: the remaining pd parameters (thrombin generation, dpt, d-dimer and prothrombin fragments 1+2) were...
2025-12-16T11:41:17.622339 - Block 5: measured using laboratory developed tests validated under clia requirements....
2025-12-16T11:41:17.626674 - Block 6: pk/pd in healthy adults...
2025-12-16T11:41:17.628587 - Block 7: following single dose sc administrations in study b7841001, the marstacimab exposure increased in a ...
2025-12-16T11:41:17.631581 - Block 8: than proportional manner. for example, when comparing sc doses of 100 mg with 300 mg (3-fold dose...
2025-12-16T11:41:17.632464 - Block 9: increase, cohort 2 vs. cohort 3, n=6 each), the geometric mean cmax increased from 1183 ng/ml to 164...
2025-12-16T11:41:17.633772 - Block 10: ng/ml (nearly 14-fold increase), and the geometric mean auclast increased from 81890 ng*hr/ml to 312...
2025-12-16T11:41:17.634598 - Block 11: ng*hr/ml (38-fold increase). depending on the sc dose, the tmax ranged from 48 to 108 hours and the ...
2025-12-16T11:41:17.635334 - Block 12: ranged from 33.3 to 98.35 hours. after single iv administrations (150 mg iv vs. 440 mg iv), the geom...
2025-12-16T11:41:17.638855 - Block 13: mean cmax increased in a roughly proportional manner (45640 ng/ml vs. 152800 ng/ml), while the geome...
2025-12-16T11:41:17.640351 - Block 14: mean auclast did also increase more than proportional (2346000 ng*hr/ml vs. 14290000 ng*hr/ml, 6-fol...
2025-12-16T11:41:17.641487 - Block 15: increase). it is assumed that marstacimab undergoes target-mediated drug disposition. based on aucin...
2025-12-16T11:41:17.642387 - Block 16: bioavailability of sc dosing compared to the iv reference dose was 27%....
2025-12-16T11:41:17.646410 - Block 17: after single administrations of different dose levels in study b7841001 in healthy adults, treatment...
2025-12-16T11:41:17.648500 - Block 18: changes were observed for all pd endpoints and the response was roughly dose dependent. as expected,...
2025-12-16T11:41:17.649360 - Block 19: increases in total tfpi, peak thrombin, d-dimer, and pf1+2 and shortening of tga lag time and dilute...
2025-12-16T11:41:17.650320 - Block 20: prothrombin time were detected. the duration of the effect of the relevant dose levels did in princi...
2025-12-16T11:41:17.652458 - Block 21: the intended weekly administrations of marstacimab....
2025-12-16T11:41:17.653330 - Block 22: additional data on sc administrations of 300 mg (consisting of 2 injections of 150 mg each) are avai...
2025-12-16T11:41:17.654107 - Block 23: the bioequivalence study b7841009, which compared the pk of a pre-filled pen (pfp) with a pre-filled...
2025-12-16T11:41:17.654970 - Block 24: (pfs, used during the phase 3 trial). the descriptive analysis of the 18 participants who contribute...
2025-12-16T11:41:17.655749 - Block 25: the calculation of pk parameters for pfp and pfs showed comparable results for both administration d...
2025-12-16T11:41:17.656469 - Block 26: (pfp vs pfs: geometric mean aucinf [ng*hr/ml]: 2523000 vs. 2482000; geometric mean auclast [ng*hr/ml...
2025-12-16T11:41:17.657722 - Block 27: 2018000 vs. 2015000; geometric mean cmax [ng/ml]: 12550 vs. 12870; median tmax [hr]: 72.00 vs. 72.00...
2025-12-16T11:41:17.659494 - Block 28: arithmetic mean t1/2 [hr]: 61.29 ± 20.073 vs. 60.24 ± 13.687). as mentioned above, the study was ter...
2025-12-16T11:41:17.660548 - Block 29: prematurely because of the occurrence of a deep vein thrombosis and pulmonary embolism. a statistica...
2025-12-16T11:41:17.661624 - Block 30: analysis using data from 11 participants who completed all 4 pk periods revealed test (pfp)/referenc...
2025-12-16T11:41:17.662482 - Block 31: ratios of adjusted geometric means for marstacimab auclast and cmax values of 107.5% (95.2%, 121.4%)...
2025-12-16T11:41:17.663378 - Block 32: and 104.1% (93.7%, 115.6%), respectively. the confidence intervals are within the pre-specified acce...
2025-12-16T11:41:17.664622 - Block 33: range of 80% ‐ 125%. this result was confirmed by a sensitivity analysis of 15 participants who comp...
2025-12-16T11:41:17.665478 - Block 34: least 2 periods (which means that they have received each treatment at least once) and also supporte...
2025-12-16T11:41:17.666387 - Block 35: descriptive pk results of 18 participants who contributed pk data. while the early termination of th...
2025-12-16T11:41:17.667219 - Block 36: not optimal, one could argue that this led to a more challenging scenario for meeting the acceptance...
2025-12-16T11:41:17.667996 - Block 37: due to the lower sample size....
2025-12-16T11:41:17.669275 - Block 38: pk/pd in patients...
2025-12-16T11:41:17.680701 - Block 39: in the phase 1 single dose (300 mg sc) study b7841010 in chinese haemophilia patients, the pk parame...
2025-12-16T11:41:17.681501 - Block 40: of tmax and cmax were comparable with results from both studies in healthy adults (study b7841001, s...
2025-12-16T11:41:17.682218 - Block 41: b7841009) in cohorts using the same dose. the auc and t1/2 values were higher in chinese patients, b...
2025-12-16T11:41:17.683059 - Block 42: consistent with a small cohort of japanese healthy adults (n=4) from study b7841001 (detailed result...
2025-12-16T11:41:17.683756 - Block 43: studies b7841010, b7841001 and b7841009 are shown in the results section). in line with the single d...
2025-12-16T11:41:17.684608 - Block 44: in healthy adults (b7841001), changes in pd parameters (increased plasma total tfpi, pf 1+2, d-dimer...
2025-12-16T11:41:17.685465 - Sanitized Start: 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 3...
2025-12-16T11:41:17.686267 - Sanitized End: sma concentrations (roughly around 21000-27000 ng/...
2025-12-16T11:41:17.692430 - Scanning Page 87...
2025-12-16T11:41:17.735500 - Found 45 blocks on page.
2025-12-16T11:41:17.736310 - Block 0: ...
2025-12-16T11:41:17.737259 - Block 1: assessment report ema/464842/2024 page 87/195...
2025-12-16T11:41:17.740559 - Block 2: more details on the variability of the sampling time points. the applicant clarified that blood samp...
2025-12-16T11:41:17.741604 - Block 3: collected at any time during the clinical visit, regardless of the time of dose administration. whil...
2025-12-16T11:41:17.742583 - Block 4: recommendation was made in the protocol that the pk sample be collected prior to dose administration...
2025-12-16T11:41:17.743777 - Block 5: was not mandatory. approximately 50% of samples were obtained pre-dose (at around 6 days post dose o...
2025-12-16T11:41:17.744481 - Block 6: later), while 50% of samples were obtained anytime between 1 – 5 days post dose. besides patient wei...
2025-12-16T11:41:17.745371 - Block 7: variable soluble and cell surface levels of tfpi may also contribute to variability....
2025-12-16T11:41:17.746052 - Block 8: based on how the data were presented in the initial submission, it seemed that marstacimab and tfpi ...
2025-12-16T11:41:17.746713 - Block 9: continuously increasing in those 14 participants who had a dose escalation to 300 mg sc qw during th...
2025-12-16T11:41:17.747524 - Block 10: 3 study. in addition, the population pk/pd model did not adequately describe the data observed for t...
2025-12-16T11:41:17.748148 - Block 11: mg sc qw dosing. this issue was raised as a major objection in the d120 loq since accumulation of...
2025-12-16T11:41:17.748779 - Block 12: marstacimab and a potential risk for thrombosis could not be excluded. a more detailed presentation ...
2025-12-16T11:41:17.751612 - Block 13: data in dose-escalated particpants was requested....
2025-12-16T11:41:17.752647 - Block 14: in the response to this major objection, the applicant provided detailed tables and figures describi...
2025-12-16T11:41:17.753665 - Block 15: points (marstacimab concentration, total tfpi) in participants who switched to the higher dose regim...
2025-12-16T11:41:17.754344 - Block 16: update of the population pk/pd model (correcting an input error), and updated discussions on the saf...
2025-12-16T11:41:17.754969 - Block 17: efficacy of marstacimab based on a later data cut-off of the extension study b7841007....
2025-12-16T11:41:17.755594 - Block 18: among the 14 participants who received 300 mg sc qw during the phase 3 study b7841005, 6 participant...
2025-12-16T11:41:17.756234 - Block 19: had 3 pk data points (marstacimab concentration in plasma) after dose escalation, covering a period ...
2025-12-16T11:41:17.758293 - Block 20: ~120 days between the sampling time points. importantly, there was no sign of accumulation in these...
2025-12-16T11:41:17.761933 - Block 21: participants. for the remaining 8 participants, only one or two pk data points were available, becau...
2025-12-16T11:41:17.766489 - Block 22: switched their dose at later time points during the study. the measured marstacimab concentrations w...
2025-12-16T11:41:17.767165 - Block 23: within the observed range of the overall study population. the mean plasma concentration in all part...
2025-12-16T11:41:17.767780 - Block 24: who had a dose escalation did only slightly increase between d300 and d360, while the median concent...
2025-12-16T11:41:17.768540 - Block 25: remained stable. based on the provided data, it seems that the data in the initially provided figure...
2025-12-16T11:41:17.769283 - Block 26: biased due to different time points of dose escalations, leading to the wrong impression of a contin...
2025-12-16T11:41:17.770219 - Block 27: of marstacimab in plasma over time. this could not be assessed in the previous round based on how th...
2025-12-16T11:41:17.770802 - Block 28: were presented in the initial submission. the same observation was made for total tfpi....
2025-12-16T11:41:17.771370 - Block 29: in addition, the applicant provided an amended population pk and pk/pd model, including an updated r...
2025-12-16T11:41:17.776161 - Block 30: the applicant claimed that this was made to correct an error in the dosing record inputs for the 300...
2025-12-16T11:41:17.777095 - Block 31: (150 mg input instead of 300 mg) in study b7841005 in the nonmem dataset used for population pk mode...
2025-12-16T11:41:17.777971 - Block 32: the data cutoff remained the same as previously (ie, all data up to day 300 was included). the model...
2025-12-16T11:41:17.778997 - Block 33: predictions (marstacimab concentration, total tfpi) for the 300 mg sc qw dose now show better agreem...
2025-12-16T11:41:17.779667 - Block 34: with the observed data. the amended model is now considered more suitable for use with the higher do...
2025-12-16T11:41:17.784761 - Block 35: mg sc qw)....
2025-12-16T11:41:17.786297 - Block 36: updated safety & efficacy data from a more recent data cut (09 oct 2023 vs. 10 mar 2023 in the previ...
2025-12-16T11:41:17.794662 - Block 37: submission) from the extension study b7841007 were provided. additional participants had a dose esca...
2025-12-16T11:41:17.795378 - Block 38: during the extension study. at the new data cut-off, there were a total of 23 participants who have ...
2025-12-16T11:41:17.801111 - Block 39: escalated from 150 mg marstacimab to 300 mg marstacimab, either in study b7841005 or study b7841007...
2025-12-16T11:41:17.801930 - Block 40: (13 ha participants, 10 hb participants). no pk/pd data are collected during the ongoing extension s...
2025-12-16T11:41:17.805778 - Block 41: there were no saes in dose escalated participants and importantly also no thromboembolic events in a...
2025-12-16T11:41:17.808257 - Block 42: haemophilia patient treated with marstacimab (regardless of the dose level). while this is reassurin...
2025-12-16T11:41:17.809926 - Block 43: small safety database needs to be considered. the applicant provided additional efficacy data based ...
2025-12-16T11:41:17.811337 - Block 44: later data cut-off (09 oct 2023) and there was no sign of reduced efficacy in this population....
2025-12-16T11:41:17.812528 - Sanitized Start: 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 3...
2025-12-16T11:41:17.814915 - Sanitized End: sma concentrations (roughly around 21000-27000 ng/...
2025-12-16T11:41:17.816931 - ERROR: Start anchor not found on pages [86, 85, 87]
2025-12-16T11:41:17.817681 - CRITICAL ERROR: Start anchor not found on pages [86, 85, 87]
2025-12-16T11:43:10.290312 - --- START REPLACEMENT on Page 86 ---
2025-12-16T11:43:10.291868 - Input Start Anchor (200 chars): 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 365: 60930 ng/ml, n=4). of note, for non-inhibitor ...
2025-12-16T11:43:10.329594 - Search Strategy: Checking pages [86, 85, 87]
2025-12-16T11:43:10.331002 - Scanning Page 86...
2025-12-16T11:43:10.380265 - Found 45 blocks on page.
2025-12-16T11:43:10.381760 - Block 0: ...
2025-12-16T11:43:10.385029 - Block 1: assessment report ema/464842/2024 page 86/195...
2025-12-16T11:43:10.386342 - Block 2: thrombin, and tga endogenous thrombin generation potential, shortening of dpt and tga lag time) were...
2025-12-16T11:43:10.387778 - Block 3: maintained for more than a week. for most of these pd parameters, the maximum effect was observed wi...
2025-12-16T11:43:10.389178 - Block 4: the first week, except for total plasma tfpi and d-dimer, which peaked later (during week 2 or 3, re...
2025-12-16T11:43:10.390356 - Block 5: in the phase 1b/2 study b7841002, weekly administration of marstacimab led to an increasing plasma...
2025-12-16T11:43:10.391928 - Block 6: concentration up to the day 29 visit. the plasma concentrations at the following visits (day 57, day...
2025-12-16T11:43:10.393221 - Block 7: lower or comparable, suggesting that a steady state may have been reached. this should however be...
2025-12-16T11:43:10.394587 - Block 8: interpreted with caution due to the small sample size and reference is made to the discussion of the...
2025-12-16T11:43:10.395918 - Block 9: term data of the phase 3 trial b7841005 were accumulation of marstacimab was noted for the weekly do...
2025-12-16T11:43:10.397197 - Block 10: 300 mg. at day 29, pk parameters such as auctau, cmax, and cmin seemed to be dose-dependent, with th...
2025-12-16T11:43:10.398259 - Block 11: highest values observed for the 450 mg sc qw group and the lowest values for the 150 mg sc qw (+300 ...
2025-12-16T11:43:10.399773 - Block 12: sc loading dose) group. importantly, the more than proportional increase in pk parameters such as cm...
2025-12-16T11:43:10.400945 - Block 13: auc (as described for the first-in-human single dose study in healthy adults) was not observed durin...
2025-12-16T11:43:10.401866 - Block 14: multiple dose study in haemophilia patients, at least not to the same extent. it should however be n...
2025-12-16T11:43:10.402694 - Block 15: the lower dose levels of study b7841001 (30 mg sc, 100 mg sc) were not investigated during study b78...
2025-12-16T11:43:10.403449 - Block 16: and that the 150 mg sc qw cohort received a loading dose of 300 mg. a possible explanation for the r...
2025-12-16T11:43:10.404403 - Block 17: dose-dependent increase in pk parameters could be that the linear elimination likely dominates at th...
2025-12-16T11:43:10.405557 - Block 18: levels (and plasma concentrations) investigated during the multiple dose trials due to a saturated d...
2025-12-16T11:43:10.406645 - Block 19: (tmdd)....
2025-12-16T11:43:10.407373 - Block 20: while study b7841002 suggested that steady state concentration of marstacimab might have been reache...
2025-12-16T11:43:10.408060 - Block 21: until day 85, the pk data of the extension study b7841003 do not allow a clear conclusion on this as...
2025-12-16T11:43:10.408737 - Block 22: for the higher dose regimen (300 mg sc qw). among the participants who received weekly doses of 300 ...
2025-12-16T11:43:10.409538 - Block 23: (participants with or without inhibitors combined) throughout the study, the mean plasma concentrati...
2025-12-16T11:43:10.410278 - Block 24: marstacimab were higher at later time points compared to day 85 (day 85: 41720 ng/ml, n=10; day 169:...
2025-12-16T11:43:10.411013 - Block 25: patients, the plasma concentrations of marstacimab did continue to increase until d365, while the le...
2025-12-16T11:43:10.411883 - Block 26: stable or decreasing for inhibitor patients. the interpretability of these one-year pk data seems li...
2025-12-16T11:43:10.413025 - Block 27: the small number of participants in the different dose cohorts of this study....
2025-12-16T11:43:10.414005 - Block 28: during the multiple dose study b7841002 and its extension study b7841003, the effects on pd paramete...
2025-12-16T11:43:10.414985 - Block 29: tended to increase until either day 85 (increased pf1+2) or day 169 (total tfpi, increased peak thro...
2025-12-16T11:43:10.417514 - Block 30: shortened tga lag time, increased endogenous thrombin generation potential) and remained roughly...
2025-12-16T11:43:10.418359 - Block 31: comparable until the end of the extension study....
2025-12-16T11:43:10.419324 - Block 32: in the phase 3 study b7841005, 102 participants (85 adults, 17 adolescents) received a weekly dose o...
2025-12-16T11:43:10.420080 - Block 33: mg sc marstacimab (after an initial loading dose of 300 mg) throughout the whole study duration of o...
2025-12-16T11:43:10.420804 - Block 34: for 14 participants (12 adults, 2 adolescents), the weekly dose was escalated to 300 mg sc after the...
2025-12-16T11:43:10.422065 - Block 35: visit....
2025-12-16T11:43:10.422961 - Block 36: among the 102 participants who remained on the 150 mg sc wq dose regimen throughout the study, the...
2025-12-16T11:43:10.423842 - Block 37: marstacimab plasma concentration seemingly reached a steady state around day 60. adolescents reached...
2025-12-16T11:43:10.424971 - Block 38: higher mean plasma concentrations (roughly around 21000-27000 ng/ml, sd ~ 12000-18000) than adults...
2025-12-16T11:43:10.425995 - Block 39: (roughly around 12000-14000 ng/ml, sd ~ 10000-13000) throughout the visits at day 60, day 120, day 1...
2025-12-16T11:43:10.426767 - Block 40: day 240, day 300 and day 360. a higher plasma concentration in adolescents was predicted by the popu...
2025-12-16T11:43:10.427513 - Block 41: pk model. the variability of these pk measurements was high, as shown by the standard deviation valu...
2025-12-16T11:43:10.428368 - Block 42: the phase 3 study, the coefficients of variation were approximately between 40% - 85% in adolescents...
2025-12-16T11:43:10.429601 - Block 43: between 62% - 92% in adults. in the csr it is argued that the variability was likely caused by diffe...
2025-12-16T11:43:10.430356 - Block 44: sampling time points. in order to support this hypothesis, the applicant was asked to provide an ove...
2025-12-16T11:43:10.431363 - Sanitized Start: 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 3...
2025-12-16T11:43:10.432866 - Sanitized End: sma concentrations (roughly around 21000-27000 ng/...
2025-12-16T11:43:10.434683 - Scanning Page 85...
2025-12-16T11:43:10.452928 - Found 45 blocks on page.
2025-12-16T11:43:10.453864 - Block 0: ...
2025-12-16T11:43:10.454875 - Block 1: assessment report ema/464842/2024 page 85/195...
2025-12-16T11:43:10.456434 - Block 2: established. they were set up correctly and fully validated according to current ema guidelines. per...
2025-12-16T11:43:10.457329 - Block 3: of the assays during clinical studies is considered acceptable....
2025-12-16T11:43:10.458198 - Block 4: the remaining pd parameters (thrombin generation, dpt, d-dimer and prothrombin fragments 1+2) were...
2025-12-16T11:43:10.459601 - Block 5: measured using laboratory developed tests validated under clia requirements....
2025-12-16T11:43:10.460494 - Block 6: pk/pd in healthy adults...
2025-12-16T11:43:10.461362 - Block 7: following single dose sc administrations in study b7841001, the marstacimab exposure increased in a ...
2025-12-16T11:43:10.462316 - Block 8: than proportional manner. for example, when comparing sc doses of 100 mg with 300 mg (3-fold dose...
2025-12-16T11:43:10.463116 - Block 9: increase, cohort 2 vs. cohort 3, n=6 each), the geometric mean cmax increased from 1183 ng/ml to 164...
2025-12-16T11:43:10.463937 - Block 10: ng/ml (nearly 14-fold increase), and the geometric mean auclast increased from 81890 ng*hr/ml to 312...
2025-12-16T11:43:10.464572 - Block 11: ng*hr/ml (38-fold increase). depending on the sc dose, the tmax ranged from 48 to 108 hours and the ...
2025-12-16T11:43:10.465770 - Block 12: ranged from 33.3 to 98.35 hours. after single iv administrations (150 mg iv vs. 440 mg iv), the geom...
2025-12-16T11:43:10.466537 - Block 13: mean cmax increased in a roughly proportional manner (45640 ng/ml vs. 152800 ng/ml), while the geome...
2025-12-16T11:43:10.467401 - Block 14: mean auclast did also increase more than proportional (2346000 ng*hr/ml vs. 14290000 ng*hr/ml, 6-fol...
2025-12-16T11:43:10.468189 - Block 15: increase). it is assumed that marstacimab undergoes target-mediated drug disposition. based on aucin...
2025-12-16T11:43:10.468938 - Block 16: bioavailability of sc dosing compared to the iv reference dose was 27%....
2025-12-16T11:43:10.469776 - Block 17: after single administrations of different dose levels in study b7841001 in healthy adults, treatment...
2025-12-16T11:43:10.470470 - Block 18: changes were observed for all pd endpoints and the response was roughly dose dependent. as expected,...
2025-12-16T11:43:10.471210 - Block 19: increases in total tfpi, peak thrombin, d-dimer, and pf1+2 and shortening of tga lag time and dilute...
2025-12-16T11:43:10.471983 - Block 20: prothrombin time were detected. the duration of the effect of the relevant dose levels did in princi...
2025-12-16T11:43:10.472630 - Block 21: the intended weekly administrations of marstacimab....
2025-12-16T11:43:10.473273 - Block 22: additional data on sc administrations of 300 mg (consisting of 2 injections of 150 mg each) are avai...
2025-12-16T11:43:10.473929 - Block 23: the bioequivalence study b7841009, which compared the pk of a pre-filled pen (pfp) with a pre-filled...
2025-12-16T11:43:10.474696 - Block 24: (pfs, used during the phase 3 trial). the descriptive analysis of the 18 participants who contribute...
2025-12-16T11:43:10.475426 - Block 25: the calculation of pk parameters for pfp and pfs showed comparable results for both administration d...
2025-12-16T11:43:10.476081 - Block 26: (pfp vs pfs: geometric mean aucinf [ng*hr/ml]: 2523000 vs. 2482000; geometric mean auclast [ng*hr/ml...
2025-12-16T11:43:10.476873 - Block 27: 2018000 vs. 2015000; geometric mean cmax [ng/ml]: 12550 vs. 12870; median tmax [hr]: 72.00 vs. 72.00...
2025-12-16T11:43:10.477724 - Block 28: arithmetic mean t1/2 [hr]: 61.29 ± 20.073 vs. 60.24 ± 13.687). as mentioned above, the study was ter...
2025-12-16T11:43:10.478552 - Block 29: prematurely because of the occurrence of a deep vein thrombosis and pulmonary embolism. a statistica...
2025-12-16T11:43:10.479185 - Block 30: analysis using data from 11 participants who completed all 4 pk periods revealed test (pfp)/referenc...
2025-12-16T11:43:10.479972 - Block 31: ratios of adjusted geometric means for marstacimab auclast and cmax values of 107.5% (95.2%, 121.4%)...
2025-12-16T11:43:10.480607 - Block 32: and 104.1% (93.7%, 115.6%), respectively. the confidence intervals are within the pre-specified acce...
2025-12-16T11:43:10.481133 - Block 33: range of 80% ‐ 125%. this result was confirmed by a sensitivity analysis of 15 participants who comp...
2025-12-16T11:43:10.481676 - Block 34: least 2 periods (which means that they have received each treatment at least once) and also supporte...
2025-12-16T11:43:10.482880 - Block 35: descriptive pk results of 18 participants who contributed pk data. while the early termination of th...
2025-12-16T11:43:10.483927 - Block 36: not optimal, one could argue that this led to a more challenging scenario for meeting the acceptance...
2025-12-16T11:43:10.484702 - Block 37: due to the lower sample size....
2025-12-16T11:43:10.485645 - Block 38: pk/pd in patients...
2025-12-16T11:43:10.486543 - Block 39: in the phase 1 single dose (300 mg sc) study b7841010 in chinese haemophilia patients, the pk parame...
2025-12-16T11:43:10.487691 - Block 40: of tmax and cmax were comparable with results from both studies in healthy adults (study b7841001, s...
2025-12-16T11:43:10.488510 - Block 41: b7841009) in cohorts using the same dose. the auc and t1/2 values were higher in chinese patients, b...
2025-12-16T11:43:10.489305 - Block 42: consistent with a small cohort of japanese healthy adults (n=4) from study b7841001 (detailed result...
2025-12-16T11:43:10.490178 - Block 43: studies b7841010, b7841001 and b7841009 are shown in the results section). in line with the single d...
2025-12-16T11:43:10.490967 - Block 44: in healthy adults (b7841001), changes in pd parameters (increased plasma total tfpi, pf 1+2, d-dimer...
2025-12-16T11:43:10.491729 - Sanitized Start: 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 3...
2025-12-16T11:43:10.492547 - Sanitized End: sma concentrations (roughly around 21000-27000 ng/...
2025-12-16T11:43:10.494022 - Scanning Page 87...
2025-12-16T11:43:10.506809 - Found 45 blocks on page.
2025-12-16T11:43:10.507845 - Block 0: ...
2025-12-16T11:43:10.508853 - Block 1: assessment report ema/464842/2024 page 87/195...
2025-12-16T11:43:10.509821 - Block 2: more details on the variability of the sampling time points. the applicant clarified that blood samp...
2025-12-16T11:43:10.511133 - Block 3: collected at any time during the clinical visit, regardless of the time of dose administration. whil...
2025-12-16T11:43:10.512095 - Block 4: recommendation was made in the protocol that the pk sample be collected prior to dose administration...
2025-12-16T11:43:10.512729 - Block 5: was not mandatory. approximately 50% of samples were obtained pre-dose (at around 6 days post dose o...
2025-12-16T11:43:10.513434 - Block 6: later), while 50% of samples were obtained anytime between 1 – 5 days post dose. besides patient wei...
2025-12-16T11:43:10.514268 - Block 7: variable soluble and cell surface levels of tfpi may also contribute to variability....
2025-12-16T11:43:10.515533 - Block 8: based on how the data were presented in the initial submission, it seemed that marstacimab and tfpi ...
2025-12-16T11:43:10.516441 - Block 9: continuously increasing in those 14 participants who had a dose escalation to 300 mg sc qw during th...
2025-12-16T11:43:10.518621 - Block 10: 3 study. in addition, the population pk/pd model did not adequately describe the data observed for t...
2025-12-16T11:43:10.519853 - Block 11: mg sc qw dosing. this issue was raised as a major objection in the d120 loq since accumulation of...
2025-12-16T11:43:10.520740 - Block 12: marstacimab and a potential risk for thrombosis could not be excluded. a more detailed presentation ...
2025-12-16T11:43:10.521502 - Block 13: data in dose-escalated particpants was requested....
2025-12-16T11:43:10.522313 - Block 14: in the response to this major objection, the applicant provided detailed tables and figures describi...
2025-12-16T11:43:10.523109 - Block 15: points (marstacimab concentration, total tfpi) in participants who switched to the higher dose regim...
2025-12-16T11:43:10.523863 - Block 16: update of the population pk/pd model (correcting an input error), and updated discussions on the saf...
2025-12-16T11:43:10.524453 - Block 17: efficacy of marstacimab based on a later data cut-off of the extension study b7841007....
2025-12-16T11:43:10.525198 - Block 18: among the 14 participants who received 300 mg sc qw during the phase 3 study b7841005, 6 participant...
2025-12-16T11:43:10.525970 - Block 19: had 3 pk data points (marstacimab concentration in plasma) after dose escalation, covering a period ...
2025-12-16T11:43:10.526788 - Block 20: ~120 days between the sampling time points. importantly, there was no sign of accumulation in these...
2025-12-16T11:43:10.527547 - Block 21: participants. for the remaining 8 participants, only one or two pk data points were available, becau...
2025-12-16T11:43:10.528594 - Block 22: switched their dose at later time points during the study. the measured marstacimab concentrations w...
2025-12-16T11:43:10.530266 - Block 23: within the observed range of the overall study population. the mean plasma concentration in all part...
2025-12-16T11:43:10.531074 - Block 24: who had a dose escalation did only slightly increase between d300 and d360, while the median concent...
2025-12-16T11:43:10.532203 - Block 25: remained stable. based on the provided data, it seems that the data in the initially provided figure...
2025-12-16T11:43:10.533028 - Block 26: biased due to different time points of dose escalations, leading to the wrong impression of a contin...
2025-12-16T11:43:10.533865 - Block 27: of marstacimab in plasma over time. this could not be assessed in the previous round based on how th...
2025-12-16T11:43:10.534906 - Block 28: were presented in the initial submission. the same observation was made for total tfpi....
2025-12-16T11:43:10.535948 - Block 29: in addition, the applicant provided an amended population pk and pk/pd model, including an updated r...
2025-12-16T11:43:10.536901 - Block 30: the applicant claimed that this was made to correct an error in the dosing record inputs for the 300...
2025-12-16T11:43:10.537784 - Block 31: (150 mg input instead of 300 mg) in study b7841005 in the nonmem dataset used for population pk mode...
2025-12-16T11:43:10.538674 - Block 32: the data cutoff remained the same as previously (ie, all data up to day 300 was included). the model...
2025-12-16T11:43:10.539894 - Block 33: predictions (marstacimab concentration, total tfpi) for the 300 mg sc qw dose now show better agreem...
2025-12-16T11:43:10.540700 - Block 34: with the observed data. the amended model is now considered more suitable for use with the higher do...
2025-12-16T11:43:10.541720 - Block 35: mg sc qw)....
2025-12-16T11:43:10.542716 - Block 36: updated safety & efficacy data from a more recent data cut (09 oct 2023 vs. 10 mar 2023 in the previ...
2025-12-16T11:43:10.543783 - Block 37: submission) from the extension study b7841007 were provided. additional participants had a dose esca...
2025-12-16T11:43:10.544525 - Block 38: during the extension study. at the new data cut-off, there were a total of 23 participants who have ...
2025-12-16T11:43:10.545347 - Block 39: escalated from 150 mg marstacimab to 300 mg marstacimab, either in study b7841005 or study b7841007...
2025-12-16T11:43:10.546443 - Block 40: (13 ha participants, 10 hb participants). no pk/pd data are collected during the ongoing extension s...
2025-12-16T11:43:10.547192 - Block 41: there were no saes in dose escalated participants and importantly also no thromboembolic events in a...
2025-12-16T11:43:10.548023 - Block 42: haemophilia patient treated with marstacimab (regardless of the dose level). while this is reassurin...
2025-12-16T11:43:10.549133 - Block 43: small safety database needs to be considered. the applicant provided additional efficacy data based ...
2025-12-16T11:43:10.550507 - Block 44: later data cut-off (09 oct 2023) and there was no sign of reduced efficacy in this population....
2025-12-16T11:43:10.551612 - Sanitized Start: 60690 ng/ml, n=9; day 253: 58420 ng/ml, n=9, day 3...
2025-12-16T11:43:10.552241 - Sanitized End: sma concentrations (roughly around 21000-27000 ng/...
2025-12-16T11:43:10.553838 - ERROR: Start anchor not found on pages [86, 85, 87]
2025-12-16T11:43:10.554754 - CRITICAL ERROR: Start anchor not found on pages [86, 85, 87]
2025-12-16T11:45:39.036601 - --- START REPLACEMENT on Page 85 ---
2025-12-16T11:45:39.038815 - Input Start Anchor (200 chars): established. they were set up correctly and fully validated according to current ema guidelines. per...
2025-12-16T11:45:39.061517 - Search Strategy: Checking pages [85, 84, 86]
2025-12-16T11:45:39.062773 - Scanning Page 85...
2025-12-16T11:45:39.100791 - Found 45 blocks on page.
2025-12-16T11:45:39.101647 - Block 0: ...
2025-12-16T11:45:39.103033 - Block 1: assessment report ema/464842/2024 page 85/195...
2025-12-16T11:45:39.104255 - Block 2: established. they were set up correctly and fully validated according to current ema guidelines. per...
2025-12-16T11:45:39.105359 - Block 3: of the assays during clinical studies is considered acceptable....
2025-12-16T11:45:39.106562 - Block 4: the remaining pd parameters (thrombin generation, dpt, d-dimer and prothrombin fragments 1+2) were...
2025-12-16T11:45:39.107332 - Block 5: measured using laboratory developed tests validated under clia requirements....
2025-12-16T11:45:39.108158 - Block 6: pk/pd in healthy adults...
2025-12-16T11:45:39.109728 - Block 7: following single dose sc administrations in study b7841001, the marstacimab exposure increased in a ...
2025-12-16T11:45:39.110743 - Block 8: than proportional manner. for example, when comparing sc doses of 100 mg with 300 mg (3-fold dose...
2025-12-16T11:45:39.111874 - Block 9: increase, cohort 2 vs. cohort 3, n=6 each), the geometric mean cmax increased from 1183 ng/ml to 164...
2025-12-16T11:45:39.112905 - Block 10: ng/ml (nearly 14-fold increase), and the geometric mean auclast increased from 81890 ng*hr/ml to 312...
2025-12-16T11:45:39.113732 - Block 11: ng*hr/ml (38-fold increase). depending on the sc dose, the tmax ranged from 48 to 108 hours and the ...
2025-12-16T11:45:39.114457 - Block 12: ranged from 33.3 to 98.35 hours. after single iv administrations (150 mg iv vs. 440 mg iv), the geom...
2025-12-16T11:45:39.115055 - Block 13: mean cmax increased in a roughly proportional manner (45640 ng/ml vs. 152800 ng/ml), while the geome...
2025-12-16T11:45:39.115821 - Block 14: mean auclast did also increase more than proportional (2346000 ng*hr/ml vs. 14290000 ng*hr/ml, 6-fol...
2025-12-16T11:45:39.116871 - Block 15: increase). it is assumed that marstacimab undergoes target-mediated drug disposition. based on aucin...
2025-12-16T11:45:39.117653 - Block 16: bioavailability of sc dosing compared to the iv reference dose was 27%....
2025-12-16T11:45:39.118529 - Block 17: after single administrations of different dose levels in study b7841001 in healthy adults, treatment...
2025-12-16T11:45:39.119474 - Block 18: changes were observed for all pd endpoints and the response was roughly dose dependent. as expected,...
2025-12-16T11:45:39.120387 - Block 19: increases in total tfpi, peak thrombin, d-dimer, and pf1+2 and shortening of tga lag time and dilute...
2025-12-16T11:45:39.121329 - Block 20: prothrombin time were detected. the duration of the effect of the relevant dose levels did in princi...
2025-12-16T11:45:39.122468 - Block 21: the intended weekly administrations of marstacimab....
2025-12-16T11:45:39.123338 - Block 22: additional data on sc administrations of 300 mg (consisting of 2 injections of 150 mg each) are avai...
2025-12-16T11:45:39.124320 - Block 23: the bioequivalence study b7841009, which compared the pk of a pre-filled pen (pfp) with a pre-filled...
2025-12-16T11:45:39.125296 - Block 24: (pfs, used during the phase 3 trial). the descriptive analysis of the 18 participants who contribute...
2025-12-16T11:45:39.126009 - Block 25: the calculation of pk parameters for pfp and pfs showed comparable results for both administration d...
2025-12-16T11:45:39.126950 - Block 26: (pfp vs pfs: geometric mean aucinf [ng*hr/ml]: 2523000 vs. 2482000; geometric mean auclast [ng*hr/ml...
2025-12-16T11:45:39.127663 - Block 27: 2018000 vs. 2015000; geometric mean cmax [ng/ml]: 12550 vs. 12870; median tmax [hr]: 72.00 vs. 72.00...
2025-12-16T11:45:39.128447 - Block 28: arithmetic mean t1/2 [hr]: 61.29 ± 20.073 vs. 60.24 ± 13.687). as mentioned above, the study was ter...
2025-12-16T11:45:39.129433 - Block 29: prematurely because of the occurrence of a deep vein thrombosis and pulmonary embolism. a statistica...
2025-12-16T11:45:39.130252 - Block 30: analysis using data from 11 participants who completed all 4 pk periods revealed test (pfp)/referenc...
2025-12-16T11:45:39.130952 - Block 31: ratios of adjusted geometric means for marstacimab auclast and cmax values of 107.5% (95.2%, 121.4%)...
2025-12-16T11:45:39.131905 - Block 32: and 104.1% (93.7%, 115.6%), respectively. the confidence intervals are within the pre-specified acce...
2025-12-16T11:45:39.132659 - Block 33: range of 80% ‐ 125%. this result was confirmed by a sensitivity analysis of 15 participants who comp...
2025-12-16T11:45:39.133491 - Block 34: least 2 periods (which means that they have received each treatment at least once) and also supporte...
2025-12-16T11:45:39.134289 - Block 35: descriptive pk results of 18 participants who contributed pk data. while the early termination of th...
2025-12-16T11:45:39.134985 - Block 36: not optimal, one could argue that this led to a more challenging scenario for meeting the acceptance...
2025-12-16T11:45:39.135784 - Block 37: due to the lower sample size....
2025-12-16T11:45:39.136569 - Block 38: pk/pd in patients...
2025-12-16T11:45:39.137283 - Block 39: in the phase 1 single dose (300 mg sc) study b7841010 in chinese haemophilia patients, the pk parame...
2025-12-16T11:45:39.137790 - Block 40: of tmax and cmax were comparable with results from both studies in healthy adults (study b7841001, s...
2025-12-16T11:45:39.138332 - Block 41: b7841009) in cohorts using the same dose. the auc and t1/2 values were higher in chinese patients, b...
2025-12-16T11:45:39.139419 - Block 42: consistent with a small cohort of japanese healthy adults (n=4) from study b7841001 (detailed result...
2025-12-16T11:45:39.140117 - Block 43: studies b7841010, b7841001 and b7841009 are shown in the results section). in line with the single d...
2025-12-16T11:45:39.140784 - Block 44: in healthy adults (b7841001), changes in pd parameters (increased plasma total tfpi, pf 1+2, d-dimer...
2025-12-16T11:45:39.141644 - Sanitized Start: established. they were set up correctly and fully ...
2025-12-16T11:45:39.142355 - Sanitized End: inf, the bioavailability of sc dosing compared to ...
2025-12-16T11:45:39.143051 - Found Start (Prefix) at block 2
2025-12-16T11:45:39.144908 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-16T11:45:39.146057 - MATCH FOUND on Page 85: 2-2
2025-12-16T11:45:39.155959 - Replacing blocks 2 to 2
2025-12-16T11:45:39.176411 - Detected Font Size: 9.0
2025-12-16T11:45:39.239248 - Failed size 9.0 (Justified)
2025-12-16T11:45:39.242786 - Failed size 8.5 (Justified)
2025-12-16T11:45:39.245594 - Failed size 8.0 (Justified)
2025-12-16T11:45:39.248482 - Failed size 7.5 (Justified)
2025-12-16T11:45:39.251730 - Failed size 7.0 (Justified)
2025-12-16T11:45:39.255470 - Failed size 6.5 (Justified)
2025-12-16T11:45:39.259745 - Failed size 6.0 (Justified)
2025-12-16T11:45:39.260827 - Fallback to Left Align
2025-12-16T11:45:39.646925 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpuwlx94mi.pdf
2025-12-16T11:53:13.415394 - --- START REPLACEMENT on Page 116 ---
2025-12-16T11:53:13.435542 - Input Start Anchor (200 chars): • baseline data study b7841005 was an adult (≥18 to <75 years of age) and adolescent (≥12 to <18 yea...
2025-12-16T11:53:13.462855 - Search Strategy: Checking pages [116, 115, 117]
2025-12-16T11:53:13.464042 - Scanning Page 116...
2025-12-16T11:53:13.496359 - Found 43 blocks on page.
2025-12-16T11:53:13.497413 - Block 0: ...
2025-12-16T11:53:13.499047 - Block 1: assessment report ema/464842/2024 page 116/195...
2025-12-16T11:53:13.500408 - Block 2: amendment 5: added the option to conduct safety assessments at a non-study centre when necessary to...
2025-12-16T11:53:13.501479 - Block 3: allow more flexibility in the event that an in-clinic visit could not be completed due to the covid-...
2025-12-16T11:53:13.502712 - Block 4: pandemic....
2025-12-16T11:53:13.504134 - Block 5: amendment 6: due to recruitment challenges and feedback received from clinical study sites, inclusio...
2025-12-16T11:53:13.506288 - Block 6: criteria were updated to enable recruitment of participants with moderately severe haemophilia b bas...
2025-12-16T11:53:13.507772 - Block 7: baseline factor activity level (factor activity level ≤2%) and hemorrhagic phenotype (≥4 bleeding ep...
2025-12-16T11:53:13.508807 - Block 8: the 6 months prior to study entry)....
2025-12-16T11:53:13.510524 - Block 9: allowed additional participants (approximately 20%) in order to provide sufficient enrollment into r...
2025-12-16T11:53:13.512227 - Block 10: which had experienced delays created by the covid-19 global pandemic....
2025-12-16T11:53:13.513401 - Block 11: based on edmc recommendation, revised to add that treatment with study intervention was to be suspen...
2025-12-16T11:53:13.514442 - Block 12: if a participant developed a presumed or confirmed symptomatic covid-19 infection due to the potenti...
2025-12-16T11:53:13.515905 - Block 13: thrombotic events....
2025-12-16T11:53:13.516869 - Block 14: amendment 7: removal of the interim analysis for futility within each participant population of inte...
2025-12-16T11:53:13.517766 - Block 15: planned after 50% of participants within each population of interest have completed the study as the...
2025-12-16T11:53:13.518631 - Block 16: analysis data cut time would be very close to the non-inhibitor cohort completions endpoint “total c...
2025-12-16T11:53:13.520293 - Block 17: factor or bypass product consumption” moved from secondary endpoints to tertiary/exploratory endpoin...
2025-12-16T11:53:13.521504 - Block 18: and removal of “percentage of participants with no treated bleeding episodes” from secondary endpoin...
2025-12-16T11:53:13.523319 - Block 19: which will however be presented as part of descriptive analysis for the primary endpoint...
2025-12-16T11:53:13.524770 - Block 20: important protocol deviations...
2025-12-16T11:53:13.526037 - Block 21: 74 (57.8%) participants had important protocol deviations reported, including those related to...
2025-12-16T11:53:13.527034 - Block 22: procedures/tests (31 participants), investigational product (25 participants), concomitant medicatio...
2025-12-16T11:53:13.527961 - Block 23: (22 participants), informed consent (18 participants), inclusion/exclusion criteria (10 participants...
2025-12-16T11:53:13.528821 - Block 24: reporting (8 participants), laboratory (4 participants), and randomization (1 participant). particip...
2025-12-16T11:53:13.529772 - Block 25: with dosing administration error protocol deviations reported a variety of different deviations that...
2025-12-16T11:53:13.530847 - Block 26: occurred typically one time and had no impact on overall efficacy or safety. participants who did no...
2025-12-16T11:53:13.531791 - Block 27: adhere to the protocol-specified washout period prior to visit 7 (1st dose of marstacimab) had no bl...
2025-12-16T11:53:13.532762 - Block 28: in the 4 weeks following visit 7, with the exception of 1 participant who had 1 treated bleed. the...
2025-12-16T11:53:13.533706 - Block 29: potential impact of this is addressed in the analysis to assess the impact of carryover effect from ...
2025-12-16T11:53:13.534614 - Block 30: there were no observed efficacy or safety effects for participants with concomitant medication or...
2025-12-16T11:53:13.535490 - Block 31: dosing/administration error protocol deviations. pros questionnaires not completed resulted in missi...
2025-12-16T11:53:13.536761 - Block 32: pro data, however, the impact of the missing data was minimal on the overall analysis of the pro dat...
2025-12-16T11:53:13.537783 - Block 33: overall, there was no observed impact to safety or efficacy due to the important protocol deviations...
2025-12-16T11:53:13.538813 - Block 34: ...
2025-12-16T11:53:13.539815 - Block 35: • baseline data...
2025-12-16T11:53:13.540820 - Block 36: study b7841005 was an adult (≥18 to <75 years of age) and adolescent (≥12 to <18 years of age) study...
2025-12-16T11:53:13.541864 - Block 37: conducted in male participants with severe haemophilia a or moderately severe to severe haemophilia ...
2025-12-16T11:53:13.542689 - Block 38: severity of haemophilia was confirmed either by documented historical evidence from a clinical labor...
2025-12-16T11:53:13.543473 - Block 39: prior to screening or by factor activity obtained from a clinical laboratory prior to study enrollme...
2025-12-16T11:53:13.544242 - Block 40: participants in study b7841005 were primarily white (65, 50.8%) and asian (61, 47.7%), with 1...
2025-12-16T11:53:13.545057 - Block 41: black/african american (0.8%) participant and 1 participant's race not reported. 42.2% and 36.7% of...
2025-12-16T11:53:13.545886 - Block 42: participants were from asia and europe, respectively....
2025-12-16T11:53:13.546878 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T11:53:13.547905 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T11:53:13.550031 - Scanning Page 115...
2025-12-16T11:53:13.559777 - Found 19 blocks on page.
2025-12-16T11:53:13.561058 - Block 0: ...
2025-12-16T11:53:13.562138 - Block 1: assessment report ema/464842/2024 page 115/195...
2025-12-16T11:53:13.563312 - Block 2: ...
2025-12-16T11:53:13.564373 - Block 3: • recruitment...
2025-12-16T11:53:13.565577 - Block 4: first patient first visit (fpfv): 09 march 2020...
2025-12-16T11:53:13.566532 - Block 5: data cutoff date (lplv for non-inhibitor cohort): 17 april 2023...
2025-12-16T11:53:13.567416 - Block 6: ...
2025-12-16T11:53:13.568567 - Block 7: • conduct of the study...
2025-12-16T11:53:13.569618 - Block 8: the study protocol was amended a total of 7 times. notably, 5 of the amendments were introduced afte...
2025-12-16T11:53:13.570623 - Block 9: study initiation date (fpfv) of 09 march 2020....
2025-12-16T11:53:13.571540 - Block 10: table 25: protocol amendments summary of changes table...
2025-12-16T11:53:13.573307 - Block 11: ...
2025-12-16T11:53:13.574345 - Block 12: a brief summary of the most important protocol amendment changes is provided below:...
2025-12-16T11:53:13.575455 - Block 13: amendment 1 and amendment 2 included changes to the protocol before study initiation (09 march 2020)...
2025-12-16T11:53:13.576425 - Block 14: amendment 3: included participation of prior prophylaxis participants in the us and canada following...
2025-12-16T11:53:13.577531 - Block 15: read-out of safety data provided from the phase 2 program....
2025-12-16T11:53:13.578570 - Block 16: amendment 4: for dose modification requirements a minimum body weight of 50 kg was added to allow...
2025-12-16T11:53:13.579574 - Block 17: dose escalation to 300 mg qw. new appendix added to the protocol detailing alternative study procedu...
2025-12-16T11:53:13.580738 - Block 18: be followed during the covid-19 global pandemic....
2025-12-16T11:53:13.581947 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T11:53:13.583242 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T11:53:13.584811 - Scanning Page 117...
2025-12-16T11:53:13.607673 - Found 21 blocks on page.
2025-12-16T11:53:13.608792 - Block 0: ...
2025-12-16T11:53:13.609740 - Block 1: assessment report ema/464842/2024 page 117/195...
2025-12-16T11:53:13.610903 - Block 2: demographic characteristics for participants are summarized in table 26 below. table 27 summarises...
2025-12-16T11:53:13.612423 - Block 3: participant haemophilia history by haemophilia type, target joint, and geographical region....
2025-12-16T11:53:13.613437 - Block 4: target joints are defined as major joints (eg, hip, elbow, wrist, shoulder, knee, and ankle) into wh...
2025-12-16T11:53:13.614680 - Block 5: repeated bleeds occur (3 or more spontaneous bleeds into a single joint within a consecutive 6-month...
2025-12-16T11:53:13.615882 - Block 6: period). target joints are a contributing factor to bleeding phenotype, eg, the bleeds from a single...
2025-12-16T11:53:13.616817 - Block 7: joint would count toward a participant having an abr of at least 6, the bleeds from 2target joints w...
2025-12-16T11:53:13.617654 - Block 8: toward a participant having an abr of at least 12, and the bleeds from 3 or more target joints would...
2025-12-16T11:53:13.618924 - Block 9: toward a participant having an abr of at least 18....
2025-12-16T11:53:13.620004 - Block 10: overall, across participants without inhibitors in study b7841005:...
2025-12-16T11:53:13.621285 - Block 11: ▪ 101 (78.9%) participants had haemophilia a and 27 (21.1%) participants had haemophilia b. ▪ 108 (8...
2025-12-16T11:53:13.622384 - Block 12: all 128 participants were male with a median age of 30.0 years and individual values ranged from 13....
2025-12-16T11:53:13.623461 - Block 13: 66.0 years. the majority of participants (78, 60.9%) were in the 18-44 age range....
2025-12-16T11:53:13.624643 - Block 14: the median participant weight was 70.7 kg (range: 35.0 to 120.0 kg) and the median participant bmi w...
2025-12-16T11:53:13.625670 - Block 15: 24.1 kg/m2 (range: 15.2 to 38.8 kg/m2). the median participant height was 170.1 cm (range: 141.0 to ...
2025-12-16T11:53:13.626616 - Block 16: cm)....
2025-12-16T11:53:13.627605 - Block 17: most participants (100, 78.1%) had normal renal function (egfr ≥90 ml/min/1.73 m2), while 24 (18.8%)...
2025-12-16T11:53:13.628575 - Block 18: participants had mild renal impairment (egfr ≥60 to <90 ml/min/1.73 m2) and 1 (0.8%) participant had...
2025-12-16T11:53:13.629542 - Block 19: moderate renal impairment (egfr 30 to <60 ml/min/1.73 m2)....
2025-12-16T11:53:13.630724 - Block 20: table 26: baseline and demographic characteristics – all safety set...
2025-12-16T11:53:13.632191 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T11:53:13.632948 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T11:53:13.634190 - ERROR: Start anchor not found on pages [116, 115, 117]
2025-12-16T11:53:13.635426 - CRITICAL ERROR: Start anchor not found on pages [116, 115, 117]
2025-12-16T12:11:32.093789 - --- START REPLACEMENT on Page 116 ---
2025-12-16T12:11:32.094239 - Input Start Anchor (200 chars): • baseline data study b7841005 was an adult (≥18 to <75 years of age) and adolescent (≥12 to <18 yea...
2025-12-16T12:11:32.137164 - Search Strategy: Checking pages [116, 115, 117]
2025-12-16T12:11:32.137493 - Scanning Page 116...
2025-12-16T12:11:32.154235 - Found 43 blocks on page.
2025-12-16T12:11:32.154546 - Block 0: ...
2025-12-16T12:11:32.154938 - Block 1: assessment report ema/464842/2024 page 116/195...
2025-12-16T12:11:32.155320 - Block 2: amendment 5: added the option to conduct safety assessments at a non-study centre when necessary to...
2025-12-16T12:11:32.155850 - Block 3: allow more flexibility in the event that an in-clinic visit could not be completed due to the covid-...
2025-12-16T12:11:32.156439 - Block 4: pandemic....
2025-12-16T12:11:32.156939 - Block 5: amendment 6: due to recruitment challenges and feedback received from clinical study sites, inclusio...
2025-12-16T12:11:32.157377 - Block 6: criteria were updated to enable recruitment of participants with moderately severe haemophilia b bas...
2025-12-16T12:11:32.157742 - Block 7: baseline factor activity level (factor activity level ≤2%) and hemorrhagic phenotype (≥4 bleeding ep...
2025-12-16T12:11:32.158057 - Block 8: the 6 months prior to study entry)....
2025-12-16T12:11:32.158369 - Block 9: allowed additional participants (approximately 20%) in order to provide sufficient enrollment into r...
2025-12-16T12:11:32.158652 - Block 10: which had experienced delays created by the covid-19 global pandemic....
2025-12-16T12:11:32.158920 - Block 11: based on edmc recommendation, revised to add that treatment with study intervention was to be suspen...
2025-12-16T12:11:32.159290 - Block 12: if a participant developed a presumed or confirmed symptomatic covid-19 infection due to the potenti...
2025-12-16T12:11:32.159699 - Block 13: thrombotic events....
2025-12-16T12:11:32.160056 - Block 14: amendment 7: removal of the interim analysis for futility within each participant population of inte...
2025-12-16T12:11:32.160478 - Block 15: planned after 50% of participants within each population of interest have completed the study as the...
2025-12-16T12:11:32.160874 - Block 16: analysis data cut time would be very close to the non-inhibitor cohort completions endpoint “total c...
2025-12-16T12:11:32.161292 - Block 17: factor or bypass product consumption” moved from secondary endpoints to tertiary/exploratory endpoin...
2025-12-16T12:11:32.161580 - Block 18: and removal of “percentage of participants with no treated bleeding episodes” from secondary endpoin...
2025-12-16T12:11:32.161860 - Block 19: which will however be presented as part of descriptive analysis for the primary endpoint...
2025-12-16T12:11:32.162179 - Block 20: important protocol deviations...
2025-12-16T12:11:32.162458 - Block 21: 74 (57.8%) participants had important protocol deviations reported, including those related to...
2025-12-16T12:11:32.162748 - Block 22: procedures/tests (31 participants), investigational product (25 participants), concomitant medicatio...
2025-12-16T12:11:32.163050 - Block 23: (22 participants), informed consent (18 participants), inclusion/exclusion criteria (10 participants...
2025-12-16T12:11:32.163465 - Block 24: reporting (8 participants), laboratory (4 participants), and randomization (1 participant). particip...
2025-12-16T12:11:32.163751 - Block 25: with dosing administration error protocol deviations reported a variety of different deviations that...
2025-12-16T12:11:32.164024 - Block 26: occurred typically one time and had no impact on overall efficacy or safety. participants who did no...
2025-12-16T12:11:32.164271 - Block 27: adhere to the protocol-specified washout period prior to visit 7 (1st dose of marstacimab) had no bl...
2025-12-16T12:11:32.164807 - Block 28: in the 4 weeks following visit 7, with the exception of 1 participant who had 1 treated bleed. the...
2025-12-16T12:11:32.165679 - Block 29: potential impact of this is addressed in the analysis to assess the impact of carryover effect from ...
2025-12-16T12:11:32.166052 - Block 30: there were no observed efficacy or safety effects for participants with concomitant medication or...
2025-12-16T12:11:32.166471 - Block 31: dosing/administration error protocol deviations. pros questionnaires not completed resulted in missi...
2025-12-16T12:11:32.166936 - Block 32: pro data, however, the impact of the missing data was minimal on the overall analysis of the pro dat...
2025-12-16T12:11:32.167428 - Block 33: overall, there was no observed impact to safety or efficacy due to the important protocol deviations...
2025-12-16T12:11:32.167819 - Block 34: ...
2025-12-16T12:11:32.168129 - Block 35: • baseline data...
2025-12-16T12:11:32.168518 - Block 36: study b7841005 was an adult (≥18 to <75 years of age) and adolescent (≥12 to <18 years of age) study...
2025-12-16T12:11:32.168844 - Block 37: conducted in male participants with severe haemophilia a or moderately severe to severe haemophilia ...
2025-12-16T12:11:32.169143 - Block 38: severity of haemophilia was confirmed either by documented historical evidence from a clinical labor...
2025-12-16T12:11:32.169442 - Block 39: prior to screening or by factor activity obtained from a clinical laboratory prior to study enrollme...
2025-12-16T12:11:32.169784 - Block 40: participants in study b7841005 were primarily white (65, 50.8%) and asian (61, 47.7%), with 1...
2025-12-16T12:11:32.170175 - Block 41: black/african american (0.8%) participant and 1 participant's race not reported. 42.2% and 36.7% of...
2025-12-16T12:11:32.170489 - Block 42: participants were from asia and europe, respectively....
2025-12-16T12:11:32.170956 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T12:11:32.171273 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T12:11:32.194546 - Found Start (Fuzzy 0.67) at block 36
2025-12-16T12:11:32.199679 - Found End (Fuzzy 0.66) at block 41
2025-12-16T12:11:32.200073 - MATCH FOUND on Page 116: 36-41
2025-12-16T12:11:32.205313 - Replacing blocks 36 to 41
2025-12-16T12:11:32.211654 - Detected Font Size: 9.0
2025-12-16T12:11:32.239859 - Failed size 9.0 (Justified)
2025-12-16T12:11:32.241065 - Failed size 8.5 (Justified)
2025-12-16T12:11:32.244744 - Inserted with size 8.0 (Justified)
2025-12-16T12:11:32.374517 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpwxru723o.pdf
2025-12-16T12:16:13.164742 - --- START REPLACEMENT on Page 80 ---
2025-12-16T12:16:13.165273 - Input Start Anchor (200 chars): effect of ada and nab on pd data profiles of key pharmacodynamic endpoints ie, tfpi (total), tga pea...
2025-12-16T12:16:13.174732 - Search Strategy: Checking pages [80, 79, 81]
2025-12-16T12:16:13.176505 - Scanning Page 80...
2025-12-16T12:16:13.192352 - Found 24 blocks on page.
2025-12-16T12:16:13.193005 - Block 0: ...
2025-12-16T12:16:13.193789 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-16T12:16:13.194383 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-16T12:16:13.194944 - Block 3: adolescents (150 mg sc)....
2025-12-16T12:16:13.195512 - Block 4: ...
2025-12-16T12:16:13.196128 - Block 5: d) total tfpi:...
2025-12-16T12:16:13.197116 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-16T12:16:13.197876 - Block 7: dose group and age group (b7841005)...
2025-12-16T12:16:13.198530 - Block 8: ...
2025-12-16T12:16:13.199504 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-16T12:16:13.200029 - Block 10: (150 mg sc)....
2025-12-16T12:16:13.200567 - Block 11: ...
2025-12-16T12:16:13.201026 - Block 12: effect of ada and nab on pd data...
2025-12-16T12:16:13.201451 - Block 13: profiles of key pharmacodynamic endpoints ie, tfpi (total), tga peak, pf1+2, dpt and d-dimer followi...
2025-12-16T12:16:13.201913 - Block 14: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-16T12:16:13.202288 - Block 15: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-16T12:16:13.202647 - Block 16: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-16T12:16:13.203010 - Block 17: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-16T12:16:13.203473 - Block 18: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-16T12:16:13.203951 - Block 19: between ada positive and ada negative participants....
2025-12-16T12:16:13.204403 - Block 20: ...
2025-12-16T12:16:13.204854 - Block 21: ...
2025-12-16T12:16:13.205289 - Block 22: ...
2025-12-16T12:16:13.205737 - Block 23: ...
2025-12-16T12:16:13.206388 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T12:16:13.206772 - Sanitized End: re comparable between ada positive and ada negativ...
2025-12-16T12:16:13.212743 - Found Start (Fuzzy 0.68) at block 13
2025-12-16T12:16:13.218354 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-16T12:16:13.218915 - MATCH FOUND on Page 80: 13-13
2025-12-16T12:16:13.221785 - Replacing blocks 13 to 13
2025-12-16T12:16:13.250226 - Detected Font Size: 9.0
2025-12-16T12:16:13.289598 - Failed size 9.0 (Justified)
2025-12-16T12:16:13.292559 - Failed size 8.5 (Justified)
2025-12-16T12:16:13.295330 - Failed size 8.0 (Justified)
2025-12-16T12:16:13.298139 - Failed size 7.5 (Justified)
2025-12-16T12:16:13.301356 - Failed size 7.0 (Justified)
2025-12-16T12:16:13.304148 - Failed size 6.5 (Justified)
2025-12-16T12:16:13.306837 - Failed size 6.0 (Justified)
2025-12-16T12:16:13.307426 - Fallback to Left Align
2025-12-16T12:16:13.478303 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmptvoxdc87.pdf
2025-12-16T12:18:09.735801 - --- START REPLACEMENT on Page 80 ---
2025-12-16T12:18:09.736313 - Input Start Anchor (200 chars): effect of ada and nab on pd data profiles of key pharmacodynamic endpoints ie, tfpi (total), tga pea...
2025-12-16T12:18:09.748848 - Search Strategy: Checking pages [80, 79, 81]
2025-12-16T12:18:09.749544 - Scanning Page 80...
2025-12-16T12:18:09.760068 - Found 23 blocks on page.
2025-12-16T12:18:09.760895 - Block 0: ...
2025-12-16T12:18:09.761877 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-16T12:18:09.762789 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-16T12:18:09.764071 - Block 3: adolescents (150 mg sc)....
2025-12-16T12:18:09.765002 - Block 4: ...
2025-12-16T12:18:09.765535 - Block 5: d) total tfpi:...
2025-12-16T12:18:09.766165 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-16T12:18:09.766856 - Block 7: dose group and age group (b7841005)...
2025-12-16T12:18:09.767479 - Block 8: ...
2025-12-16T12:18:09.768066 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-16T12:18:09.768551 - Block 10: (150 mg sc)....
2025-12-16T12:18:09.769069 - Block 11: ...
2025-12-16T12:18:09.769535 - Block 12: effect of ada and nab on pd data...
2025-12-16T12:18:09.770024 - Block 13: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-16T12:18:09.770547 - Block 14: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-16T12:18:09.771203 - Block 15: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-16T12:18:09.771566 - Block 16: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-16T12:18:09.772070 - Block 17: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-16T12:18:09.772443 - Block 18: between ada positive and ada negative participants....
2025-12-16T12:18:09.772873 - Block 19: ...
2025-12-16T12:18:09.773263 - Block 20: ...
2025-12-16T12:18:09.773782 - Block 21: ...
2025-12-16T12:18:09.774104 - Block 22: ...
2025-12-16T12:18:09.774649 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T12:18:09.775060 - Sanitized End: re comparable between ada positive and ada negativ...
2025-12-16T12:18:09.789106 - Scanning Page 79...
2025-12-16T12:18:09.792042 - Found 12 blocks on page.
2025-12-16T12:18:09.792709 - Block 0: ...
2025-12-16T12:18:09.793426 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T12:18:09.794156 - Block 2: b) pf 1+2:...
2025-12-16T12:18:09.795091 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T12:18:09.795935 - Block 4: group (b7841005)...
2025-12-16T12:18:09.796548 - Block 5: ...
2025-12-16T12:18:09.797167 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T12:18:09.797711 - Block 7: adolescents (150 mg sc)....
2025-12-16T12:18:09.798311 - Block 8: c) d-dimer:...
2025-12-16T12:18:09.801082 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T12:18:09.801579 - Block 10: group (b7841005)...
2025-12-16T12:18:09.801996 - Block 11: ...
2025-12-16T12:18:09.802706 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T12:18:09.803079 - Sanitized End: re comparable between ada positive and ada negativ...
2025-12-16T12:18:09.807625 - Scanning Page 81...
2025-12-16T12:18:09.813661 - Found 24 blocks on page.
2025-12-16T12:18:09.814173 - Block 0: ...
2025-12-16T12:18:09.814743 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-16T12:18:09.815224 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-16T12:18:09.815708 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-16T12:18:09.816331 - Block 4: ...
2025-12-16T12:18:09.816926 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-16T12:18:09.817427 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-16T12:18:09.817904 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-16T12:18:09.818416 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-16T12:18:09.818927 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-16T12:18:09.819417 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-16T12:18:09.819771 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-16T12:18:09.820146 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-16T12:18:09.820515 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-16T12:18:09.820867 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-16T12:18:09.821372 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-16T12:18:09.821823 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-16T12:18:09.822270 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-16T12:18:09.822700 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-16T12:18:09.823203 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-16T12:18:09.823639 - Block 20: parameters....
2025-12-16T12:18:09.824072 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-16T12:18:09.824451 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-16T12:18:09.824804 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-16T12:18:09.825248 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T12:18:09.825585 - Sanitized End: re comparable between ada positive and ada negativ...
2025-12-16T12:18:09.846151 - ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-16T12:18:09.846635 - CRITICAL ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-16T12:22:19.259609 - --- START REPLACEMENT on Page 116 ---
2025-12-16T12:22:19.260240 - Input Start Anchor (200 chars): • baseline data study b7841005 was an adult (≥18 to <75 years of age) and adolescent (≥12 to <18 yea...
2025-12-16T12:22:19.310424 - Search Strategy: Checking pages [116, 115, 117]
2025-12-16T12:22:19.311106 - Scanning Page 116...
2025-12-16T12:22:19.335590 - Found 38 blocks on page.
2025-12-16T12:22:19.336096 - Block 0: ...
2025-12-16T12:22:19.336580 - Block 1: assessment report ema/464842/2024 page 116/195...
2025-12-16T12:22:19.337061 - Block 2: amendment 5: added the option to conduct safety assessments at a non-study centre when necessary to...
2025-12-16T12:22:19.337509 - Block 3: allow more flexibility in the event that an in-clinic visit could not be completed due to the covid-...
2025-12-16T12:22:19.337979 - Block 4: pandemic....
2025-12-16T12:22:19.338425 - Block 5: amendment 6: due to recruitment challenges and feedback received from clinical study sites, inclusio...
2025-12-16T12:22:19.338878 - Block 6: criteria were updated to enable recruitment of participants with moderately severe haemophilia b bas...
2025-12-16T12:22:19.339317 - Block 7: baseline factor activity level (factor activity level ≤2%) and hemorrhagic phenotype (≥4 bleeding ep...
2025-12-16T12:22:19.339769 - Block 8: the 6 months prior to study entry)....
2025-12-16T12:22:19.340339 - Block 9: allowed additional participants (approximately 20%) in order to provide sufficient enrollment into r...
2025-12-16T12:22:19.341133 - Block 10: which had experienced delays created by the covid-19 global pandemic....
2025-12-16T12:22:19.341589 - Block 11: based on edmc recommendation, revised to add that treatment with study intervention was to be suspen...
2025-12-16T12:22:19.342076 - Block 12: if a participant developed a presumed or confirmed symptomatic covid-19 infection due to the potenti...
2025-12-16T12:22:19.342446 - Block 13: thrombotic events....
2025-12-16T12:22:19.342839 - Block 14: amendment 7: removal of the interim analysis for futility within each participant population of inte...
2025-12-16T12:22:19.343210 - Block 15: planned after 50% of participants within each population of interest have completed the study as the...
2025-12-16T12:22:19.343867 - Block 16: analysis data cut time would be very close to the non-inhibitor cohort completions endpoint “total c...
2025-12-16T12:22:19.344398 - Block 17: factor or bypass product consumption” moved from secondary endpoints to tertiary/exploratory endpoin...
2025-12-16T12:22:19.344983 - Block 18: and removal of “percentage of participants with no treated bleeding episodes” from secondary endpoin...
2025-12-16T12:22:19.345498 - Block 19: which will however be presented as part of descriptive analysis for the primary endpoint...
2025-12-16T12:22:19.346118 - Block 20: important protocol deviations...
2025-12-16T12:22:19.346725 - Block 21: 74 (57.8%) participants had important protocol deviations reported, including those related to...
2025-12-16T12:22:19.347437 - Block 22: procedures/tests (31 participants), investigational product (25 participants), concomitant medicatio...
2025-12-16T12:22:19.348046 - Block 23: (22 participants), informed consent (18 participants), inclusion/exclusion criteria (10 participants...
2025-12-16T12:22:19.348619 - Block 24: reporting (8 participants), laboratory (4 participants), and randomization (1 participant). particip...
2025-12-16T12:22:19.349360 - Block 25: with dosing administration error protocol deviations reported a variety of different deviations that...
2025-12-16T12:22:19.349945 - Block 26: occurred typically one time and had no impact on overall efficacy or safety. participants who did no...
2025-12-16T12:22:19.350534 - Block 27: adhere to the protocol-specified washout period prior to visit 7 (1st dose of marstacimab) had no bl...
2025-12-16T12:22:19.350947 - Block 28: in the 4 weeks following visit 7, with the exception of 1 participant who had 1 treated bleed. the...
2025-12-16T12:22:19.351353 - Block 29: potential impact of this is addressed in the analysis to assess the impact of carryover effect from ...
2025-12-16T12:22:19.351744 - Block 30: there were no observed efficacy or safety effects for participants with concomitant medication or...
2025-12-16T12:22:19.352192 - Block 31: dosing/administration error protocol deviations. pros questionnaires not completed resulted in missi...
2025-12-16T12:22:19.352593 - Block 32: pro data, however, the impact of the missing data was minimal on the overall analysis of the pro dat...
2025-12-16T12:22:19.352982 - Block 33: overall, there was no observed impact to safety or efficacy due to the important protocol deviations...
2025-12-16T12:22:19.353403 - Block 34: ...
2025-12-16T12:22:19.353784 - Block 35: • baseline data...
2025-12-16T12:22:19.354202 - Block 36: participants were from asia and europe, respectively....
2025-12-16T12:22:19.354786 - Block 37: ? baseline data study b7841005 was an adult (?18 to <75 years of age) and adolescent (?12 to <18 yea...
2025-12-16T12:22:19.355231 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T12:22:19.355547 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T12:22:19.392266 - Scanning Page 115...
2025-12-16T12:22:19.398563 - Found 19 blocks on page.
2025-12-16T12:22:19.399186 - Block 0: ...
2025-12-16T12:22:19.399668 - Block 1: assessment report ema/464842/2024 page 115/195...
2025-12-16T12:22:19.400157 - Block 2: ...
2025-12-16T12:22:19.400571 - Block 3: • recruitment...
2025-12-16T12:22:19.401028 - Block 4: first patient first visit (fpfv): 09 march 2020...
2025-12-16T12:22:19.401384 - Block 5: data cutoff date (lplv for non-inhibitor cohort): 17 april 2023...
2025-12-16T12:22:19.401741 - Block 6: ...
2025-12-16T12:22:19.402159 - Block 7: • conduct of the study...
2025-12-16T12:22:19.402683 - Block 8: the study protocol was amended a total of 7 times. notably, 5 of the amendments were introduced afte...
2025-12-16T12:22:19.403110 - Block 9: study initiation date (fpfv) of 09 march 2020....
2025-12-16T12:22:19.403527 - Block 10: table 25: protocol amendments summary of changes table...
2025-12-16T12:22:19.403988 - Block 11: ...
2025-12-16T12:22:19.404483 - Block 12: a brief summary of the most important protocol amendment changes is provided below:...
2025-12-16T12:22:19.404895 - Block 13: amendment 1 and amendment 2 included changes to the protocol before study initiation (09 march 2020)...
2025-12-16T12:22:19.405346 - Block 14: amendment 3: included participation of prior prophylaxis participants in the us and canada following...
2025-12-16T12:22:19.405750 - Block 15: read-out of safety data provided from the phase 2 program....
2025-12-16T12:22:19.406232 - Block 16: amendment 4: for dose modification requirements a minimum body weight of 50 kg was added to allow...
2025-12-16T12:22:19.406798 - Block 17: dose escalation to 300 mg qw. new appendix added to the protocol detailing alternative study procedu...
2025-12-16T12:22:19.407225 - Block 18: be followed during the covid-19 global pandemic....
2025-12-16T12:22:19.408030 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T12:22:19.408417 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T12:22:19.423308 - Scanning Page 117...
2025-12-16T12:22:19.431928 - Found 21 blocks on page.
2025-12-16T12:22:19.432624 - Block 0: ...
2025-12-16T12:22:19.433076 - Block 1: assessment report ema/464842/2024 page 117/195...
2025-12-16T12:22:19.433451 - Block 2: demographic characteristics for participants are summarized in table 26 below. table 27 summarises...
2025-12-16T12:22:19.433847 - Block 3: participant haemophilia history by haemophilia type, target joint, and geographical region....
2025-12-16T12:22:19.434215 - Block 4: target joints are defined as major joints (eg, hip, elbow, wrist, shoulder, knee, and ankle) into wh...
2025-12-16T12:22:19.434608 - Block 5: repeated bleeds occur (3 or more spontaneous bleeds into a single joint within a consecutive 6-month...
2025-12-16T12:22:19.435000 - Block 6: period). target joints are a contributing factor to bleeding phenotype, eg, the bleeds from a single...
2025-12-16T12:22:19.435405 - Block 7: joint would count toward a participant having an abr of at least 6, the bleeds from 2target joints w...
2025-12-16T12:22:19.435803 - Block 8: toward a participant having an abr of at least 12, and the bleeds from 3 or more target joints would...
2025-12-16T12:22:19.436186 - Block 9: toward a participant having an abr of at least 18....
2025-12-16T12:22:19.436596 - Block 10: overall, across participants without inhibitors in study b7841005:...
2025-12-16T12:22:19.437050 - Block 11: ▪ 101 (78.9%) participants had haemophilia a and 27 (21.1%) participants had haemophilia b. ▪ 108 (8...
2025-12-16T12:22:19.437647 - Block 12: all 128 participants were male with a median age of 30.0 years and individual values ranged from 13....
2025-12-16T12:22:19.438081 - Block 13: 66.0 years. the majority of participants (78, 60.9%) were in the 18-44 age range....
2025-12-16T12:22:19.438529 - Block 14: the median participant weight was 70.7 kg (range: 35.0 to 120.0 kg) and the median participant bmi w...
2025-12-16T12:22:19.439050 - Block 15: 24.1 kg/m2 (range: 15.2 to 38.8 kg/m2). the median participant height was 170.1 cm (range: 141.0 to ...
2025-12-16T12:22:19.439536 - Block 16: cm)....
2025-12-16T12:22:19.439962 - Block 17: most participants (100, 78.1%) had normal renal function (egfr ≥90 ml/min/1.73 m2), while 24 (18.8%)...
2025-12-16T12:22:19.440396 - Block 18: participants had mild renal impairment (egfr ≥60 to <90 ml/min/1.73 m2) and 1 (0.8%) participant had...
2025-12-16T12:22:19.440837 - Block 19: moderate renal impairment (egfr 30 to <60 ml/min/1.73 m2)....
2025-12-16T12:22:19.441297 - Block 20: table 26: baseline and demographic characteristics – all safety set...
2025-12-16T12:22:19.441900 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T12:22:19.442283 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T12:22:19.458105 - ERROR: Start anchor not found on pages [116, 115, 117]
2025-12-16T12:22:19.458545 - CRITICAL ERROR: Start anchor not found on pages [116, 115, 117]
2025-12-16T12:24:15.314594 - --- START REPLACEMENT on Page 116 ---
2025-12-16T12:24:15.315185 - Input Start Anchor (200 chars): • baseline data study b7841005 was an adult (≥18 to <75 years of age) and adolescent (≥12 to <18 yea...
2025-12-16T12:24:15.324155 - Search Strategy: Checking pages [116, 115, 117]
2025-12-16T12:24:15.324808 - Scanning Page 116...
2025-12-16T12:24:15.349131 - Found 38 blocks on page.
2025-12-16T12:24:15.349675 - Block 0: ...
2025-12-16T12:24:15.350213 - Block 1: assessment report ema/464842/2024 page 116/195...
2025-12-16T12:24:15.350779 - Block 2: amendment 5: added the option to conduct safety assessments at a non-study centre when necessary to...
2025-12-16T12:24:15.351263 - Block 3: allow more flexibility in the event that an in-clinic visit could not be completed due to the covid-...
2025-12-16T12:24:15.351778 - Block 4: pandemic....
2025-12-16T12:24:15.352322 - Block 5: amendment 6: due to recruitment challenges and feedback received from clinical study sites, inclusio...
2025-12-16T12:24:15.352843 - Block 6: criteria were updated to enable recruitment of participants with moderately severe haemophilia b bas...
2025-12-16T12:24:15.353650 - Block 7: baseline factor activity level (factor activity level ≤2%) and hemorrhagic phenotype (≥4 bleeding ep...
2025-12-16T12:24:15.354190 - Block 8: the 6 months prior to study entry)....
2025-12-16T12:24:15.354866 - Block 9: allowed additional participants (approximately 20%) in order to provide sufficient enrollment into r...
2025-12-16T12:24:15.355453 - Block 10: which had experienced delays created by the covid-19 global pandemic....
2025-12-16T12:24:15.356079 - Block 11: based on edmc recommendation, revised to add that treatment with study intervention was to be suspen...
2025-12-16T12:24:15.356776 - Block 12: if a participant developed a presumed or confirmed symptomatic covid-19 infection due to the potenti...
2025-12-16T12:24:15.357283 - Block 13: thrombotic events....
2025-12-16T12:24:15.357783 - Block 14: amendment 7: removal of the interim analysis for futility within each participant population of inte...
2025-12-16T12:24:15.358284 - Block 15: planned after 50% of participants within each population of interest have completed the study as the...
2025-12-16T12:24:15.358991 - Block 16: analysis data cut time would be very close to the non-inhibitor cohort completions endpoint “total c...
2025-12-16T12:24:15.359601 - Block 17: factor or bypass product consumption” moved from secondary endpoints to tertiary/exploratory endpoin...
2025-12-16T12:24:15.360267 - Block 18: and removal of “percentage of participants with no treated bleeding episodes” from secondary endpoin...
2025-12-16T12:24:15.361166 - Block 19: which will however be presented as part of descriptive analysis for the primary endpoint...
2025-12-16T12:24:15.361926 - Block 20: important protocol deviations...
2025-12-16T12:24:15.362623 - Block 21: 74 (57.8%) participants had important protocol deviations reported, including those related to...
2025-12-16T12:24:15.363158 - Block 22: procedures/tests (31 participants), investigational product (25 participants), concomitant medicatio...
2025-12-16T12:24:15.363672 - Block 23: (22 participants), informed consent (18 participants), inclusion/exclusion criteria (10 participants...
2025-12-16T12:24:15.364320 - Block 24: reporting (8 participants), laboratory (4 participants), and randomization (1 participant). particip...
2025-12-16T12:24:15.364895 - Block 25: with dosing administration error protocol deviations reported a variety of different deviations that...
2025-12-16T12:24:15.365408 - Block 26: occurred typically one time and had no impact on overall efficacy or safety. participants who did no...
2025-12-16T12:24:15.366069 - Block 27: adhere to the protocol-specified washout period prior to visit 7 (1st dose of marstacimab) had no bl...
2025-12-16T12:24:15.366551 - Block 28: in the 4 weeks following visit 7, with the exception of 1 participant who had 1 treated bleed. the...
2025-12-16T12:24:15.367001 - Block 29: potential impact of this is addressed in the analysis to assess the impact of carryover effect from ...
2025-12-16T12:24:15.367493 - Block 30: there were no observed efficacy or safety effects for participants with concomitant medication or...
2025-12-16T12:24:15.367940 - Block 31: dosing/administration error protocol deviations. pros questionnaires not completed resulted in missi...
2025-12-16T12:24:15.368472 - Block 32: pro data, however, the impact of the missing data was minimal on the overall analysis of the pro dat...
2025-12-16T12:24:15.368887 - Block 33: overall, there was no observed impact to safety or efficacy due to the important protocol deviations...
2025-12-16T12:24:15.369372 - Block 34: ...
2025-12-16T12:24:15.369773 - Block 35: • baseline data...
2025-12-16T12:24:15.370243 - Block 36: participants were from asia and europe, respectively....
2025-12-16T12:24:15.370753 - Block 37: ? baseline data study b7841005 was an adult (?18 to <75 years of age) and adolescent (?12 to <18 yea...
2025-12-16T12:24:15.371602 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T12:24:15.372798 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T12:24:15.412656 - Scanning Page 115...
2025-12-16T12:24:15.418543 - Found 19 blocks on page.
2025-12-16T12:24:15.419167 - Block 0: ...
2025-12-16T12:24:15.419839 - Block 1: assessment report ema/464842/2024 page 115/195...
2025-12-16T12:24:15.420556 - Block 2: ...
2025-12-16T12:24:15.421080 - Block 3: • recruitment...
2025-12-16T12:24:15.421592 - Block 4: first patient first visit (fpfv): 09 march 2020...
2025-12-16T12:24:15.422014 - Block 5: data cutoff date (lplv for non-inhibitor cohort): 17 april 2023...
2025-12-16T12:24:15.422529 - Block 6: ...
2025-12-16T12:24:15.422993 - Block 7: • conduct of the study...
2025-12-16T12:24:15.423458 - Block 8: the study protocol was amended a total of 7 times. notably, 5 of the amendments were introduced afte...
2025-12-16T12:24:15.423931 - Block 9: study initiation date (fpfv) of 09 march 2020....
2025-12-16T12:24:15.424392 - Block 10: table 25: protocol amendments summary of changes table...
2025-12-16T12:24:15.424900 - Block 11: ...
2025-12-16T12:24:15.425365 - Block 12: a brief summary of the most important protocol amendment changes is provided below:...
2025-12-16T12:24:15.425774 - Block 13: amendment 1 and amendment 2 included changes to the protocol before study initiation (09 march 2020)...
2025-12-16T12:24:15.426131 - Block 14: amendment 3: included participation of prior prophylaxis participants in the us and canada following...
2025-12-16T12:24:15.426460 - Block 15: read-out of safety data provided from the phase 2 program....
2025-12-16T12:24:15.426797 - Block 16: amendment 4: for dose modification requirements a minimum body weight of 50 kg was added to allow...
2025-12-16T12:24:15.427190 - Block 17: dose escalation to 300 mg qw. new appendix added to the protocol detailing alternative study procedu...
2025-12-16T12:24:15.427888 - Block 18: be followed during the covid-19 global pandemic....
2025-12-16T12:24:15.428550 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T12:24:15.428983 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T12:24:15.441207 - Scanning Page 117...
2025-12-16T12:24:15.446900 - Found 21 blocks on page.
2025-12-16T12:24:15.447449 - Block 0: ...
2025-12-16T12:24:15.448096 - Block 1: assessment report ema/464842/2024 page 117/195...
2025-12-16T12:24:15.448605 - Block 2: demographic characteristics for participants are summarized in table 26 below. table 27 summarises...
2025-12-16T12:24:15.449079 - Block 3: participant haemophilia history by haemophilia type, target joint, and geographical region....
2025-12-16T12:24:15.449564 - Block 4: target joints are defined as major joints (eg, hip, elbow, wrist, shoulder, knee, and ankle) into wh...
2025-12-16T12:24:15.450399 - Block 5: repeated bleeds occur (3 or more spontaneous bleeds into a single joint within a consecutive 6-month...
2025-12-16T12:24:15.450790 - Block 6: period). target joints are a contributing factor to bleeding phenotype, eg, the bleeds from a single...
2025-12-16T12:24:15.451206 - Block 7: joint would count toward a participant having an abr of at least 6, the bleeds from 2target joints w...
2025-12-16T12:24:15.451621 - Block 8: toward a participant having an abr of at least 12, and the bleeds from 3 or more target joints would...
2025-12-16T12:24:15.452023 - Block 9: toward a participant having an abr of at least 18....
2025-12-16T12:24:15.452440 - Block 10: overall, across participants without inhibitors in study b7841005:...
2025-12-16T12:24:15.452934 - Block 11: ▪ 101 (78.9%) participants had haemophilia a and 27 (21.1%) participants had haemophilia b. ▪ 108 (8...
2025-12-16T12:24:15.453435 - Block 12: all 128 participants were male with a median age of 30.0 years and individual values ranged from 13....
2025-12-16T12:24:15.453859 - Block 13: 66.0 years. the majority of participants (78, 60.9%) were in the 18-44 age range....
2025-12-16T12:24:15.454322 - Block 14: the median participant weight was 70.7 kg (range: 35.0 to 120.0 kg) and the median participant bmi w...
2025-12-16T12:24:15.454717 - Block 15: 24.1 kg/m2 (range: 15.2 to 38.8 kg/m2). the median participant height was 170.1 cm (range: 141.0 to ...
2025-12-16T12:24:15.455158 - Block 16: cm)....
2025-12-16T12:24:15.455673 - Block 17: most participants (100, 78.1%) had normal renal function (egfr ≥90 ml/min/1.73 m2), while 24 (18.8%)...
2025-12-16T12:24:15.456354 - Block 18: participants had mild renal impairment (egfr ≥60 to <90 ml/min/1.73 m2) and 1 (0.8%) participant had...
2025-12-16T12:24:15.456867 - Block 19: moderate renal impairment (egfr 30 to <60 ml/min/1.73 m2)....
2025-12-16T12:24:15.457322 - Block 20: table 26: baseline and demographic characteristics – all safety set...
2025-12-16T12:24:15.458114 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T12:24:15.458619 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T12:24:15.474292 - ERROR: Start anchor not found on pages [116, 115, 117]
2025-12-16T12:24:15.474963 - CRITICAL ERROR: Start anchor not found on pages [116, 115, 117]
2025-12-16T12:26:11.520402 - --- START REPLACEMENT on Page 80 ---
2025-12-16T12:26:11.520989 - Input Start Anchor (200 chars): effect of ada and nab on pd data profiles of key pharmacodynamic endpoints ie, tfpi (total), tga pea...
2025-12-16T12:26:11.531425 - Search Strategy: Checking pages [80, 79, 81]
2025-12-16T12:26:11.532019 - Scanning Page 80...
2025-12-16T12:26:11.545075 - Found 23 blocks on page.
2025-12-16T12:26:11.545654 - Block 0: ...
2025-12-16T12:26:11.546336 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-16T12:26:11.546861 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-16T12:26:11.547341 - Block 3: adolescents (150 mg sc)....
2025-12-16T12:26:11.547798 - Block 4: ...
2025-12-16T12:26:11.548250 - Block 5: d) total tfpi:...
2025-12-16T12:26:11.548774 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-16T12:26:11.549251 - Block 7: dose group and age group (b7841005)...
2025-12-16T12:26:11.549740 - Block 8: ...
2025-12-16T12:26:11.550274 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-16T12:26:11.550827 - Block 10: (150 mg sc)....
2025-12-16T12:26:11.551348 - Block 11: ...
2025-12-16T12:26:11.551842 - Block 12: effect of ada and nab on pd data...
2025-12-16T12:26:11.552327 - Block 13: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-16T12:26:11.552877 - Block 14: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-16T12:26:11.553449 - Block 15: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-16T12:26:11.554002 - Block 16: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-16T12:26:11.554423 - Block 17: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-16T12:26:11.554901 - Block 18: between ada positive and ada negative participants....
2025-12-16T12:26:11.555328 - Block 19: ...
2025-12-16T12:26:11.556153 - Block 20: ...
2025-12-16T12:26:11.556622 - Block 21: ...
2025-12-16T12:26:11.557001 - Block 22: ...
2025-12-16T12:26:11.557465 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T12:26:11.557819 - Sanitized End: re comparable between ada positive and ada negativ...
2025-12-16T12:26:11.569067 - Scanning Page 79...
2025-12-16T12:26:11.571676 - Found 12 blocks on page.
2025-12-16T12:26:11.572229 - Block 0: ...
2025-12-16T12:26:11.572689 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T12:26:11.573460 - Block 2: b) pf 1+2:...
2025-12-16T12:26:11.573871 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T12:26:11.574224 - Block 4: group (b7841005)...
2025-12-16T12:26:11.574820 - Block 5: ...
2025-12-16T12:26:11.575288 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T12:26:11.575747 - Block 7: adolescents (150 mg sc)....
2025-12-16T12:26:11.576152 - Block 8: c) d-dimer:...
2025-12-16T12:26:11.576647 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T12:26:11.577070 - Block 10: group (b7841005)...
2025-12-16T12:26:11.577446 - Block 11: ...
2025-12-16T12:26:11.577961 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T12:26:11.578317 - Sanitized End: re comparable between ada positive and ada negativ...
2025-12-16T12:26:11.582734 - Scanning Page 81...
2025-12-16T12:26:11.586555 - Found 24 blocks on page.
2025-12-16T12:26:11.587024 - Block 0: ...
2025-12-16T12:26:11.587642 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-16T12:26:11.588023 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-16T12:26:11.588527 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-16T12:26:11.588994 - Block 4: ...
2025-12-16T12:26:11.589488 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-16T12:26:11.590011 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-16T12:26:11.590440 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-16T12:26:11.590838 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-16T12:26:11.591277 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-16T12:26:11.591850 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-16T12:26:11.592309 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-16T12:26:11.592736 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-16T12:26:11.593127 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-16T12:26:11.593486 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-16T12:26:11.593787 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-16T12:26:11.594079 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-16T12:26:11.594625 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-16T12:26:11.595051 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-16T12:26:11.595415 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-16T12:26:11.595705 - Block 20: parameters....
2025-12-16T12:26:11.595990 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-16T12:26:11.596369 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-16T12:26:11.596664 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-16T12:26:11.597059 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T12:26:11.597549 - Sanitized End: re comparable between ada positive and ada negativ...
2025-12-16T12:26:11.617823 - ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-16T12:26:11.618320 - CRITICAL ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-16T12:37:02.100663 - --- START REPLACEMENT on Page 116 ---
2025-12-16T12:37:02.101205 - Input Start Anchor (200 chars): • baseline data study b7841005 was an adult (≥18 to <75 years of age) and adolescent (≥12 to <18 yea...
2025-12-16T12:37:02.113279 - Search Strategy: Checking pages [116, 115, 117]
2025-12-16T12:37:02.113866 - Scanning Page 116...
2025-12-16T12:37:02.139718 - Found 38 blocks on page.
2025-12-16T12:37:02.140230 - Block 0: ...
2025-12-16T12:37:02.140745 - Block 1: assessment report ema/464842/2024 page 116/195...
2025-12-16T12:37:02.141257 - Block 2: amendment 5: added the option to conduct safety assessments at a non-study centre when necessary to...
2025-12-16T12:37:02.141773 - Block 3: allow more flexibility in the event that an in-clinic visit could not be completed due to the covid-...
2025-12-16T12:37:02.142349 - Block 4: pandemic....
2025-12-16T12:37:02.142824 - Block 5: amendment 6: due to recruitment challenges and feedback received from clinical study sites, inclusio...
2025-12-16T12:37:02.143302 - Block 6: criteria were updated to enable recruitment of participants with moderately severe haemophilia b bas...
2025-12-16T12:37:02.143778 - Block 7: baseline factor activity level (factor activity level ≤2%) and hemorrhagic phenotype (≥4 bleeding ep...
2025-12-16T12:37:02.144344 - Block 8: the 6 months prior to study entry)....
2025-12-16T12:37:02.144822 - Block 9: allowed additional participants (approximately 20%) in order to provide sufficient enrollment into r...
2025-12-16T12:37:02.145620 - Block 10: which had experienced delays created by the covid-19 global pandemic....
2025-12-16T12:37:02.146323 - Block 11: based on edmc recommendation, revised to add that treatment with study intervention was to be suspen...
2025-12-16T12:37:02.146997 - Block 12: if a participant developed a presumed or confirmed symptomatic covid-19 infection due to the potenti...
2025-12-16T12:37:02.147657 - Block 13: thrombotic events....
2025-12-16T12:37:02.148190 - Block 14: amendment 7: removal of the interim analysis for futility within each participant population of inte...
2025-12-16T12:37:02.148580 - Block 15: planned after 50% of participants within each population of interest have completed the study as the...
2025-12-16T12:37:02.149088 - Block 16: analysis data cut time would be very close to the non-inhibitor cohort completions endpoint “total c...
2025-12-16T12:37:02.149612 - Block 17: factor or bypass product consumption” moved from secondary endpoints to tertiary/exploratory endpoin...
2025-12-16T12:37:02.150093 - Block 18: and removal of “percentage of participants with no treated bleeding episodes” from secondary endpoin...
2025-12-16T12:37:02.150528 - Block 19: which will however be presented as part of descriptive analysis for the primary endpoint...
2025-12-16T12:37:02.150958 - Block 20: important protocol deviations...
2025-12-16T12:37:02.151320 - Block 21: 74 (57.8%) participants had important protocol deviations reported, including those related to...
2025-12-16T12:37:02.151801 - Block 22: procedures/tests (31 participants), investigational product (25 participants), concomitant medicatio...
2025-12-16T12:37:02.152215 - Block 23: (22 participants), informed consent (18 participants), inclusion/exclusion criteria (10 participants...
2025-12-16T12:37:02.152629 - Block 24: reporting (8 participants), laboratory (4 participants), and randomization (1 participant). particip...
2025-12-16T12:37:02.153061 - Block 25: with dosing administration error protocol deviations reported a variety of different deviations that...
2025-12-16T12:37:02.154022 - Block 26: occurred typically one time and had no impact on overall efficacy or safety. participants who did no...
2025-12-16T12:37:02.154780 - Block 27: adhere to the protocol-specified washout period prior to visit 7 (1st dose of marstacimab) had no bl...
2025-12-16T12:37:02.155185 - Block 28: in the 4 weeks following visit 7, with the exception of 1 participant who had 1 treated bleed. the...
2025-12-16T12:37:02.155665 - Block 29: potential impact of this is addressed in the analysis to assess the impact of carryover effect from ...
2025-12-16T12:37:02.156071 - Block 30: there were no observed efficacy or safety effects for participants with concomitant medication or...
2025-12-16T12:37:02.156620 - Block 31: dosing/administration error protocol deviations. pros questionnaires not completed resulted in missi...
2025-12-16T12:37:02.156990 - Block 32: pro data, however, the impact of the missing data was minimal on the overall analysis of the pro dat...
2025-12-16T12:37:02.157365 - Block 33: overall, there was no observed impact to safety or efficacy due to the important protocol deviations...
2025-12-16T12:37:02.157881 - Block 34: ...
2025-12-16T12:37:02.158257 - Block 35: • baseline data...
2025-12-16T12:37:02.158619 - Block 36: participants were from asia and europe, respectively....
2025-12-16T12:37:02.159049 - Block 37: ? baseline data study b7841005 was an adult (?18 to <75 years of age) and adolescent (?12 to <18 yea...
2025-12-16T12:37:02.159695 - Sanitized Start: • baseline data study b7841005 was an adult (≥18 t...
2025-12-16T12:37:02.160087 - Sanitized End: hite (65, 50.8%) and asian (61, 47.7%), with 1 bla...
2025-12-16T12:37:02.204745 - Found Start (Inverse Fuzzy Prefix 1.00) at block 35
2025-12-16T12:37:02.205535 - Found End (Suffix) at block 36
2025-12-16T12:37:02.206200 - MATCH FOUND on Page 116: 35-36
2025-12-16T12:37:02.213214 - Replacing blocks 35 to 36
2025-12-16T12:37:02.225410 - Detected Font Size: 9.0
2025-12-16T12:37:02.304107 - Failed size 9.0 (Justified)
2025-12-16T12:37:02.306581 - Failed size 8.5 (Justified)
2025-12-16T12:37:02.308405 - Failed size 8.0 (Justified)
2025-12-16T12:37:02.310416 - Failed size 7.5 (Justified)
2025-12-16T12:37:02.317966 - Inserted with size 7.0 (Justified)
2025-12-16T12:37:02.522024 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpad1d2_79.pdf
2025-12-16T12:40:00.191168 - --- START REPLACEMENT on Page 78 ---
2025-12-16T12:40:00.191917 - Input Start Anchor (200 chars): pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-16T12:40:00.204132 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T12:40:00.204790 - Scanning Page 78...
2025-12-16T12:40:00.212272 - Found 3 blocks on page.
2025-12-16T12:40:00.213097 - Block 0: ...
2025-12-16T12:40:00.213667 - Block 1: ...
2025-12-16T12:40:00.214211 - Block 2: ...
2025-12-16T12:40:00.214830 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T12:40:00.215432 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T12:40:00.216017 - Scanning Page 77...
2025-12-16T12:40:00.223308 - Found 14 blocks on page.
2025-12-16T12:40:00.223979 - Block 0: ...
2025-12-16T12:40:00.224785 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T12:40:00.225336 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T12:40:00.225822 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T12:40:00.226311 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T12:40:00.226818 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T12:40:00.227316 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T12:40:00.227765 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T12:40:00.228349 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T12:40:00.228839 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T12:40:00.229235 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T12:40:00.229601 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T12:40:00.229977 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T12:40:00.230334 - Block 13: ...
2025-12-16T12:40:00.230759 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T12:40:00.231077 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T12:40:00.246845 - Scanning Page 79...
2025-12-16T12:40:00.248673 - Found 12 blocks on page.
2025-12-16T12:40:00.249108 - Block 0: ...
2025-12-16T12:40:00.249579 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T12:40:00.250063 - Block 2: b) pf 1+2:...
2025-12-16T12:40:00.250529 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T12:40:00.251090 - Block 4: group (b7841005)...
2025-12-16T12:40:00.251716 - Block 5: ...
2025-12-16T12:40:00.252099 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T12:40:00.252501 - Block 7: adolescents (150 mg sc)....
2025-12-16T12:40:00.252855 - Block 8: c) d-dimer:...
2025-12-16T12:40:00.253411 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T12:40:00.253839 - Block 10: group (b7841005)...
2025-12-16T12:40:00.254339 - Block 11: ...
2025-12-16T12:40:00.254856 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T12:40:00.255476 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T12:40:00.261367 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T12:40:00.261818 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T12:49:09.115995 - --- START REPLACEMENT on Page 78 ---
2025-12-16T12:49:09.117334 - Input Start Anchor (200 chars): pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-16T12:49:09.129375 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T12:49:09.129804 - Scanning Page 78...
2025-12-16T12:49:09.137178 - Found 3 blocks on page.
2025-12-16T12:49:09.138082 - Block 0: ...
2025-12-16T12:49:09.138507 - Block 1: ...
2025-12-16T12:49:09.138796 - Block 2: ...
2025-12-16T12:49:09.139172 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T12:49:09.139603 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T12:49:09.140005 - Scanning Page 77...
2025-12-16T12:49:09.146055 - Found 14 blocks on page.
2025-12-16T12:49:09.146477 - Block 0: ...
2025-12-16T12:49:09.147012 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T12:49:09.147425 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T12:49:09.147808 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T12:49:09.148269 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T12:49:09.148641 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T12:49:09.149024 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T12:49:09.149358 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T12:49:09.149751 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T12:49:09.150281 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T12:49:09.150830 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T12:49:09.151278 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T12:49:09.151688 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T12:49:09.152298 - Block 13: ...
2025-12-16T12:49:09.152844 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T12:49:09.153218 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T12:49:09.164557 - Scanning Page 79...
2025-12-16T12:49:09.167564 - Found 12 blocks on page.
2025-12-16T12:49:09.168042 - Block 0: ...
2025-12-16T12:49:09.168483 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T12:49:09.168959 - Block 2: b) pf 1+2:...
2025-12-16T12:49:09.169419 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T12:49:09.169902 - Block 4: group (b7841005)...
2025-12-16T12:49:09.170439 - Block 5: ...
2025-12-16T12:49:09.170896 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T12:49:09.171382 - Block 7: adolescents (150 mg sc)....
2025-12-16T12:49:09.171855 - Block 8: c) d-dimer:...
2025-12-16T12:49:09.173149 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T12:49:09.173635 - Block 10: group (b7841005)...
2025-12-16T12:49:09.174137 - Block 11: ...
2025-12-16T12:49:09.174681 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T12:49:09.175092 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T12:49:09.182851 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T12:49:09.183409 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T12:54:15.541715 - --- START REPLACEMENT on Page 78 ---
2025-12-16T12:54:15.543513 - Input Start Anchor (200 chars): pd results of phase 2 study b7841003 (extension of study b7841002) consistent with the pd results se...
2025-12-16T12:54:15.601367 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T12:54:15.601834 - Scanning Page 78...
2025-12-16T12:54:15.609744 - Found 3 blocks on page.
2025-12-16T12:54:15.610244 - Block 0: ...
2025-12-16T12:54:15.610690 - Block 1: ...
2025-12-16T12:54:15.611093 - Block 2: ...
2025-12-16T12:54:15.611660 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T12:54:15.612078 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T12:54:15.612612 - Scanning Page 77...
2025-12-16T12:54:15.620165 - Found 14 blocks on page.
2025-12-16T12:54:15.620657 - Block 0: ...
2025-12-16T12:54:15.621096 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T12:54:15.621542 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T12:54:15.622007 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T12:54:15.622455 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T12:54:15.622848 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T12:54:15.623254 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T12:54:15.623626 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T12:54:15.624017 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T12:54:15.624565 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T12:54:15.625014 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T12:54:15.625381 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T12:54:15.625854 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T12:54:15.626208 - Block 13: ...
2025-12-16T12:54:15.626703 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T12:54:15.627068 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T12:54:15.637648 - Scanning Page 79...
2025-12-16T12:54:15.640308 - Found 12 blocks on page.
2025-12-16T12:54:15.640806 - Block 0: ...
2025-12-16T12:54:15.641302 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T12:54:15.641778 - Block 2: b) pf 1+2:...
2025-12-16T12:54:15.642388 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T12:54:15.642891 - Block 4: group (b7841005)...
2025-12-16T12:54:15.643354 - Block 5: ...
2025-12-16T12:54:15.643812 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T12:54:15.644281 - Block 7: adolescents (150 mg sc)....
2025-12-16T12:54:15.644695 - Block 8: c) d-dimer:...
2025-12-16T12:54:15.645714 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T12:54:15.646071 - Block 10: group (b7841005)...
2025-12-16T12:54:15.646493 - Block 11: ...
2025-12-16T12:54:15.646897 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T12:54:15.647225 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T12:54:15.652949 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T12:54:15.653305 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T13:24:48.706711 - --- START REPLACEMENT on Page 1 ---
2025-12-16T13:24:48.709028 - Input Start Anchor (200 chars): 1000 mg/kg/week groups after a 6-week recovery period. in the glp-compliant study 20089324, the toxi...
2025-12-16T13:24:48.857037 - Search Strategy: Checking pages [1, 2]
2025-12-16T13:24:48.858360 - Scanning Page 1...
2025-12-16T13:24:48.885090 - Found 12 blocks on page.
2025-12-16T13:24:48.886476 - Block 0: ...
2025-12-16T13:24:48.887831 - Block 1: ...
2025-12-16T13:24:48.889265 - Block 2: official address domenico scarlattilaan 6 ● 1083 hs amsterdam ● the netherlands...
2025-12-16T13:24:48.890487 - Block 3: an agency of the european union address for visits and deliveries refer to www.ema.europa.eu/how-to-...
2025-12-16T13:24:48.891922 - Block 4: © european medicines agency, 2024. reproduction is authorised provided the source is acknowledged....
2025-12-16T13:24:48.893192 - Block 5: 19 september 2024 ema/464842/2024 committee for medicinal products for human use (chmp)...
2025-12-16T13:24:48.894241 - Block 6: assessment report...
2025-12-16T13:24:48.895075 - Block 7: hympavzi...
2025-12-16T13:24:48.895912 - Block 8: international non-proprietary name: marstacimab...
2025-12-16T13:24:48.899082 - Block 9: procedure no. emea/h/c/006240/0000...
2025-12-16T13:24:48.901871 - Block 10: note...
2025-12-16T13:24:48.903173 - Block 11: assessment report as adopted by the chmp with all information of a commercially confidential nature ...
2025-12-16T13:24:48.904477 - Sanitized Start: 1000 mg/kg/week groups after a 6-week recovery per...
2025-12-16T13:24:48.905516 - Sanitized End: (i.v. and s.c.) turned out to be the studies’ noae...
2025-12-16T13:24:48.932760 - Scanning Page 2...
2025-12-16T13:24:48.954020 - Found 15 blocks on page.
2025-12-16T13:24:48.955092 - Block 0: ...
2025-12-16T13:24:48.955962 - Block 1: assessment report ema/464842/2024 page 2/195...
2025-12-16T13:24:48.957430 - Block 2: table of contents...
2025-12-16T13:24:48.958408 - Block 3: 1. background information on the procedure ............................................ 11...
2025-12-16T13:24:48.959261 - Block 4: 1.1. submission of the dossier ........................................................................
2025-12-16T13:24:48.960313 - Block 5: 1.5. applicant’s request for consideration ............................................................
2025-12-16T13:24:48.961169 - Block 6: 2. scientific discussion ..............................................................................
2025-12-16T13:24:48.962404 - Block 7: 2.1. problem statement ................................................................................
2025-12-16T13:24:48.963631 - Block 8: 2.1.5. management .....................................................................................
2025-12-16T13:24:48.964764 - Block 9: 2.4.2. active substance ...............................................................................
2025-12-16T13:24:48.965729 - Block 10: 2.5. non-clinical aspects .............................................................................
2025-12-16T13:24:48.967235 - Block 11: 2.5.5. ecotoxicity/environmental risk assessment ......................................................
2025-12-16T13:24:48.968286 - Block 12: 2.5.6. discussion on non-clinical aspects .............................................................
2025-12-16T13:24:48.969090 - Block 13: 2.6.3. discussion on clinical pharmacology ............................................................
2025-12-16T13:24:48.969836 - Block 14: 2.6.4. conclusions on clinical pharmacology ...........................................................
2025-12-16T13:24:48.970881 - Sanitized Start: 1000 mg/kg/week groups after a 6-week recovery per...
2025-12-16T13:24:48.971728 - Sanitized End: (i.v. and s.c.) turned out to be the studies’ noae...
2025-12-16T13:24:49.004076 - ERROR: Start anchor not found on pages [1, 2]
2025-12-16T13:24:49.004976 - CRITICAL ERROR: Start anchor not found on pages [1, 2]
2025-12-16T13:25:25.364847 - --- START REPLACEMENT on Page 1 ---
2025-12-16T13:25:25.365965 - Input Start Anchor (200 chars): 1000 mg/kg/week groups after a 6-week recovery period. in the glp-compliant study 20089324, the toxi...
2025-12-16T13:25:25.387085 - Search Strategy: Checking pages [1, 2]
2025-12-16T13:25:25.388120 - Scanning Page 1...
2025-12-16T13:25:25.411582 - Found 12 blocks on page.
2025-12-16T13:25:25.412313 - Block 0: ...
2025-12-16T13:25:25.412934 - Block 1: ...
2025-12-16T13:25:25.413674 - Block 2: official address domenico scarlattilaan 6 ● 1083 hs amsterdam ● the netherlands...
2025-12-16T13:25:25.414475 - Block 3: an agency of the european union address for visits and deliveries refer to www.ema.europa.eu/how-to-...
2025-12-16T13:25:25.415266 - Block 4: © european medicines agency, 2024. reproduction is authorised provided the source is acknowledged....
2025-12-16T13:25:25.416019 - Block 5: 19 september 2024 ema/464842/2024 committee for medicinal products for human use (chmp)...
2025-12-16T13:25:25.416764 - Block 6: assessment report...
2025-12-16T13:25:25.417498 - Block 7: hympavzi...
2025-12-16T13:25:25.418264 - Block 8: international non-proprietary name: marstacimab...
2025-12-16T13:25:25.418992 - Block 9: procedure no. emea/h/c/006240/0000...
2025-12-16T13:25:25.419837 - Block 10: note...
2025-12-16T13:25:25.420628 - Block 11: assessment report as adopted by the chmp with all information of a commercially confidential nature ...
2025-12-16T13:25:25.421660 - Sanitized Start: 1000 mg/kg/week groups after a 6-week recovery per...
2025-12-16T13:25:25.422426 - Sanitized End: (i.v. and s.c.) turned out to be the studies’ noae...
2025-12-16T13:25:25.441703 - Scanning Page 2...
2025-12-16T13:25:25.456104 - Found 15 blocks on page.
2025-12-16T13:25:25.456791 - Block 0: ...
2025-12-16T13:25:25.457485 - Block 1: assessment report ema/464842/2024 page 2/195...
2025-12-16T13:25:25.458062 - Block 2: table of contents...
2025-12-16T13:25:25.458708 - Block 3: 1. background information on the procedure ............................................ 11...
2025-12-16T13:25:25.459444 - Block 4: 1.1. submission of the dossier ........................................................................
2025-12-16T13:25:25.460140 - Block 5: 1.5. applicant’s request for consideration ............................................................
2025-12-16T13:25:25.461291 - Block 6: 2. scientific discussion ..............................................................................
2025-12-16T13:25:25.462436 - Block 7: 2.1. problem statement ................................................................................
2025-12-16T13:25:25.463334 - Block 8: 2.1.5. management .....................................................................................
2025-12-16T13:25:25.464665 - Block 9: 2.4.2. active substance ...............................................................................
2025-12-16T13:25:25.465559 - Block 10: 2.5. non-clinical aspects .............................................................................
2025-12-16T13:25:25.466344 - Block 11: 2.5.5. ecotoxicity/environmental risk assessment ......................................................
2025-12-16T13:25:25.467565 - Block 12: 2.5.6. discussion on non-clinical aspects .............................................................
2025-12-16T13:25:25.468633 - Block 13: 2.6.3. discussion on clinical pharmacology ............................................................
2025-12-16T13:25:25.469372 - Block 14: 2.6.4. conclusions on clinical pharmacology ...........................................................
2025-12-16T13:25:25.470181 - Sanitized Start: 1000 mg/kg/week groups after a 6-week recovery per...
2025-12-16T13:25:25.470839 - Sanitized End: (i.v. and s.c.) turned out to be the studies’ noae...
2025-12-16T13:25:25.492736 - ERROR: Start anchor not found on pages [1, 2]
2025-12-16T13:25:25.493389 - CRITICAL ERROR: Start anchor not found on pages [1, 2]
2025-12-16T13:28:56.357033 - --- START REPLACEMENT on Page 1 ---
2025-12-16T13:28:56.359510 - Input Start Anchor (200 chars): 1000 mg/kg/week groups after a 6-week recovery period. in the glp-compliant study 20089324, the toxi...
2025-12-16T13:28:56.408945 - Search Strategy: Checking pages [1, 2]
2025-12-16T13:28:56.409669 - Scanning Page 1...
2025-12-16T13:28:56.488721 - Found 12 blocks on page.
2025-12-16T13:28:56.489473 - Block 0: ...
2025-12-16T13:28:56.490540 - Block 1: ...
2025-12-16T13:28:56.492649 - Block 2: official address domenico scarlattilaan 6 ● 1083 hs amsterdam ● the netherlands...
2025-12-16T13:28:56.494224 - Block 3: an agency of the european union address for visits and deliveries refer to www.ema.europa.eu/how-to-...
2025-12-16T13:28:56.495126 - Block 4: © european medicines agency, 2024. reproduction is authorised provided the source is acknowledged....
2025-12-16T13:28:56.495858 - Block 5: 19 september 2024 ema/464842/2024 committee for medicinal products for human use (chmp)...
2025-12-16T13:28:56.496763 - Block 6: assessment report...
2025-12-16T13:28:56.497492 - Block 7: hympavzi...
2025-12-16T13:28:56.498106 - Block 8: international non-proprietary name: marstacimab...
2025-12-16T13:28:56.498761 - Block 9: procedure no. emea/h/c/006240/0000...
2025-12-16T13:28:56.499388 - Block 10: note...
2025-12-16T13:28:56.500041 - Block 11: assessment report as adopted by the chmp with all information of a commercially confidential nature ...
2025-12-16T13:28:56.500967 - Sanitized Start: 1000 mg/kg/week groups after a 6-week recovery per...
2025-12-16T13:28:56.501567 - Sanitized End: (i.v. and s.c.) turned out to be the studies’ noae...
2025-12-16T13:28:56.530067 - Scanning Page 2...
2025-12-16T13:28:56.553434 - Found 15 blocks on page.
2025-12-16T13:28:56.554140 - Block 0: ...
2025-12-16T13:28:56.554922 - Block 1: assessment report ema/464842/2024 page 2/195...
2025-12-16T13:28:56.555635 - Block 2: table of contents...
2025-12-16T13:28:56.556551 - Block 3: 1. background information on the procedure ............................................ 11...
2025-12-16T13:28:56.557240 - Block 4: 1.1. submission of the dossier ........................................................................
2025-12-16T13:28:56.559433 - Block 5: 1.5. applicant’s request for consideration ............................................................
2025-12-16T13:28:56.560508 - Block 6: 2. scientific discussion ..............................................................................
2025-12-16T13:28:56.561413 - Block 7: 2.1. problem statement ................................................................................
2025-12-16T13:28:56.562242 - Block 8: 2.1.5. management .....................................................................................
2025-12-16T13:28:56.563057 - Block 9: 2.4.2. active substance ...............................................................................
2025-12-16T13:28:56.563779 - Block 10: 2.5. non-clinical aspects .............................................................................
2025-12-16T13:28:56.564615 - Block 11: 2.5.5. ecotoxicity/environmental risk assessment ......................................................
2025-12-16T13:28:56.565532 - Block 12: 2.5.6. discussion on non-clinical aspects .............................................................
2025-12-16T13:28:56.566185 - Block 13: 2.6.3. discussion on clinical pharmacology ............................................................
2025-12-16T13:28:56.566824 - Block 14: 2.6.4. conclusions on clinical pharmacology ...........................................................
2025-12-16T13:28:56.567687 - Sanitized Start: 1000 mg/kg/week groups after a 6-week recovery per...
2025-12-16T13:28:56.568336 - Sanitized End: (i.v. and s.c.) turned out to be the studies’ noae...
2025-12-16T13:28:56.613550 - ERROR: Start anchor not found on pages [1, 2]
2025-12-16T13:28:56.614355 - CRITICAL ERROR: Start anchor not found on pages [1, 2]
2025-12-16T14:45:10.421910 - --- START REPLACEMENT on Page 2 ---
2025-12-16T14:45:10.423391 - Input Start Anchor (197 chars): table of contents 1. background information on the procedure ..........................................
2025-12-16T14:45:10.476967 - Search Strategy: Checking pages [2, 1, 3]
2025-12-16T14:45:10.477653 - Scanning Page 2...
2025-12-16T14:45:10.498558 - Found 15 blocks on page.
2025-12-16T14:45:10.499262 - Block 0: ...
2025-12-16T14:45:10.499811 - Block 1: assessment report ema/464842/2024 page 2/195...
2025-12-16T14:45:10.500697 - Block 2: table of contents...
2025-12-16T14:45:10.501268 - Block 3: 1. background information on the procedure ............................................ 11...
2025-12-16T14:45:10.501925 - Block 4: 1.1. submission of the dossier ........................................................................
2025-12-16T14:45:10.502419 - Block 5: 1.5. applicant’s request for consideration ............................................................
2025-12-16T14:45:10.502799 - Block 6: 2. scientific discussion ..............................................................................
2025-12-16T14:45:10.503242 - Block 7: 2.1. problem statement ................................................................................
2025-12-16T14:45:10.503676 - Block 8: 2.1.5. management .....................................................................................
2025-12-16T14:45:10.504320 - Block 9: 2.4.2. active substance ...............................................................................
2025-12-16T14:45:10.504929 - Block 10: 2.5. non-clinical aspects .............................................................................
2025-12-16T14:45:10.505330 - Block 11: 2.5.5. ecotoxicity/environmental risk assessment ......................................................
2025-12-16T14:45:10.505906 - Block 12: 2.5.6. discussion on non-clinical aspects .............................................................
2025-12-16T14:45:10.506393 - Block 13: 2.6.3. discussion on clinical pharmacology ............................................................
2025-12-16T14:45:10.506918 - Block 14: 2.6.4. conclusions on clinical pharmacology ...........................................................
2025-12-16T14:45:10.507402 - Sanitized Start: table of contents 1. background information on the...
2025-12-16T14:45:10.508041 - Sanitized End: ...................................... 2.1.1. dise...
2025-12-16T14:45:10.509511 - Found Start (Inverse Fuzzy Prefix 1.00) at block 2
2025-12-16T14:45:10.510106 - Found End (Suffix) at block 3
2025-12-16T14:45:10.510634 - MATCH FOUND on Page 2: 2-3
2025-12-16T14:45:10.518186 - Replacing blocks 2 to 3
2025-12-16T14:45:10.531341 - Detected Font Size: 13.5
2025-12-16T14:45:10.549878 - Error inserting 13.5: need font file or buffer
2025-12-16T14:45:10.551732 - Error inserting 13.0: need font file or buffer
2025-12-16T14:45:10.553352 - Error inserting 12.5: need font file or buffer
2025-12-16T14:45:10.555000 - Error inserting 12.0: need font file or buffer
2025-12-16T14:45:10.556462 - Error inserting 11.5: need font file or buffer
2025-12-16T14:45:10.558060 - Error inserting 11.0: need font file or buffer
2025-12-16T14:45:10.559864 - Error inserting 10.5: need font file or buffer
2025-12-16T14:45:10.561529 - Error inserting 10.0: need font file or buffer
2025-12-16T14:45:10.563244 - Error inserting 9.5: need font file or buffer
2025-12-16T14:45:10.565537 - Error inserting 9.0: need font file or buffer
2025-12-16T14:45:10.567425 - Error inserting 8.5: need font file or buffer
2025-12-16T14:45:10.568894 - Error inserting 8.0: need font file or buffer
2025-12-16T14:45:10.570629 - Error inserting 7.5: need font file or buffer
2025-12-16T14:45:10.572383 - Error inserting 7.0: need font file or buffer
2025-12-16T14:45:10.574272 - Error inserting 6.5: need font file or buffer
2025-12-16T14:45:10.575582 - Error inserting 6.0: need font file or buffer
2025-12-16T14:45:10.576044 - Fallback to Left Align
2025-12-16T14:45:10.577181 - CRITICAL ERROR: need font file or buffer
2025-12-16T16:15:42.622590 - --- START REPLACEMENT on Page 78 ---
2025-12-16T16:15:42.623473 - Input Start Anchor (149 chars): PD results of phase 2 Study B7841003 (extension of Study B7841002) Consistent with the PD results se...
2025-12-16T16:15:42.667516 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T16:15:42.668364 - Scanning Page 78...
2025-12-16T16:15:42.682458 - Found 3 blocks on page.
2025-12-16T16:15:42.684588 - Block 0: ...
2025-12-16T16:15:42.685576 - Block 1: ...
2025-12-16T16:15:42.686611 - Block 2: ...
2025-12-16T16:15:42.688134 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T16:15:42.689113 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-16T16:15:42.689872 - Scanning Page 77...
2025-12-16T16:15:42.708393 - Found 14 blocks on page.
2025-12-16T16:15:42.709578 - Block 0: ...
2025-12-16T16:15:42.710568 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T16:15:42.711629 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T16:15:42.712502 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T16:15:42.713365 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T16:15:42.714265 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T16:15:42.715265 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T16:15:42.716391 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T16:15:42.717402 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T16:15:42.718912 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T16:15:42.720313 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T16:15:42.721182 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T16:15:42.722238 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T16:15:42.723517 - Block 13: ...
2025-12-16T16:15:42.725350 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T16:15:42.726567 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-16T16:15:42.748334 - Scanning Page 79...
2025-12-16T16:15:42.755290 - Found 12 blocks on page.
2025-12-16T16:15:42.756351 - Block 0: ...
2025-12-16T16:15:42.757591 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T16:15:42.758420 - Block 2: b) pf 1+2:...
2025-12-16T16:15:42.759442 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T16:15:42.760276 - Block 4: group (b7841005)...
2025-12-16T16:15:42.761215 - Block 5: ...
2025-12-16T16:15:42.762292 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T16:15:42.763253 - Block 7: adolescents (150 mg sc)....
2025-12-16T16:15:42.764048 - Block 8: c) d-dimer:...
2025-12-16T16:15:42.765716 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T16:15:42.766441 - Block 10: group (b7841005)...
2025-12-16T16:15:42.767607 - Block 11: ...
2025-12-16T16:15:42.768658 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T16:15:42.769558 - Sanitized End: inhibitor dose cohort except tga lag time. these c...
2025-12-16T16:15:42.776959 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T16:15:42.777698 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T16:58:53.336292 - --- START REPLACEMENT on Page 78 ---
2025-12-16T16:58:53.338852 - Input Start Anchor (200 chars): PD results of phase 2 Study B7841003 (extension of Study B7841002) Consistent with the PD results se...
2025-12-16T16:58:53.428627 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T16:58:53.429773 - Scanning Page 78...
2025-12-16T16:58:53.443551 - Found 3 blocks on page.
2025-12-16T16:58:53.444385 - Block 0: ...
2025-12-16T16:58:53.445224 - Block 1: ...
2025-12-16T16:58:53.445863 - Block 2: ...
2025-12-16T16:58:53.446941 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T16:58:53.447767 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T16:58:53.448429 - Scanning Page 77...
2025-12-16T16:58:53.459754 - Found 14 blocks on page.
2025-12-16T16:58:53.460941 - Block 0: ...
2025-12-16T16:58:53.461900 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T16:58:53.462868 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T16:58:53.463687 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T16:58:53.464502 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T16:58:53.465655 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T16:58:53.466845 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T16:58:53.467728 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T16:58:53.468460 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T16:58:53.470187 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T16:58:53.471169 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T16:58:53.472039 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T16:58:53.472837 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T16:58:53.473482 - Block 13: ...
2025-12-16T16:58:53.474339 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T16:58:53.474964 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T16:58:53.502232 - Scanning Page 79...
2025-12-16T16:58:53.508885 - Found 12 blocks on page.
2025-12-16T16:58:53.509962 - Block 0: ...
2025-12-16T16:58:53.511017 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T16:58:53.511707 - Block 2: b) pf 1+2:...
2025-12-16T16:58:53.512364 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T16:58:53.512922 - Block 4: group (b7841005)...
2025-12-16T16:58:53.513568 - Block 5: ...
2025-12-16T16:58:53.514029 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T16:58:53.514649 - Block 7: adolescents (150 mg sc)....
2025-12-16T16:58:53.515279 - Block 8: c) d-dimer:...
2025-12-16T16:58:53.515807 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T16:58:53.516850 - Block 10: group (b7841005)...
2025-12-16T16:58:53.517545 - Block 11: ...
2025-12-16T16:58:53.518273 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T16:58:53.519030 - Sanitized End: g inhibitor dose cohort except tga lag time. these...
2025-12-16T16:58:53.525490 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T16:58:53.526042 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T17:09:06.479683 - --- START REPLACEMENT on Page 78 ---
2025-12-16T17:09:06.480326 - Input Start Anchor (19 chars): PD results of phase...
2025-12-16T17:09:06.488448 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T17:09:06.488808 - Scanning Page 78...
2025-12-16T17:09:06.493305 - Found 3 blocks on page.
2025-12-16T17:09:06.493688 - Block 0: ...
2025-12-16T17:09:06.493976 - Block 1: ...
2025-12-16T17:09:06.494262 - Block 2: ...
2025-12-16T17:09:06.494632 - Sanitized Start: pd results of phase...
2025-12-16T17:09:06.494937 - Sanitized End: increases in pf 1+2....
2025-12-16T17:09:06.495244 - Scanning Page 77...
2025-12-16T17:09:06.500738 - Found 14 blocks on page.
2025-12-16T17:09:06.501222 - Block 0: ...
2025-12-16T17:09:06.501688 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T17:09:06.502097 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T17:09:06.502498 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T17:09:06.502846 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T17:09:06.503190 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T17:09:06.503537 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T17:09:06.503903 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T17:09:06.504195 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T17:09:06.504606 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T17:09:06.505153 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T17:09:06.505517 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T17:09:06.505853 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T17:09:06.506200 - Block 13: ...
2025-12-16T17:09:06.506607 - Sanitized Start: pd results of phase...
2025-12-16T17:09:06.506925 - Sanitized End: increases in pf 1+2....
2025-12-16T17:09:06.509020 - Scanning Page 79...
2025-12-16T17:09:06.511280 - Found 12 blocks on page.
2025-12-16T17:09:06.511695 - Block 0: ...
2025-12-16T17:09:06.512227 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T17:09:06.512578 - Block 2: b) pf 1+2:...
2025-12-16T17:09:06.512932 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T17:09:06.513247 - Block 4: group (b7841005)...
2025-12-16T17:09:06.513536 - Block 5: ...
2025-12-16T17:09:06.513983 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T17:09:06.514331 - Block 7: adolescents (150 mg sc)....
2025-12-16T17:09:06.514802 - Block 8: c) d-dimer:...
2025-12-16T17:09:06.515097 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T17:09:06.515578 - Block 10: group (b7841005)...
2025-12-16T17:09:06.515964 - Block 11: ...
2025-12-16T17:09:06.516586 - Sanitized Start: pd results of phase...
2025-12-16T17:09:06.517004 - Sanitized End: increases in pf 1+2....
2025-12-16T17:09:06.518249 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T17:09:06.518681 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T17:14:05.787356 - --- START REPLACEMENT on Page 78 ---
2025-12-16T17:14:05.788333 - Input Start Anchor (19 chars): PD results of phase...
2025-12-16T17:14:05.803462 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T17:14:05.804036 - Scanning Page 78...
2025-12-16T17:14:05.810786 - Found 3 blocks on page.
2025-12-16T17:14:05.811279 - Block 0: ...
2025-12-16T17:14:05.811902 - Block 1: ...
2025-12-16T17:14:05.812273 - Block 2: ...
2025-12-16T17:14:05.813198 - Sanitized Start: pd results of phase...
2025-12-16T17:14:05.813626 - Sanitized End: increases in pf 1+2....
2025-12-16T17:14:05.814073 - Scanning Page 77...
2025-12-16T17:14:05.821146 - Found 14 blocks on page.
2025-12-16T17:14:05.821637 - Block 0: ...
2025-12-16T17:14:05.822072 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T17:14:05.822631 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T17:14:05.823046 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T17:14:05.823483 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T17:14:05.823777 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T17:14:05.824282 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T17:14:05.824739 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T17:14:05.825243 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T17:14:05.825675 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T17:14:05.825989 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T17:14:05.826528 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T17:14:05.826996 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T17:14:05.827364 - Block 13: ...
2025-12-16T17:14:05.827892 - Sanitized Start: pd results of phase...
2025-12-16T17:14:05.828303 - Sanitized End: increases in pf 1+2....
2025-12-16T17:14:05.830143 - Scanning Page 79...
2025-12-16T17:14:05.831786 - Found 12 blocks on page.
2025-12-16T17:14:05.832122 - Block 0: ...
2025-12-16T17:14:05.832402 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T17:14:05.832697 - Block 2: b) pf 1+2:...
2025-12-16T17:14:05.833134 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T17:14:05.833404 - Block 4: group (b7841005)...
2025-12-16T17:14:05.833691 - Block 5: ...
2025-12-16T17:14:05.834104 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T17:14:05.834448 - Block 7: adolescents (150 mg sc)....
2025-12-16T17:14:05.834722 - Block 8: c) d-dimer:...
2025-12-16T17:14:05.835205 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T17:14:05.835629 - Block 10: group (b7841005)...
2025-12-16T17:14:05.835899 - Block 11: ...
2025-12-16T17:14:05.836367 - Sanitized Start: pd results of phase...
2025-12-16T17:14:05.836768 - Sanitized End: increases in pf 1+2....
2025-12-16T17:14:05.837560 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T17:14:05.837849 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T17:42:09.896613 - --- START REPLACEMENT on Page 78 ---
2025-12-16T17:42:09.897645 - Input Start Anchor (20 chars): PD results of phase ...
2025-12-16T17:42:09.941326 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T17:42:09.941838 - Scanning Page 78...
2025-12-16T17:42:09.950583 - Found 3 blocks on page.
2025-12-16T17:42:09.951093 - Block 0: ...
2025-12-16T17:42:09.951643 - Block 1: ...
2025-12-16T17:42:09.952313 - Block 2: ...
2025-12-16T17:42:09.953417 - Sanitized Start: pd results of phase...
2025-12-16T17:42:09.954641 - Sanitized End: increases in pf 1+2....
2025-12-16T17:42:09.955521 - Scanning Page 77...
2025-12-16T17:42:09.964427 - Found 14 blocks on page.
2025-12-16T17:42:09.965020 - Block 0: ...
2025-12-16T17:42:09.965539 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T17:42:09.966105 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T17:42:09.966651 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T17:42:09.967166 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T17:42:09.967708 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T17:42:09.968377 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T17:42:09.969275 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T17:42:09.970085 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T17:42:09.970909 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T17:42:09.971661 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T17:42:09.972164 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T17:42:09.972678 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T17:42:09.973344 - Block 13: ...
2025-12-16T17:42:09.974263 - Sanitized Start: pd results of phase...
2025-12-16T17:42:09.975016 - Sanitized End: increases in pf 1+2....
2025-12-16T17:42:09.976733 - Scanning Page 79...
2025-12-16T17:42:09.980324 - Found 12 blocks on page.
2025-12-16T17:42:09.980757 - Block 0: ...
2025-12-16T17:42:09.981156 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T17:42:09.981504 - Block 2: b) pf 1+2:...
2025-12-16T17:42:09.981839 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T17:42:09.982228 - Block 4: group (b7841005)...
2025-12-16T17:42:09.982612 - Block 5: ...
2025-12-16T17:42:09.983002 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T17:42:09.983412 - Block 7: adolescents (150 mg sc)....
2025-12-16T17:42:09.983786 - Block 8: c) d-dimer:...
2025-12-16T17:42:09.987405 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T17:42:09.989027 - Block 10: group (b7841005)...
2025-12-16T17:42:09.989543 - Block 11: ...
2025-12-16T17:42:09.989992 - Sanitized Start: pd results of phase...
2025-12-16T17:42:09.990513 - Sanitized End: increases in pf 1+2....
2025-12-16T17:42:09.991962 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T17:42:09.992427 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T17:49:33.561083 - --- START REPLACEMENT on Page 78 ---
2025-12-16T17:49:33.561966 - Input Start Anchor (20 chars): PD results of phase ...
2025-12-16T17:49:33.573431 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T17:49:33.573920 - Scanning Page 78...
2025-12-16T17:49:33.581969 - Found 3 blocks on page.
2025-12-16T17:49:33.582369 - Block 0: ...
2025-12-16T17:49:33.582807 - Block 1: ...
2025-12-16T17:49:33.583176 - Block 2: ...
2025-12-16T17:49:33.583643 - Sanitized Start: pd results of phase...
2025-12-16T17:49:33.584054 - Sanitized End: increases in pf 1+2....
2025-12-16T17:49:33.584475 - Scanning Page 77...
2025-12-16T17:49:33.593415 - Found 14 blocks on page.
2025-12-16T17:49:33.593984 - Block 0: ...
2025-12-16T17:49:33.594429 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T17:49:33.594853 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T17:49:33.595212 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T17:49:33.595628 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T17:49:33.596291 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T17:49:33.596835 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T17:49:33.597304 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T17:49:33.597768 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T17:49:33.598080 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T17:49:33.598545 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T17:49:33.599009 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T17:49:33.599460 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T17:49:33.600057 - Block 13: ...
2025-12-16T17:49:33.600494 - Sanitized Start: pd results of phase...
2025-12-16T17:49:33.601211 - Sanitized End: increases in pf 1+2....
2025-12-16T17:49:33.603903 - Scanning Page 79...
2025-12-16T17:49:33.607867 - Found 12 blocks on page.
2025-12-16T17:49:33.608526 - Block 0: ...
2025-12-16T17:49:33.609170 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T17:49:33.609679 - Block 2: b) pf 1+2:...
2025-12-16T17:49:33.610133 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T17:49:33.610641 - Block 4: group (b7841005)...
2025-12-16T17:49:33.611188 - Block 5: ...
2025-12-16T17:49:33.611652 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T17:49:33.612231 - Block 7: adolescents (150 mg sc)....
2025-12-16T17:49:33.612700 - Block 8: c) d-dimer:...
2025-12-16T17:49:33.613144 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T17:49:33.613657 - Block 10: group (b7841005)...
2025-12-16T17:49:33.614035 - Block 11: ...
2025-12-16T17:49:33.614484 - Sanitized Start: pd results of phase...
2025-12-16T17:49:33.614941 - Sanitized End: increases in pf 1+2....
2025-12-16T17:49:33.616143 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T17:49:33.616748 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T18:07:03.578649 - --- START REPLACEMENT on Page 78 ---
2025-12-16T18:07:03.579123 - Input Start Anchor (50 chars): PD results of phase 2 Study B7841003 (extension of...
2025-12-16T18:07:03.618763 - Search Strategy: Checking pages [78, 77, 79]
2025-12-16T18:07:03.619539 - Scanning Page 78...
2025-12-16T18:07:03.626532 - Found 3 blocks on page.
2025-12-16T18:07:03.627246 - Block 0: ...
2025-12-16T18:07:03.628509 - Block 1: ...
2025-12-16T18:07:03.629290 - Block 2: ...
2025-12-16T18:07:03.630085 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T18:07:03.630755 - Sanitized End: reases in peak tga level, and increases in pf 1+2....
2025-12-16T18:07:03.631381 - Scanning Page 77...
2025-12-16T18:07:03.640833 - Found 14 blocks on page.
2025-12-16T18:07:03.641483 - Block 0: ...
2025-12-16T18:07:03.642203 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-16T18:07:03.643043 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-16T18:07:03.643722 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-16T18:07:03.644444 - Block 4: pd in phase 2 and 3 studies...
2025-12-16T18:07:03.645506 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-16T18:07:03.646095 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-16T18:07:03.646682 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-16T18:07:03.647191 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-16T18:07:03.647717 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-16T18:07:03.648165 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-16T18:07:03.648537 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-16T18:07:03.649068 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-16T18:07:03.649505 - Block 13: ...
2025-12-16T18:07:03.650016 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T18:07:03.650456 - Sanitized End: reases in peak tga level, and increases in pf 1+2....
2025-12-16T18:07:03.654744 - Scanning Page 79...
2025-12-16T18:07:03.657087 - Found 12 blocks on page.
2025-12-16T18:07:03.657647 - Block 0: ...
2025-12-16T18:07:03.658158 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T18:07:03.658635 - Block 2: b) pf 1+2:...
2025-12-16T18:07:03.659258 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T18:07:03.659669 - Block 4: group (b7841005)...
2025-12-16T18:07:03.660151 - Block 5: ...
2025-12-16T18:07:03.660562 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T18:07:03.660990 - Block 7: adolescents (150 mg sc)....
2025-12-16T18:07:03.661540 - Block 8: c) d-dimer:...
2025-12-16T18:07:03.662199 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T18:07:03.662800 - Block 10: group (b7841005)...
2025-12-16T18:07:03.663337 - Block 11: ...
2025-12-16T18:07:03.663844 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-16T18:07:03.664231 - Sanitized End: reases in peak tga level, and increases in pf 1+2....
2025-12-16T18:07:03.665884 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T18:07:03.666289 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-16T18:10:52.098818 - --- START REPLACEMENT on Page 80 ---
2025-12-16T18:10:52.099412 - Input Start Anchor (50 chars): Effect of ADA and NAb on PD Data
Profiles of key p...
2025-12-16T18:10:52.112165 - Search Strategy: Checking pages [80, 79, 81]
2025-12-16T18:10:52.112726 - Scanning Page 80...
2025-12-16T18:10:52.122457 - Found 23 blocks on page.
2025-12-16T18:10:52.123083 - Block 0: ...
2025-12-16T18:10:52.123803 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-16T18:10:52.124343 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-16T18:10:52.124819 - Block 3: adolescents (150 mg sc)....
2025-12-16T18:10:52.125383 - Block 4: ...
2025-12-16T18:10:52.125879 - Block 5: d) total tfpi:...
2025-12-16T18:10:52.126383 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-16T18:10:52.126849 - Block 7: dose group and age group (b7841005)...
2025-12-16T18:10:52.127711 - Block 8: ...
2025-12-16T18:10:52.128275 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-16T18:10:52.128758 - Block 10: (150 mg sc)....
2025-12-16T18:10:52.129220 - Block 11: ...
2025-12-16T18:10:52.129715 - Block 12: effect of ada and nab on pd data...
2025-12-16T18:10:52.130215 - Block 13: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-16T18:10:52.130649 - Block 14: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-16T18:10:52.131063 - Block 15: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-16T18:10:52.131581 - Block 16: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-16T18:10:52.132270 - Block 17: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-16T18:10:52.132947 - Block 18: between ada positive and ada negative participants....
2025-12-16T18:10:52.133412 - Block 19: ...
2025-12-16T18:10:52.133968 - Block 20: ...
2025-12-16T18:10:52.134392 - Block 21: ...
2025-12-16T18:10:52.134881 - Block 22: ...
2025-12-16T18:10:52.135302 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T18:10:52.135706 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-16T18:10:52.137876 - Found Start (Fuzzy 0.78) at block 12
2025-12-16T18:10:52.140901 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-16T18:10:52.141488 - MATCH FOUND on Page 80: 12-12
2025-12-16T18:10:52.144996 - Replacing blocks 12 to 12
2025-12-16T18:10:52.178353 - Detected Font Size: 9.0
2025-12-16T18:10:52.220011 - Failed size 9.0 (Justified)
2025-12-16T18:10:52.222918 - Failed size 8.5 (Justified)
2025-12-16T18:10:52.224699 - Failed size 8.0 (Justified)
2025-12-16T18:10:52.226314 - Failed size 7.5 (Justified)
2025-12-16T18:10:52.227721 - Failed size 7.0 (Justified)
2025-12-16T18:10:52.229279 - Failed size 6.5 (Justified)
2025-12-16T18:10:52.230782 - Failed size 6.0 (Justified)
2025-12-16T18:10:52.231138 - Fallback to Left Align
2025-12-16T18:10:52.393784 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmp1f3tgos2.pdf
2025-12-16T18:20:58.628395 - --- START REPLACEMENT on Page 80 ---
2025-12-16T18:20:58.629151 - Input Start Anchor (50 chars): Effect of ADA and NAb on PD Data
Profiles of key p...
2025-12-16T18:20:58.681907 - Search Strategy: Checking pages [80, 79, 81]
2025-12-16T18:20:58.682390 - Scanning Page 80...
2025-12-16T18:20:58.696696 - Found 22 blocks on page.
2025-12-16T18:20:58.697479 - Block 0: ...
2025-12-16T18:20:58.698126 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-16T18:20:58.698671 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-16T18:20:58.699241 - Block 3: adolescents (150 mg sc)....
2025-12-16T18:20:58.699865 - Block 4: ...
2025-12-16T18:20:58.700450 - Block 5: d) total tfpi:...
2025-12-16T18:20:58.700920 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-16T18:20:58.701398 - Block 7: dose group and age group (b7841005)...
2025-12-16T18:20:58.701820 - Block 8: ...
2025-12-16T18:20:58.702605 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-16T18:20:58.703204 - Block 10: (150 mg sc)....
2025-12-16T18:20:58.703710 - Block 11: ...
2025-12-16T18:20:58.704131 - Block 12: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-16T18:20:58.704522 - Block 13: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-16T18:20:58.704904 - Block 14: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-16T18:20:58.705421 - Block 15: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-16T18:20:58.705971 - Block 16: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-16T18:20:58.706542 - Block 17: between ada positive and ada negative participants....
2025-12-16T18:20:58.707075 - Block 18: ...
2025-12-16T18:20:58.707678 - Block 19: ...
2025-12-16T18:20:58.708361 - Block 20: ...
2025-12-16T18:20:58.708834 - Block 21: ...
2025-12-16T18:20:58.709426 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T18:20:58.709972 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-16T18:20:58.713789 - Scanning Page 79...
2025-12-16T18:20:58.716279 - Found 12 blocks on page.
2025-12-16T18:20:58.716744 - Block 0: ...
2025-12-16T18:20:58.717215 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-16T18:20:58.717674 - Block 2: b) pf 1+2:...
2025-12-16T18:20:58.718212 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-16T18:20:58.718684 - Block 4: group (b7841005)...
2025-12-16T18:20:58.719460 - Block 5: ...
2025-12-16T18:20:58.719839 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-16T18:20:58.720225 - Block 7: adolescents (150 mg sc)....
2025-12-16T18:20:58.720578 - Block 8: c) d-dimer:...
2025-12-16T18:20:58.720982 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-16T18:20:58.721367 - Block 10: group (b7841005)...
2025-12-16T18:20:58.721839 - Block 11: ...
2025-12-16T18:20:58.722271 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T18:20:58.722595 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-16T18:20:58.724373 - Scanning Page 81...
2025-12-16T18:20:58.728444 - Found 24 blocks on page.
2025-12-16T18:20:58.728954 - Block 0: ...
2025-12-16T18:20:58.729563 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-16T18:20:58.730037 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-16T18:20:58.730521 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-16T18:20:58.730977 - Block 4: ...
2025-12-16T18:20:58.731470 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-16T18:20:58.731972 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-16T18:20:58.732329 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-16T18:20:58.732744 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-16T18:20:58.733105 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-16T18:20:58.733518 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-16T18:20:58.734052 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-16T18:20:58.734597 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-16T18:20:58.735047 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-16T18:20:58.735938 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-16T18:20:58.736449 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-16T18:20:58.736905 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-16T18:20:58.737394 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-16T18:20:58.737879 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-16T18:20:58.738300 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-16T18:20:58.738890 - Block 20: parameters....
2025-12-16T18:20:58.739312 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-16T18:20:58.739748 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-16T18:20:58.740117 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-16T18:20:58.740484 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-16T18:20:58.740774 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-16T18:20:58.746901 - ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-16T18:20:58.747375 - CRITICAL ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:13:26.840275 - --- START REPLACEMENT on Page 80 ---
2025-12-17T09:13:26.841357 - Input Start Anchor (50 chars): Effect of ADA and NAb on PD Data 
Profiles of key ...
2025-12-17T09:13:26.911421 - Search Strategy: Checking pages [80, 79, 81]
2025-12-17T09:13:26.913893 - Scanning Page 80...
2025-12-17T09:13:26.959164 - Found 22 blocks on page.
2025-12-17T09:13:26.959955 - Block 0: ...
2025-12-17T09:13:26.960554 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-17T09:13:26.961257 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-17T09:13:26.961872 - Block 3: adolescents (150 mg sc)....
2025-12-17T09:13:26.962577 - Block 4: ...
2025-12-17T09:13:26.963174 - Block 5: d) total tfpi:...
2025-12-17T09:13:26.963736 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-17T09:13:26.964422 - Block 7: dose group and age group (b7841005)...
2025-12-17T09:13:26.965116 - Block 8: ...
2025-12-17T09:13:26.965843 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-17T09:13:26.969021 - Block 10: (150 mg sc)....
2025-12-17T09:13:26.970102 - Block 11: ...
2025-12-17T09:13:26.970715 - Block 12: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-17T09:13:26.971333 - Block 13: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-17T09:13:26.972243 - Block 14: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-17T09:13:26.972801 - Block 15: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-17T09:13:26.973306 - Block 16: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-17T09:13:26.973815 - Block 17: between ada positive and ada negative participants....
2025-12-17T09:13:26.974338 - Block 18: ...
2025-12-17T09:13:26.975052 - Block 19: ...
2025-12-17T09:13:26.975601 - Block 20: ...
2025-12-17T09:13:26.976122 - Block 21: ...
2025-12-17T09:13:26.976725 - Sanitized Start: effect of ada and nab on pd data profiles of key...
2025-12-17T09:13:26.977202 - Sanitized End: s by age for study b7841005 – marstacimab dataset...
2025-12-17T09:13:26.988355 - Scanning Page 79...
2025-12-17T09:13:26.992553 - Found 12 blocks on page.
2025-12-17T09:13:26.994630 - Block 0: ...
2025-12-17T09:13:26.995290 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-17T09:13:26.996128 - Block 2: b) pf 1+2:...
2025-12-17T09:13:26.996735 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-17T09:13:26.997245 - Block 4: group (b7841005)...
2025-12-17T09:13:26.997881 - Block 5: ...
2025-12-17T09:13:26.998739 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-17T09:13:26.999458 - Block 7: adolescents (150 mg sc)....
2025-12-17T09:13:27.000451 - Block 8: c) d-dimer:...
2025-12-17T09:13:27.002066 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-17T09:13:27.003167 - Block 10: group (b7841005)...
2025-12-17T09:13:27.003781 - Block 11: ...
2025-12-17T09:13:27.004475 - Sanitized Start: effect of ada and nab on pd data profiles of key...
2025-12-17T09:13:27.005051 - Sanitized End: s by age for study b7841005 – marstacimab dataset...
2025-12-17T09:13:27.007978 - Scanning Page 81...
2025-12-17T09:13:27.019711 - Found 24 blocks on page.
2025-12-17T09:13:27.021424 - Block 0: ...
2025-12-17T09:13:27.022122 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-17T09:13:27.022849 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-17T09:13:27.023510 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-17T09:13:27.024060 - Block 4: ...
2025-12-17T09:13:27.024564 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-17T09:13:27.025060 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-17T09:13:27.025555 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-17T09:13:27.028074 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-17T09:13:27.028916 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-17T09:13:27.030034 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-17T09:13:27.030714 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-17T09:13:27.031348 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-17T09:13:27.032004 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-17T09:13:27.032660 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-17T09:13:27.033391 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-17T09:13:27.033967 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-17T09:13:27.034456 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-17T09:13:27.035037 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-17T09:13:27.035602 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-17T09:13:27.036114 - Block 20: parameters....
2025-12-17T09:13:27.036704 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-17T09:13:27.037389 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-17T09:13:27.038052 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-17T09:13:27.038827 - Sanitized Start: effect of ada and nab on pd data profiles of key...
2025-12-17T09:13:27.039355 - Sanitized End: s by age for study b7841005 – marstacimab dataset...
2025-12-17T09:13:27.051500 - ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:13:27.052090 - CRITICAL ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:17:27.686061 - --- START REPLACEMENT on Page 80 ---
2025-12-17T09:17:27.686619 - Input Start Anchor (50 chars): Effect of ADA and NAb on PD Data
Profiles of key p...
2025-12-17T09:17:27.720967 - Search Strategy: Checking pages [80, 79, 81]
2025-12-17T09:17:27.721440 - Scanning Page 80...
2025-12-17T09:17:27.731130 - Found 22 blocks on page.
2025-12-17T09:17:27.731790 - Block 0: ...
2025-12-17T09:17:27.732358 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-17T09:17:27.732887 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-17T09:17:27.733310 - Block 3: adolescents (150 mg sc)....
2025-12-17T09:17:27.733751 - Block 4: ...
2025-12-17T09:17:27.734433 - Block 5: d) total tfpi:...
2025-12-17T09:17:27.734908 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-17T09:17:27.735317 - Block 7: dose group and age group (b7841005)...
2025-12-17T09:17:27.735721 - Block 8: ...
2025-12-17T09:17:27.736092 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-17T09:17:27.736461 - Block 10: (150 mg sc)....
2025-12-17T09:17:27.737003 - Block 11: ...
2025-12-17T09:17:27.737336 - Block 12: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-17T09:17:27.737688 - Block 13: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-17T09:17:27.738088 - Block 14: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-17T09:17:27.738436 - Block 15: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-17T09:17:27.738852 - Block 16: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-17T09:17:27.739227 - Block 17: between ada positive and ada negative participants....
2025-12-17T09:17:27.739603 - Block 18: ...
2025-12-17T09:17:27.739952 - Block 19: ...
2025-12-17T09:17:27.740282 - Block 20: ...
2025-12-17T09:17:27.740597 - Block 21: ...
2025-12-17T09:17:27.740965 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:17:27.741343 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-17T09:17:27.745565 - Scanning Page 79...
2025-12-17T09:17:27.747703 - Found 12 blocks on page.
2025-12-17T09:17:27.748162 - Block 0: ...
2025-12-17T09:17:27.748603 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-17T09:17:27.748983 - Block 2: b) pf 1+2:...
2025-12-17T09:17:27.749428 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-17T09:17:27.749811 - Block 4: group (b7841005)...
2025-12-17T09:17:27.750439 - Block 5: ...
2025-12-17T09:17:27.750809 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-17T09:17:27.751152 - Block 7: adolescents (150 mg sc)....
2025-12-17T09:17:27.751464 - Block 8: c) d-dimer:...
2025-12-17T09:17:27.751810 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-17T09:17:27.752150 - Block 10: group (b7841005)...
2025-12-17T09:17:27.752594 - Block 11: ...
2025-12-17T09:17:27.753057 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:17:27.753612 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-17T09:17:27.755408 - Scanning Page 81...
2025-12-17T09:17:27.759576 - Found 24 blocks on page.
2025-12-17T09:17:27.759982 - Block 0: ...
2025-12-17T09:17:27.760424 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-17T09:17:27.760828 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-17T09:17:27.761252 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-17T09:17:27.761637 - Block 4: ...
2025-12-17T09:17:27.762013 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-17T09:17:27.762373 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-17T09:17:27.762750 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-17T09:17:27.763142 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-17T09:17:27.763547 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-17T09:17:27.763914 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-17T09:17:27.764279 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-17T09:17:27.764625 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-17T09:17:27.764969 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-17T09:17:27.765359 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-17T09:17:27.765709 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-17T09:17:27.766049 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-17T09:17:27.766433 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-17T09:17:27.766888 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-17T09:17:27.767243 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-17T09:17:27.767564 - Block 20: parameters....
2025-12-17T09:17:27.767904 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-17T09:17:27.768264 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-17T09:17:27.768806 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-17T09:17:27.769825 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:17:27.770721 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-17T09:17:27.779145 - ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:17:27.779763 - CRITICAL ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:27:23.296299 - --- START REPLACEMENT on Page 1 ---
2025-12-17T09:27:23.297028 - Input Start Anchor (34 chars): assessment report - September 2024...
2025-12-17T09:27:23.305892 - Search Strategy: Checking pages [1, 2]
2025-12-17T09:27:23.306330 - Scanning Page 1...
2025-12-17T09:27:23.324267 - Found 12 blocks on page.
2025-12-17T09:27:23.324727 - Block 0: ...
2025-12-17T09:27:23.325237 - Block 1: ...
2025-12-17T09:27:23.325937 - Block 2: official address domenico scarlattilaan 6 ● 1083 hs amsterdam ● the netherlands...
2025-12-17T09:27:23.326533 - Block 3: an agency of the european union address for visits and deliveries refer to www.ema.europa.eu/how-to-...
2025-12-17T09:27:23.326934 - Block 4: © european medicines agency, 2024. reproduction is authorised provided the source is acknowledged....
2025-12-17T09:27:23.327529 - Block 5: 19 september 2024 ema/464842/2024 committee for medicinal products for human use (chmp)...
2025-12-17T09:27:23.328058 - Block 6: assessment report...
2025-12-17T09:27:23.328434 - Block 7: hympavzi...
2025-12-17T09:27:23.329156 - Block 8: international non-proprietary name: marstacimab...
2025-12-17T09:27:23.329761 - Block 9: procedure no. emea/h/c/006240/0000...
2025-12-17T09:27:23.330305 - Block 10: note...
2025-12-17T09:27:23.330795 - Block 11: assessment report as adopted by the chmp with all information of a commercially confidential nature ...
2025-12-17T09:27:23.331275 - Sanitized Start: assessment report - september 2024...
2025-12-17T09:27:23.331882 - Sanitized End: procedure...
2025-12-17T09:27:23.333587 - Scanning Page 2...
2025-12-17T09:27:23.340178 - Found 15 blocks on page.
2025-12-17T09:27:23.340632 - Block 0: ...
2025-12-17T09:27:23.341081 - Block 1: assessment report ema/464842/2024 page 2/195...
2025-12-17T09:27:23.341471 - Block 2: table of contents...
2025-12-17T09:27:23.342030 - Block 3: 1. background information on the procedure ............................................ 11...
2025-12-17T09:27:23.342451 - Block 4: 1.1. submission of the dossier ........................................................................
2025-12-17T09:27:23.342993 - Block 5: 1.5. applicant’s request for consideration ............................................................
2025-12-17T09:27:23.343484 - Block 6: 2. scientific discussion ..............................................................................
2025-12-17T09:27:23.344039 - Block 7: 2.1. problem statement ................................................................................
2025-12-17T09:27:23.344604 - Block 8: 2.1.5. management .....................................................................................
2025-12-17T09:27:23.345253 - Block 9: 2.4.2. active substance ...............................................................................
2025-12-17T09:27:23.345798 - Block 10: 2.5. non-clinical aspects .............................................................................
2025-12-17T09:27:23.346404 - Block 11: 2.5.5. ecotoxicity/environmental risk assessment ......................................................
2025-12-17T09:27:23.347276 - Block 12: 2.5.6. discussion on non-clinical aspects .............................................................
2025-12-17T09:27:23.347854 - Block 13: 2.6.3. discussion on clinical pharmacology ............................................................
2025-12-17T09:27:23.348462 - Block 14: 2.6.4. conclusions on clinical pharmacology ...........................................................
2025-12-17T09:27:23.349056 - Sanitized Start: assessment report - september 2024...
2025-12-17T09:27:23.349594 - Sanitized End: procedure...
2025-12-17T09:27:23.350124 - Found Start (Fuzzy 0.62) at block 1
2025-12-17T09:27:23.350973 - Found End (Exact) at block 3
2025-12-17T09:27:23.351518 - MATCH FOUND on Page 2: 1-3
2025-12-17T09:27:23.356781 - Replacing blocks 1 to 3
2025-12-17T09:27:23.367799 - Detected Font Size: 7.0
2025-12-17T09:27:23.408562 - Inserted with size 7.0 (Justified)
2025-12-17T09:27:23.526400 - Saved new PDF to c:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmp4drbs69r.pdf
2025-12-17T09:32:07.199920 - --- START REPLACEMENT on Page 80 ---
2025-12-17T09:32:07.200350 - Input Start Anchor (50 chars): Effect of ADA and NAb on PD Data
Profiles of key p...
2025-12-17T09:32:07.207688 - Search Strategy: Checking pages [80, 79, 81]
2025-12-17T09:32:07.208241 - Scanning Page 80...
2025-12-17T09:32:07.217475 - Found 22 blocks on page.
2025-12-17T09:32:07.218099 - Block 0: ...
2025-12-17T09:32:07.218650 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-17T09:32:07.219229 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-17T09:32:07.219795 - Block 3: adolescents (150 mg sc)....
2025-12-17T09:32:07.220439 - Block 4: ...
2025-12-17T09:32:07.221300 - Block 5: d) total tfpi:...
2025-12-17T09:32:07.222079 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-17T09:32:07.222601 - Block 7: dose group and age group (b7841005)...
2025-12-17T09:32:07.222978 - Block 8: ...
2025-12-17T09:32:07.223386 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-17T09:32:07.223770 - Block 10: (150 mg sc)....
2025-12-17T09:32:07.224566 - Block 11: ...
2025-12-17T09:32:07.224958 - Block 12: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-17T09:32:07.225339 - Block 13: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-17T09:32:07.225716 - Block 14: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-17T09:32:07.226099 - Block 15: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-17T09:32:07.226379 - Block 16: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-17T09:32:07.226724 - Block 17: between ada positive and ada negative participants....
2025-12-17T09:32:07.227053 - Block 18: ...
2025-12-17T09:32:07.227487 - Block 19: ...
2025-12-17T09:32:07.227915 - Block 20: ...
2025-12-17T09:32:07.228405 - Block 21: ...
2025-12-17T09:32:07.228886 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:32:07.229276 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-17T09:32:07.233568 - Scanning Page 79...
2025-12-17T09:32:07.235716 - Found 12 blocks on page.
2025-12-17T09:32:07.236197 - Block 0: ...
2025-12-17T09:32:07.236748 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-17T09:32:07.237399 - Block 2: b) pf 1+2:...
2025-12-17T09:32:07.238285 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-17T09:32:07.238771 - Block 4: group (b7841005)...
2025-12-17T09:32:07.239271 - Block 5: ...
2025-12-17T09:32:07.239677 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-17T09:32:07.240154 - Block 7: adolescents (150 mg sc)....
2025-12-17T09:32:07.240693 - Block 8: c) d-dimer:...
2025-12-17T09:32:07.241128 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-17T09:32:07.241526 - Block 10: group (b7841005)...
2025-12-17T09:32:07.241890 - Block 11: ...
2025-12-17T09:32:07.242453 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:32:07.242832 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-17T09:32:07.244898 - Scanning Page 81...
2025-12-17T09:32:07.248656 - Found 24 blocks on page.
2025-12-17T09:32:07.249050 - Block 0: ...
2025-12-17T09:32:07.249581 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-17T09:32:07.250029 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-17T09:32:07.250571 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-17T09:32:07.250856 - Block 4: ...
2025-12-17T09:32:07.251363 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-17T09:32:07.251786 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-17T09:32:07.252207 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-17T09:32:07.252615 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-17T09:32:07.252952 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-17T09:32:07.253301 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-17T09:32:07.253813 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-17T09:32:07.254212 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-17T09:32:07.254650 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-17T09:32:07.254984 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-17T09:32:07.255350 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-17T09:32:07.255724 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-17T09:32:07.256268 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-17T09:32:07.256765 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-17T09:32:07.257172 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-17T09:32:07.257556 - Block 20: parameters....
2025-12-17T09:32:07.257923 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-17T09:32:07.258330 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-17T09:32:07.258834 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-17T09:32:07.259384 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:32:07.259862 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-17T09:32:07.265292 - ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:32:07.265742 - Start anchor missing - attempting hybrid semantic search + coordinate caching
2025-12-17T09:32:11.357596 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 1, 'bbox': [56.025001525878906, 175.50498962402344, 367.6239929199219, 342.0840148925781]}
2025-12-17T09:32:11.796341 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 80, 'bbox': [56.025001525878906, 497.10498046875, 537.7920532226562, 564.032958984375]}
2025-12-17T09:32:11.851818 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 1, 'bbox': [56.025001525878906, 175.50498962402344, 367.6239929199219, 342.0840148925781]}
2025-12-17T09:32:11.881694 - Hybrid search failed: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:32:11.882346 - CRITICAL ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:39:23.260386 - --- START REPLACEMENT on Page 80 ---
2025-12-17T09:39:23.260762 - Input Start Anchor (61 chars): Effect of ADA and NAb on PD Data Profiles of key participants...
2025-12-17T09:39:23.266770 - Search Strategy: Checking pages [80, 79, 81]
2025-12-17T09:39:23.267090 - Scanning Page 80...
2025-12-17T09:39:23.280613 - Found 24 blocks on page.
2025-12-17T09:39:23.281148 - Block 0: ...
2025-12-17T09:39:23.281529 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-17T09:39:23.281990 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-17T09:39:23.282382 - Block 3: adolescents (150 mg sc)....
2025-12-17T09:39:23.282752 - Block 4: ...
2025-12-17T09:39:23.283116 - Block 5: d) total tfpi:...
2025-12-17T09:39:23.283393 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-17T09:39:23.283694 - Block 7: dose group and age group (b7841005)...
2025-12-17T09:39:23.283919 - Block 8: ...
2025-12-17T09:39:23.284271 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-17T09:39:23.284542 - Block 10: (150 mg sc)....
2025-12-17T09:39:23.284766 - Block 11: ...
2025-12-17T09:39:23.285097 - Block 12: effect of ada and nab on pd data...
2025-12-17T09:39:23.285390 - Block 13: profiles of key pharmacodynamic endpoints ie, tfpi (total), tga peak, pf1+2, dpt and d-dimer followi...
2025-12-17T09:39:23.285744 - Block 14: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-17T09:39:23.286142 - Block 15: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-17T09:39:23.286669 - Block 16: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-17T09:39:23.287018 - Block 17: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-17T09:39:23.287335 - Block 18: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-17T09:39:23.287646 - Block 19: between ada positive and ada negative participants....
2025-12-17T09:39:23.287915 - Block 20: ...
2025-12-17T09:39:23.288277 - Block 21: ...
2025-12-17T09:39:23.288541 - Block 22: ...
2025-12-17T09:39:23.288765 - Block 23: ...
2025-12-17T09:39:23.289086 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:39:23.289425 - Sanitized End: by age for study b7841005 – marstacimab dataset...
2025-12-17T09:39:23.292308 - Found Start (Window Prefix) at block 10
2025-12-17T09:39:23.292909 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-17T09:39:23.293479 - MATCH FOUND on Page 80: 10-10
2025-12-17T09:39:23.295112 - Replacing blocks 10 to 10
2025-12-17T09:39:23.312705 - Detected Font Size: 9.0
2025-12-17T09:39:23.317883 - Failed size 9.0 (Justified)
2025-12-17T09:39:23.318946 - Failed size 8.5 (Justified)
2025-12-17T09:39:23.320091 - Failed size 8.0 (Justified)
2025-12-17T09:39:23.320993 - Failed size 7.5 (Justified)
2025-12-17T09:39:23.321821 - Failed size 7.0 (Justified)
2025-12-17T09:39:23.323531 - Inserted with size 6.5 (Justified)
2025-12-17T09:39:23.377410 - Saved new PDF to c:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpzo6puvsu.pdf
2025-12-17T09:49:00.625015 - --- START REPLACEMENT on Page 80 ---
2025-12-17T09:49:00.627985 - Input Start Anchor (50 chars): Effect of ADA and NAb on PD Data
Profiles of key p...
2025-12-17T09:49:00.661277 - Search Strategy: Checking pages [80, 79, 81]
2025-12-17T09:49:00.662922 - Scanning Page 80...
2025-12-17T09:49:00.685006 - Found 22 blocks on page.
2025-12-17T09:49:00.686034 - Block 0: ...
2025-12-17T09:49:00.687049 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-17T09:49:00.688306 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-17T09:49:00.689237 - Block 3: adolescents (150 mg sc)....
2025-12-17T09:49:00.690513 - Block 4: ...
2025-12-17T09:49:00.691509 - Block 5: d) total tfpi:...
2025-12-17T09:49:00.692403 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-17T09:49:00.693265 - Block 7: dose group and age group (b7841005)...
2025-12-17T09:49:00.694036 - Block 8: ...
2025-12-17T09:49:00.694963 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-17T09:49:00.695952 - Block 10: (150 mg sc)....
2025-12-17T09:49:00.696662 - Block 11: ...
2025-12-17T09:49:00.697223 - Block 12: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-17T09:49:00.697876 - Block 13: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-17T09:49:00.698534 - Block 14: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-17T09:49:00.699214 - Block 15: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-17T09:49:00.700119 - Block 16: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-17T09:49:00.700716 - Block 17: between ada positive and ada negative participants....
2025-12-17T09:49:00.701259 - Block 18: ...
2025-12-17T09:49:00.701780 - Block 19: ...
2025-12-17T09:49:00.702337 - Block 20: ...
2025-12-17T09:49:00.702879 - Block 21: ...
2025-12-17T09:49:00.703586 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:49:00.704187 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-17T09:49:00.712208 - Scanning Page 79...
2025-12-17T09:49:00.714079 - Found 12 blocks on page.
2025-12-17T09:49:00.714500 - Block 0: ...
2025-12-17T09:49:00.715020 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-17T09:49:00.715569 - Block 2: b) pf 1+2:...
2025-12-17T09:49:00.716147 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-17T09:49:00.716834 - Block 4: group (b7841005)...
2025-12-17T09:49:00.717362 - Block 5: ...
2025-12-17T09:49:00.717798 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-17T09:49:00.718546 - Block 7: adolescents (150 mg sc)....
2025-12-17T09:49:00.718976 - Block 8: c) d-dimer:...
2025-12-17T09:49:00.719505 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-17T09:49:00.720095 - Block 10: group (b7841005)...
2025-12-17T09:49:00.720766 - Block 11: ...
2025-12-17T09:49:00.721533 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:49:00.722040 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-17T09:49:00.727228 - Scanning Page 81...
2025-12-17T09:49:00.732883 - Found 24 blocks on page.
2025-12-17T09:49:00.733519 - Block 0: ...
2025-12-17T09:49:00.734019 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-17T09:49:00.734594 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-17T09:49:00.735313 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-17T09:49:00.735778 - Block 4: ...
2025-12-17T09:49:00.736279 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-17T09:49:00.736772 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-17T09:49:00.737432 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-17T09:49:00.738118 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-17T09:49:00.738701 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-17T09:49:00.739187 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-17T09:49:00.739712 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-17T09:49:00.740180 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-17T09:49:00.740741 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-17T09:49:00.741219 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-17T09:49:00.741621 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-17T09:49:00.742096 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-17T09:49:00.742490 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-17T09:49:00.742880 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-17T09:49:00.743312 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-17T09:49:00.743804 - Block 20: parameters....
2025-12-17T09:49:00.744259 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-17T09:49:00.744654 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-17T09:49:00.745069 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-17T09:49:00.745581 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-17T09:49:00.745913 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-17T09:49:00.749950 - ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:49:00.750338 - Start anchor missing - attempting hybrid semantic search + coordinate caching
2025-12-17T09:49:04.728217 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 1, 'bbox': [56.025001525878906, 175.50498962402344, 367.6239929199219, 342.0840148925781]}
2025-12-17T09:49:05.081209 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 80, 'bbox': [56.025001525878906, 497.10498046875, 537.7920532226562, 564.032958984375]}
2025-12-17T09:49:05.099703 - Found start inside cached bbox (window) at block 10
2025-12-17T09:49:05.102733 - HYBRID MATCH FOUND at hympavzi-epar-public-assessment-report_en (2).pdf page 80 blocks -1--1
2025-12-17T09:49:05.104729 - Hybrid search failed: Start anchor not found on pages [80, 79, 81]
2025-12-17T09:49:05.105149 - CRITICAL ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-17T13:22:23.309478 - --- START REPLACEMENT on Page 172 ---
2025-12-17T13:22:23.310056 - Input Start Anchor (33 chars): B7841007
(N=87) 
n (%) 
B7841005/...
2025-12-17T13:22:23.350041 - Search Strategy: Checking pages [172, 171, 173]
2025-12-17T13:22:23.351094 - Scanning Page 172...
2025-12-17T13:22:23.396055 - Found 52 blocks on page.
2025-12-17T13:22:23.396721 - Block 0: ...
2025-12-17T13:22:23.397366 - Block 1: assessment report ema/464842/2024 page 172/195...
2025-12-17T13:22:23.398076 - Block 2: table 49: incidence of treatment-emergent adverse events by system organ class and preferred...
2025-12-17T13:22:23.398620 - Block 3: term (treatment related) – marstacimab dataset...
2025-12-17T13:22:23.399239 - Block 4: number (%) of participants: by system organ class and preferred term...
2025-12-17T13:22:23.399802 - Block 5: b7841002...
2025-12-17T13:22:23.401196 - Block 6: (n=26)...
2025-12-17T13:22:23.403568 - Block 7: n (%)...
2025-12-17T13:22:23.404483 - Block 8: b7841002/...
2025-12-17T13:22:23.405180 - Block 9: b7841003...
2025-12-17T13:22:23.405914 - Block 10: (n=28)...
2025-12-17T13:22:23.407030 - Block 11: n (%)...
2025-12-17T13:22:23.407799 - Block 12: b7841005...
2025-12-17T13:22:23.408258 - Block 13: (n=116)...
2025-12-17T13:22:23.408851 - Block 14: n (%)...
2025-12-17T13:22:23.409342 - Block 15: b7841007...
2025-12-17T13:22:23.409884 - Block 16: (n=87)...
2025-12-17T13:22:23.410225 - Block 17: n (%)...
2025-12-17T13:22:23.410515 - Block 18: b7841005/...
2025-12-17T13:22:23.410812 - Block 19: b7841007...
2025-12-17T13:22:23.411088 - Block 20: (n=116)...
2025-12-17T13:22:23.411367 - Block 21: n (%)...
2025-12-17T13:22:23.411811 - Block 22: ...
2025-12-17T13:22:23.412253 - Block 23: with any ae 14 ( 53.8) 16 ( 57.1) 23 ( 19.8) 3 ( 3.4) 24 ( 20.7)...
2025-12-17T13:22:23.412660 - Block 24: gastrointestinal disorders 1 ( 3.8) 1 ( 3.6) 1 ( 0.9) 0 1 ( 0.9)...
2025-12-17T13:22:23.413081 - Block 25: dyspepsia 1 ( 3.8) 1 ( 3.6) 0 0 0...
2025-12-17T13:22:23.413455 - Block 26: haemorrhoids 0 0 1 ( 0.9) 0 1 ( 0.9)...
2025-12-17T13:22:23.413832 - Block 27: haemorrhoids thrombosed 0 0 1 ( 0.9) 0 1 ( 0.9)...
2025-12-17T13:22:23.414204 - Block 28: general disorders and administration site conditions...
2025-12-17T13:22:23.414783 - Block 29: 7 ( 26.9) 10 ( 35.7) 13 ( 11.2) 3 ( 3.4) 15 ( 12.9)...
2025-12-17T13:22:23.415256 - Block 30: fatigue 1 ( 3.8) 1 ( 3.6) 1 ( 0.9) 0 1 ( 0.9)...
2025-12-17T13:22:23.415643 - Block 31: injection site bruising 2 ( 7.7) 2 ( 7.1) 1 ( 0.9) 1 ( 1.1) 2 ( 1.7)...
2025-12-17T13:22:23.416070 - Block 32: injection site erythema 1 ( 3.8) 1 ( 3.6) 3 ( 2.6) 0 3 ( 2.6)...
2025-12-17T13:22:23.416611 - Block 33: injection site haematoma 0 1 ( 3.6) 1 ( 0.9) 0 1 ( 0.9)...
2025-12-17T13:22:23.417191 - Block 34: injection site haemorrhage 1 ( 3.8) 1 ( 3.6) 0 0 0...
2025-12-17T13:22:23.417659 - Block 35: injection site induration 2 ( 7.7) 2 ( 7.1) 1 ( 0.9) 1 ( 1.1) 2 ( 1.7)...
2025-12-17T13:22:23.418094 - Block 36: injection site oedema 0 0 1 ( 0.9) 0 1 ( 0.9)...
2025-12-17T13:22:23.419428 - Block 37: injection site pain 3 ( 11.5) 3 ( 10.7) 2 ( 1.7) 0 2 ( 1.7)...
2025-12-17T13:22:23.420313 - Block 38: injection site pruritus 1 ( 3.8) 1 ( 3.6) 4 ( 3.4) 0 4 ( 3.4)...
2025-12-17T13:22:23.420855 - Block 39: injection site reaction 0 2 ( 7.1) 0 0 0...
2025-12-17T13:22:23.421572 - Block 40: injection site swelling 3 ( 11.5) 3 ( 10.7) 2 ( 1.7) 1 ( 1.1) 3 ( 2.6)...
2025-12-17T13:22:23.422246 - Block 41: injection site warmth 1 ( 3.8) 1 ( 3.6) 0 0 0...
2025-12-17T13:22:23.422748 - Block 42: peripheral swelling 0 0 1 ( 0.9) 0 1 ( 0.9)...
2025-12-17T13:22:23.423261 - Block 43: injury, poisoning and procedural complications...
2025-12-17T13:22:23.423655 - Block 44: 1 ( 3.8) 1 ( 3.6) 1 ( 0.9) 0 1 ( 0.9)...
2025-12-17T13:22:23.424063 - Block 45: contusion 0 0 1 ( 0.9) 0 1 ( 0.9)...
2025-12-17T13:22:23.424465 - Block 46: occupational exposure to product 1 ( 3.8) 1 ( 3.6) 0 0 0...
2025-12-17T13:22:23.424993 - Block 47: investigations 5 ( 19.2) 5 ( 17.9) 3 ( 2.6) 0 3 ( 2.6)...
2025-12-17T13:22:23.425368 - Block 48: blood fibrinogen decreased 1 ( 3.8) 1 ( 3.6) 0 0 0...
2025-12-17T13:22:23.425749 - Block 49: fibrin d dimer increased 1 ( 3.8) 1 ( 3.6) 2 ( 1.7) 0 2 ( 1.7)...
2025-12-17T13:22:23.426224 - Block 50: prothrombin fragment 1.2 increased 0 0 3 ( 2.6) 0 3 ( 2.6)...
2025-12-17T13:22:23.426614 - Block 51: prothrombin time prolonged 1 ( 3.8) 1 ( 3.6) 0 0 0...
2025-12-17T13:22:23.427017 - Sanitized Start: b7841007 (n=87) n (%) b7841005/...
2025-12-17T13:22:23.427533 - Sanitized End: b7841007 (n=87) n (%) b7841005/...
2025-12-17T13:22:23.429320 - Found Start (Window Fuzzy 0.87) at block 5
2025-12-17T13:22:23.429996 - Found End (Window Fuzzy 0.87) at block 5
2025-12-17T13:22:23.431496 - MATCH FOUND on Page 172: 5-5
2025-12-17T13:22:23.447348 - Replacing blocks 5 to 5
2025-12-17T13:22:23.469173 - Detected Font Size: 9.0
2025-12-17T13:22:23.516604 - Failed size 9.0 (Justified)
2025-12-17T13:22:23.519054 - Failed size 8.5 (Justified)
2025-12-17T13:22:23.521246 - Failed size 8.0 (Justified)
2025-12-17T13:22:23.523666 - Failed size 7.5 (Justified)
2025-12-17T13:22:23.526227 - Failed size 7.0 (Justified)
2025-12-17T13:22:23.528624 - Failed size 6.5 (Justified)
2025-12-17T13:22:23.530772 - Failed size 6.0 (Justified)
2025-12-17T13:22:23.531262 - Fallback to Left Align
2025-12-17T13:22:23.733301 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpmtvrpezs.pdf
2025-12-17T14:30:13.189990 - --- START REPLACEMENT on Page 78 ---
2025-12-17T14:30:13.192506 - Input Start Anchor (50 chars): PD results of phase 2 Study B7841003 (extension of...
2025-12-17T14:30:13.326713 - Search Strategy: Checking pages [78, 77, 79]
2025-12-17T14:30:13.327593 - Scanning Page 78...
2025-12-17T14:30:13.336341 - Found 3 blocks on page.
2025-12-17T14:30:13.337332 - Block 0: ...
2025-12-17T14:30:13.338204 - Block 1: ...
2025-12-17T14:30:13.339132 - Block 2: ...
2025-12-17T14:30:13.340178 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-17T14:30:13.341186 - Sanitized End: reases in peak tga level, and increases in pf 1+2....
2025-12-17T14:30:13.342004 - Scanning Page 77...
2025-12-17T14:30:13.352017 - Found 14 blocks on page.
2025-12-17T14:30:13.352728 - Block 0: ...
2025-12-17T14:30:13.353379 - Block 1: assessment report ema/464842/2024 page 77/195...
2025-12-17T14:30:13.354042 - Block 2: sc dose of marstacimab 300 mg. for all pd biomarkers, maximum or near maximum effect occurred most...
2025-12-17T14:30:13.354713 - Block 3: frequently within the first week based on maximum change from baseline....
2025-12-17T14:30:13.355343 - Block 4: pd in phase 2 and 3 studies...
2025-12-17T14:30:13.355948 - Block 5: treatment-related changes were observed for all pd endpoints in all dose cohorts as expected. these...
2025-12-17T14:30:13.356616 - Block 6: changes included increases in total tfpi consistent with binding of free tfpi with marstacimab resul...
2025-12-17T14:30:13.357379 - Block 7: delayed elimination of tfpi (bound to marstacimab) due to much longer half-life of marstacimab compa...
2025-12-17T14:30:13.358071 - Block 8: the target tfpi, shortening of tga lag time, increases in peak tga, tga endogenous thrombin potentia...
2025-12-17T14:30:13.358708 - Block 9: 1+2, and d-dimer, and shortening of dpt. there were no clinical findings suggesting that these pd ch...
2025-12-17T14:30:13.359587 - Block 10: were reflective of excessive pharmacology. pd responses were mostly consistent between participants ...
2025-12-17T14:30:13.360483 - Block 11: and without inhibitors and between participants with haemophilia a and b....
2025-12-17T14:30:13.361518 - Block 12: figure 15: plot of median absolute values vs time for pf endpoints following single and multiple dos...
2025-12-17T14:30:13.362647 - Block 13: ...
2025-12-17T14:30:13.363493 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-17T14:30:13.364118 - Sanitized End: reases in peak tga level, and increases in pf 1+2....
2025-12-17T14:30:13.369662 - Scanning Page 79...
2025-12-17T14:30:13.374578 - Found 12 blocks on page.
2025-12-17T14:30:13.375461 - Block 0: ...
2025-12-17T14:30:13.376365 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-17T14:30:13.376995 - Block 2: b) pf 1+2:...
2025-12-17T14:30:13.377630 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-17T14:30:13.378245 - Block 4: group (b7841005)...
2025-12-17T14:30:13.378920 - Block 5: ...
2025-12-17T14:30:13.379537 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-17T14:30:13.380350 - Block 7: adolescents (150 mg sc)....
2025-12-17T14:30:13.381027 - Block 8: c) d-dimer:...
2025-12-17T14:30:13.384427 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-17T14:30:13.385541 - Block 10: group (b7841005)...
2025-12-17T14:30:13.386613 - Block 11: ...
2025-12-17T14:30:13.387491 - Sanitized Start: pd results of phase 2 study b7841003 (extension of...
2025-12-17T14:30:13.388473 - Sanitized End: reases in peak tga level, and increases in pf 1+2....
2025-12-17T14:30:13.394655 - ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-17T14:30:13.395290 - Start anchor missing - attempting hybrid semantic search + coordinate caching
2025-12-17T14:30:18.843774 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 1, 'bbox': [56.025001525878906, 175.50498962402344, 367.6239929199219, 342.0840148925781]}
2025-12-17T14:30:18.952249 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 1, 'bbox': [56.025001525878906, 175.50498962402344, 367.6239929199219, 342.0840148925781]}
2025-12-17T14:30:19.050992 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 1, 'bbox': [56.025001525878906, 175.50498962402344, 367.6239929199219, 342.0840148925781]}
2025-12-17T14:30:19.102413 - Hybrid search failed: Start anchor not found on pages [78, 77, 79]
2025-12-17T14:30:19.103746 - CRITICAL ERROR: Start anchor not found on pages [78, 77, 79]
2025-12-18T01:46:47.896621 - --- START REPLACEMENT on Page 80 ---
2025-12-18T01:46:47.898671 - Input Start Anchor (50 chars): Effect of ADA and NAb on PD Data
Profiles of key p...
2025-12-18T01:46:47.959120 - Search Strategy: Checking pages [80, 79, 81]
2025-12-18T01:46:47.959642 - Scanning Page 80...
2025-12-18T01:46:47.977946 - Found 22 blocks on page.
2025-12-18T01:46:47.978559 - Block 0: ...
2025-12-18T01:46:47.979133 - Block 1: assessment report ema/464842/2024 page 80/195...
2025-12-18T01:46:47.979610 - Block 2: post-treatment variability (geometric %cv) in d-dimer data ranged from 40% - 76% across adults and...
2025-12-18T01:46:47.980187 - Block 3: adolescents (150 mg sc)....
2025-12-18T01:46:47.980653 - Block 4: ...
2025-12-18T01:46:47.981196 - Block 5: d) total tfpi:...
2025-12-18T01:46:47.981696 - Block 6: figure 19: plot of median absolute value vs time for tissue factor pathway inhibitor (ng/ml) by...
2025-12-18T01:46:47.982186 - Block 7: dose group and age group (b7841005)...
2025-12-18T01:46:47.982700 - Block 8: ...
2025-12-18T01:46:47.983207 - Block 9: post-treatment variability (geometric %cv) in tfpi ranged from 19% - 58% across adults and adolescen...
2025-12-18T01:46:47.983691 - Block 10: (150 mg sc)....
2025-12-18T01:46:47.984338 - Block 11: ...
2025-12-18T01:46:47.984843 - Block 12: weekly sc administration of 150 mg of marstacimab to haemophilia participants from the phase 3 study...
2025-12-18T01:46:47.985730 - Block 13: (b7841005) were compared between ada positive and ada-negative participants for assessment of...
2025-12-18T01:46:47.986350 - Block 14: differences in pd between the 2 groups (only tfpi data shown, figure below). for adults, there were...
2025-12-18T01:46:47.986749 - Block 15: consistently lower mean and median values for tfpi concentrations in ada positive subjects at nearly...
2025-12-18T01:46:47.987285 - Block 16: study visits. the remaining pd parameters (peak thrombin, pf 1+2, d-dimer) were more comparable...
2025-12-18T01:46:47.987968 - Block 17: between ada positive and ada negative participants....
2025-12-18T01:46:47.988419 - Block 18: ...
2025-12-18T01:46:47.989243 - Block 19: ...
2025-12-18T01:46:47.990506 - Block 20: ...
2025-12-18T01:46:47.991263 - Block 21: ...
2025-12-18T01:46:47.991962 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-18T01:46:47.992473 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-18T01:46:48.000610 - Scanning Page 79...
2025-12-18T01:46:48.004885 - Found 12 blocks on page.
2025-12-18T01:46:48.005558 - Block 0: ...
2025-12-18T01:46:48.006278 - Block 1: assessment report ema/464842/2024 page 79/195...
2025-12-18T01:46:48.006865 - Block 2: b) pf 1+2:...
2025-12-18T01:46:48.007399 - Block 3: figure 17: plot of median absolute values vs time for pf 1+2 (pmol/l) by dose group and age...
2025-12-18T01:46:48.007794 - Block 4: group (b7841005)...
2025-12-18T01:46:48.008121 - Block 5: ...
2025-12-18T01:46:48.008561 - Block 6: post-treatment variability (geometric %cv) in pf 1+2 data ranged from 25% - 99% across adults and...
2025-12-18T01:46:48.008950 - Block 7: adolescents (150 mg sc)....
2025-12-18T01:46:48.009423 - Block 8: c) d-dimer:...
2025-12-18T01:46:48.010685 - Block 9: figure 18: plot of median absolute values vs time for d-dimer (μg/ml) by dose group and age...
2025-12-18T01:46:48.011194 - Block 10: group (b7841005)...
2025-12-18T01:46:48.011569 - Block 11: ...
2025-12-18T01:46:48.012045 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-18T01:46:48.012392 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-18T01:46:48.015659 - Scanning Page 81...
2025-12-18T01:46:48.022581 - Found 24 blocks on page.
2025-12-18T01:46:48.023084 - Block 0: ...
2025-12-18T01:46:48.023668 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-18T01:46:48.024269 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-18T01:46:48.024889 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-18T01:46:48.025419 - Block 4: ...
2025-12-18T01:46:48.025987 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-18T01:46:48.026430 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-18T01:46:48.026940 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-18T01:46:48.027497 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-18T01:46:48.028017 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-18T01:46:48.028493 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-18T01:46:48.028978 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-18T01:46:48.029465 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-18T01:46:48.029958 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-18T01:46:48.030416 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-18T01:46:48.031074 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-18T01:46:48.031585 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-18T01:46:48.032069 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-18T01:46:48.032630 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-18T01:46:48.033094 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-18T01:46:48.033650 - Block 20: parameters....
2025-12-18T01:46:48.034178 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-18T01:46:48.034664 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-18T01:46:48.035122 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-18T01:46:48.035744 - Sanitized Start: effect of ada and nab on pd data profiles of key p...
2025-12-18T01:46:48.036195 - Sanitized End: us by age for study b7841005 – marstacimab dataset...
2025-12-18T01:46:48.042670 - ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-18T01:46:48.043135 - Start anchor missing - attempting hybrid semantic search + coordinate caching
2025-12-18T01:46:52.229084 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 1, 'bbox': [56.025001525878906, 175.50498962402344, 367.6239929199219, 342.0840148925781]}
2025-12-18T01:46:52.740427 - Checking candidate coords: {'file': 'hympavzi-epar-public-assessment-report_en (2).pdf', 'page': 80, 'bbox': [56.025001525878906, 497.10498046875, 537.7920532226562, 564.032958984375]}
2025-12-18T01:46:52.771458 - Found start inside cached bbox (window) at block 10
2025-12-18T01:46:52.775339 - HYBRID MATCH FOUND at hympavzi-epar-public-assessment-report_en (2).pdf page 80 blocks -1--1
2025-12-18T01:46:52.778019 - Hybrid search failed: Start anchor not found on pages [80, 79, 81]
2025-12-18T01:46:52.778636 - CRITICAL ERROR: Start anchor not found on pages [80, 79, 81]
2025-12-18T01:51:46.162060 - --- START REPLACEMENT on Page 81 ---
2025-12-18T01:51:46.164072 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-18T01:51:46.189362 - Search Strategy: Checking pages [81, 80, 82]
2025-12-18T01:51:46.190307 - Scanning Page 81...
2025-12-18T01:51:46.216289 - Found 24 blocks on page.
2025-12-18T01:51:46.217323 - Block 0: ...
2025-12-18T01:51:46.218242 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-18T01:51:46.219427 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-18T01:51:46.220077 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-18T01:51:46.220801 - Block 4: ...
2025-12-18T01:51:46.221785 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-18T01:51:46.222553 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-18T01:51:46.223520 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-18T01:51:46.224376 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-18T01:51:46.225307 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-18T01:51:46.226208 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-18T01:51:46.227085 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-18T01:51:46.228117 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-18T01:51:46.228868 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-18T01:51:46.229727 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-18T01:51:46.230363 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-18T01:51:46.230971 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-18T01:51:46.231569 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-18T01:51:46.232252 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-18T01:51:46.232924 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-18T01:51:46.233545 - Block 20: parameters....
2025-12-18T01:51:46.234391 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-18T01:51:46.235636 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-18T01:51:46.236751 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-18T01:51:46.237709 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-18T01:51:46.238435 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-18T01:51:46.240406 - Found Start (Window Exact) at block 3
2025-12-18T01:51:46.241714 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-18T01:51:46.242709 - MATCH FOUND on Page 81: 3-3
2025-12-18T01:51:46.246653 - Replacing blocks 3 to 3
2025-12-18T01:51:46.260609 - Detected Font Size: 9.0
2025-12-18T01:51:46.287825 - Error inserting 9.0: need font file or buffer
2025-12-18T01:51:46.289422 - Error inserting 8.5: need font file or buffer
2025-12-18T01:51:46.291237 - Error inserting 8.0: need font file or buffer
2025-12-18T01:51:46.293302 - Error inserting 7.5: need font file or buffer
2025-12-18T01:51:46.295293 - Error inserting 7.0: need font file or buffer
2025-12-18T01:51:46.297252 - Error inserting 6.5: need font file or buffer
2025-12-18T01:51:46.298989 - Error inserting 6.0: need font file or buffer
2025-12-18T01:51:46.299556 - Fallback to Left Align
2025-12-18T01:51:46.302141 - CRITICAL ERROR: need font file or buffer
2025-12-18T01:52:04.081758 - --- START REPLACEMENT on Page 81 ---
2025-12-18T01:52:04.084836 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-18T01:52:04.131030 - Search Strategy: Checking pages [81, 80, 82]
2025-12-18T01:52:04.132825 - Scanning Page 81...
2025-12-18T01:52:04.159207 - Found 24 blocks on page.
2025-12-18T01:52:04.160106 - Block 0: ...
2025-12-18T01:52:04.160828 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-18T01:52:04.161660 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-18T01:52:04.162417 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-18T01:52:04.162946 - Block 4: ...
2025-12-18T01:52:04.163435 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-18T01:52:04.164021 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-18T01:52:04.164901 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-18T01:52:04.165569 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-18T01:52:04.166302 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-18T01:52:04.166845 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-18T01:52:04.167377 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-18T01:52:04.167897 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-18T01:52:04.168539 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-18T01:52:04.169054 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-18T01:52:04.170045 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-18T01:52:04.170758 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-18T01:52:04.171293 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-18T01:52:04.171941 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-18T01:52:04.172476 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-18T01:52:04.173040 - Block 20: parameters....
2025-12-18T01:52:04.173630 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-18T01:52:04.174335 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-18T01:52:04.174994 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-18T01:52:04.175731 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-18T01:52:04.176255 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-18T01:52:04.178214 - Found Start (Window Exact) at block 3
2025-12-18T01:52:04.179318 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-18T01:52:04.179873 - MATCH FOUND on Page 81: 3-3
2025-12-18T01:52:04.183405 - Replacing blocks 3 to 3
2025-12-18T01:52:04.187603 - Detected Font Size: 9.0
2025-12-18T01:52:04.198570 - Error inserting 9.0: need font file or buffer
2025-12-18T01:52:04.200685 - Error inserting 8.5: need font file or buffer
2025-12-18T01:52:04.202743 - Error inserting 8.0: need font file or buffer
2025-12-18T01:52:04.204706 - Error inserting 7.5: need font file or buffer
2025-12-18T01:52:04.206715 - Error inserting 7.0: need font file or buffer
2025-12-18T01:52:04.208613 - Error inserting 6.5: need font file or buffer
2025-12-18T01:52:04.210362 - Error inserting 6.0: need font file or buffer
2025-12-18T01:52:04.210836 - Fallback to Left Align
2025-12-18T01:52:04.212248 - CRITICAL ERROR: need font file or buffer
2025-12-18T01:55:20.261074 - --- START REPLACEMENT on Page 81 ---
2025-12-18T01:55:20.263091 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-18T01:55:20.280987 - Search Strategy: Checking pages [81, 80, 82]
2025-12-18T01:55:20.281562 - Scanning Page 81...
2025-12-18T01:55:20.306246 - Found 24 blocks on page.
2025-12-18T01:55:20.306905 - Block 0: ...
2025-12-18T01:55:20.307478 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-18T01:55:20.308074 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-18T01:55:20.308600 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-18T01:55:20.309165 - Block 4: ...
2025-12-18T01:55:20.309767 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-18T01:55:20.310367 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-18T01:55:20.310846 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-18T01:55:20.311325 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-18T01:55:20.311853 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-18T01:55:20.312374 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-18T01:55:20.312831 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-18T01:55:20.313375 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-18T01:55:20.313892 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-18T01:55:20.314341 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-18T01:55:20.314810 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-18T01:55:20.316219 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-18T01:55:20.316852 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-18T01:55:20.317427 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-18T01:55:20.317940 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-18T01:55:20.318406 - Block 20: parameters....
2025-12-18T01:55:20.318872 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-18T01:55:20.319590 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-18T01:55:20.320261 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-18T01:55:20.321083 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-18T01:55:20.321831 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-18T01:55:20.323929 - Found Start (Window Exact) at block 3
2025-12-18T01:55:20.325376 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-18T01:55:20.326215 - MATCH FOUND on Page 81: 3-3
2025-12-18T01:55:20.330076 - Replacing blocks 3 to 3
2025-12-18T01:55:20.336331 - Detected Font Size: 9.0
2025-12-18T01:55:20.336908 - Using font name: helv
2025-12-18T01:55:20.354777 - Failed size 9.0 (Justified)
2025-12-18T01:55:20.356905 - Failed size 8.5 (Justified)
2025-12-18T01:55:20.358376 - Failed size 8.0 (Justified)
2025-12-18T01:55:20.359760 - Failed size 7.5 (Justified)
2025-12-18T01:55:20.361163 - Failed size 7.0 (Justified)
2025-12-18T01:55:20.362564 - Failed size 6.5 (Justified)
2025-12-18T01:55:20.363950 - Failed size 6.0 (Justified)
2025-12-18T01:55:20.364292 - Fallback to Left Align (safe font)
2025-12-18T01:55:20.540045 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmp210tiswe.pdf
2025-12-18T01:58:39.155919 - --- START REPLACEMENT on Page 81 ---
2025-12-18T01:58:39.158439 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-18T01:58:39.195172 - Search Strategy: Checking pages [81, 80, 82]
2025-12-18T01:58:39.196426 - Scanning Page 81...
2025-12-18T01:58:39.229108 - Found 23 blocks on page.
2025-12-18T01:58:39.230002 - Block 0: ...
2025-12-18T01:58:39.231081 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-18T01:58:39.231996 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-18T01:58:39.232696 - Block 3: ...
2025-12-18T01:58:39.233333 - Block 4: 2.6.3. discussion on clinical pharmacology...
2025-12-18T01:58:39.235022 - Block 5: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-18T01:58:39.235865 - Block 6: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-18T01:58:39.236637 - Block 7: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-18T01:58:39.237252 - Block 8: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-18T01:58:39.238352 - Block 9: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-18T01:58:39.239113 - Block 10: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-18T01:58:39.239872 - Block 11: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-18T01:58:39.240559 - Block 12: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-18T01:58:39.241173 - Block 13: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-18T01:58:39.242290 - Block 14: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-18T01:58:39.242998 - Block 15: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-18T01:58:39.243751 - Block 16: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-18T01:58:39.244285 - Block 17: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-18T01:58:39.245010 - Block 18: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-18T01:58:39.245600 - Block 19: parameters....
2025-12-18T01:58:39.246198 - Block 20: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-18T01:58:39.246691 - Block 21: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-18T01:58:39.247318 - Block 22: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-18T01:58:39.247867 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-18T01:58:39.248299 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-18T01:58:39.249430 - Found Start (Window Exact) at block 2
2025-12-18T01:58:39.250002 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-18T01:58:39.250461 - MATCH FOUND on Page 81: 2-2
2025-12-18T01:58:39.254737 - Replacing blocks 2 to 2
2025-12-18T01:58:39.260025 - Detected Font Size: 9.0
2025-12-18T01:58:39.260418 - Using font name: helv
2025-12-18T01:58:39.272601 - Failed size 9.0 (Justified)
2025-12-18T01:58:39.275454 - Failed size 8.5 (Justified)
2025-12-18T01:58:39.277238 - Failed size 8.0 (Justified)
2025-12-18T01:58:39.278492 - Failed size 7.5 (Justified)
2025-12-18T01:58:39.280039 - Failed size 7.0 (Justified)
2025-12-18T01:58:39.281729 - Failed size 6.5 (Justified)
2025-12-18T01:58:39.283414 - Failed size 6.0 (Justified)
2025-12-18T01:58:39.283840 - Fallback to Left Align (safe font)
2025-12-18T01:58:39.399042 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmp4zmb10nb.pdf
2025-12-18T02:19:00.689780 - --- START REPLACEMENT on Page 81 ---
2025-12-18T02:19:00.691770 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-18T02:19:00.762505 - Search Strategy: Checking pages [81, 80, 82]
2025-12-18T02:19:00.763207 - Scanning Page 81...
2025-12-18T02:19:00.787488 - Found 24 blocks on page.
2025-12-18T02:19:00.788220 - Block 0: ...
2025-12-18T02:19:00.788882 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-18T02:19:00.789540 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-18T02:19:00.790358 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-18T02:19:00.791535 - Block 4: ...
2025-12-18T02:19:00.792396 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-18T02:19:00.793279 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-18T02:19:00.794358 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-18T02:19:00.795384 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-18T02:19:00.796127 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-18T02:19:00.797075 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-18T02:19:00.797936 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-18T02:19:00.798997 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-18T02:19:00.799823 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-18T02:19:00.800531 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-18T02:19:00.801237 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-18T02:19:00.802066 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-18T02:19:00.802825 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-18T02:19:00.803579 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-18T02:19:00.804428 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-18T02:19:00.805282 - Block 20: parameters....
2025-12-18T02:19:00.806156 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-18T02:19:00.807039 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-18T02:19:00.807922 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-18T02:19:00.808936 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-18T02:19:00.809743 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-18T02:19:00.812506 - Found Start (Window Exact) at block 3
2025-12-18T02:19:00.814442 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-18T02:19:00.815682 - MATCH FOUND on Page 81: 3-3
2025-12-18T02:19:00.821712 - Replacing blocks 3 to 3
2025-12-18T02:19:00.828821 - Detected Font Size: 9.0
2025-12-18T02:19:00.829736 - Using font name: helv
2025-12-18T02:19:00.856002 - Failed size 9.0 (Justified)
2025-12-18T02:19:00.859444 - Failed size 8.5 (Justified)
2025-12-18T02:19:00.862733 - Failed size 8.0 (Justified)
2025-12-18T02:19:00.866081 - Failed size 7.5 (Justified)
2025-12-18T02:19:00.869560 - Failed size 7.0 (Justified)
2025-12-18T02:19:00.872496 - Failed size 6.5 (Justified)
2025-12-18T02:19:00.875351 - Failed size 6.0 (Justified)
2025-12-18T02:19:00.876074 - Fallback to Left Align (safe font)
2025-12-18T02:19:01.022484 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpoy0d_dzv.pdf
2025-12-18T02:27:13.930673 - --- START REPLACEMENT on Page 81 ---
2025-12-18T02:27:13.931685 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-18T02:27:13.950651 - Search Strategy: Checking pages [81, 80, 82]
2025-12-18T02:27:13.952044 - Scanning Page 81...
2025-12-18T02:27:13.989756 - Found 24 blocks on page.
2025-12-18T02:27:13.991108 - Block 0: ...
2025-12-18T02:27:13.992582 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-18T02:27:13.993608 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-18T02:27:13.994268 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-18T02:27:13.995148 - Block 4: ...
2025-12-18T02:27:13.996128 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-18T02:27:13.996954 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-18T02:27:13.997719 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-18T02:27:13.998381 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-18T02:27:13.999008 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-18T02:27:13.999656 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-18T02:27:14.000436 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-18T02:27:14.001154 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-18T02:27:14.001929 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-18T02:27:14.003042 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-18T02:27:14.003752 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-18T02:27:14.004305 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-18T02:27:14.004995 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-18T02:27:14.005757 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-18T02:27:14.006373 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-18T02:27:14.007194 - Block 20: parameters....
2025-12-18T02:27:14.007921 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-18T02:27:14.008766 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-18T02:27:14.009448 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-18T02:27:14.010116 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-18T02:27:14.011064 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-18T02:27:14.013103 - Found Start (Window Exact) at block 3
2025-12-18T02:27:14.015279 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-18T02:27:14.016543 - MATCH FOUND on Page 81: 3-3
2025-12-18T02:27:14.024951 - Replacing blocks 3 to 3
2025-12-18T02:27:14.034229 - Detected Font Size: 9.0
2025-12-18T02:27:14.035313 - Using font name: helv
2025-12-18T02:27:14.062065 - Failed size 9.0 (Justified)
2025-12-18T02:27:14.066296 - Failed size 8.5 (Justified)
2025-12-18T02:27:14.070830 - Failed size 8.0 (Justified)
2025-12-18T02:27:14.075201 - Failed size 7.5 (Justified)
2025-12-18T02:27:14.079681 - Failed size 7.0 (Justified)
2025-12-18T02:27:14.083351 - Failed size 6.5 (Justified)
2025-12-18T02:27:14.086486 - Failed size 6.0 (Justified)
2025-12-18T02:27:14.087369 - Fallback to Left Align (safe font)
2025-12-18T02:27:14.260759 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmp6wpyshet.pdf
2025-12-18T02:34:49.253918 - --- START REPLACEMENT on Page 81 ---
2025-12-18T02:34:49.255897 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-18T02:34:49.287292 - Search Strategy: Checking pages [81, 80, 82]
2025-12-18T02:34:49.288314 - Scanning Page 81...
2025-12-18T02:34:49.318875 - Found 24 blocks on page.
2025-12-18T02:34:49.319514 - Block 0: ...
2025-12-18T02:34:49.320417 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-18T02:34:49.321010 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-18T02:34:49.321520 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-18T02:34:49.322007 - Block 4: ...
2025-12-18T02:34:49.322540 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-18T02:34:49.323079 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-18T02:34:49.323769 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-18T02:34:49.324462 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-18T02:34:49.324965 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-18T02:34:49.325410 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-18T02:34:49.325821 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-18T02:34:49.326300 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-18T02:34:49.326751 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-18T02:34:49.327233 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-18T02:34:49.327708 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-18T02:34:49.328122 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-18T02:34:49.328414 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-18T02:34:49.328756 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-18T02:34:49.329133 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-18T02:34:49.329515 - Block 20: parameters....
2025-12-18T02:34:49.329902 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-18T02:34:49.330248 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-18T02:34:49.330558 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-18T02:34:49.330959 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-18T02:34:49.331518 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-18T02:34:49.332787 - Found Start (Window Exact) at block 3
2025-12-18T02:34:49.333695 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-18T02:34:49.334396 - MATCH FOUND on Page 81: 3-3
2025-12-18T02:34:49.339798 - Replacing blocks 3 to 3
2025-12-18T02:34:49.349198 - Detected Font Size: 9.0
2025-12-18T02:34:49.350290 - Using font name: helv
2025-12-18T02:34:49.368394 - Failed size 9.0 (Justified)
2025-12-18T02:34:49.371943 - Failed size 8.5 (Justified)
2025-12-18T02:34:49.375549 - Failed size 8.0 (Justified)
2025-12-18T02:34:49.378823 - Failed size 7.5 (Justified)
2025-12-18T02:34:49.381851 - Failed size 7.0 (Justified)
2025-12-18T02:34:49.384806 - Failed size 6.5 (Justified)
2025-12-18T02:34:49.387822 - Failed size 6.0 (Justified)
2025-12-18T02:34:49.388609 - Fallback to Left Align (safe font)
2025-12-18T02:34:49.536497 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpqxmnqc3h.pdf
2025-12-19T13:14:50.129354 - --- START REPLACEMENT on Page 81 ---
2025-12-19T13:14:50.130533 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-19T13:14:50.205206 - Search Strategy: Checking pages [81, 80, 82]
2025-12-19T13:14:50.206339 - Scanning Page 81...
2025-12-19T13:14:50.255636 - Found 24 blocks on page.
2025-12-19T13:14:50.256935 - Block 0: ...
2025-12-19T13:14:50.258361 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-19T13:14:50.259586 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-19T13:14:50.260956 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-19T13:14:50.262191 - Block 4: ...
2025-12-19T13:14:50.263791 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-19T13:14:50.265095 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-19T13:14:50.266492 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-19T13:14:50.268039 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-19T13:14:50.269174 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-19T13:14:50.269930 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-19T13:14:50.270743 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-19T13:14:50.271481 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-19T13:14:50.272368 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-19T13:14:50.273244 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-19T13:14:50.274492 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-19T13:14:50.275424 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-19T13:14:50.276269 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-19T13:14:50.277051 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-19T13:14:50.277869 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-19T13:14:50.278725 - Block 20: parameters....
2025-12-19T13:14:50.279788 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-19T13:14:50.280676 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-19T13:14:50.281518 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-19T13:14:50.282506 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-19T13:14:50.283388 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-19T13:14:50.287186 - Found Start (Window Exact) at block 3
2025-12-19T13:14:50.289545 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-19T13:14:50.290893 - MATCH FOUND on Page 81: 3-3
2025-12-19T13:14:50.296539 - Replacing blocks 3 to 3
2025-12-19T13:14:50.304508 - Detected Font Size: 9.0
2025-12-19T13:14:50.305854 - Using font name: helv
2025-12-19T13:14:50.327931 - Failed size 9.0 (Justified)
2025-12-19T13:14:50.333439 - Failed size 8.5 (Justified)
2025-12-19T13:14:50.338033 - Failed size 8.0 (Justified)
2025-12-19T13:14:50.341969 - Failed size 7.5 (Justified)
2025-12-19T13:14:50.345727 - Failed size 7.0 (Justified)
2025-12-19T13:14:50.349809 - Failed size 6.5 (Justified)
2025-12-19T13:14:50.355296 - Failed size 6.0 (Justified)
2025-12-19T13:14:50.356907 - Fallback to Left Align (safe font)
2025-12-19T13:14:50.539379 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpy9gor50b.pdf
2025-12-19T13:30:58.803356 - --- START REPLACEMENT on Page 81 ---
2025-12-19T13:30:58.805260 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-19T13:30:58.899081 - Search Strategy: Checking pages [81, 80, 82]
2025-12-19T13:30:58.900173 - Scanning Page 81...
2025-12-19T13:30:58.945680 - Found 24 blocks on page.
2025-12-19T13:30:58.946803 - Block 0: ...
2025-12-19T13:30:58.947919 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-19T13:30:58.949164 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-19T13:30:58.950397 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-19T13:30:58.951516 - Block 4: ...
2025-12-19T13:30:58.952904 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-19T13:30:58.954431 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-19T13:30:58.955781 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-19T13:30:58.956938 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-19T13:30:58.958053 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-19T13:30:58.959081 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-19T13:30:58.960200 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-19T13:30:58.961398 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-19T13:30:58.962512 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-19T13:30:58.963406 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-19T13:30:58.964334 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-19T13:30:58.965242 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-19T13:30:58.966400 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-19T13:30:58.967586 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-19T13:30:58.969274 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-19T13:30:58.970747 - Block 20: parameters....
2025-12-19T13:30:58.972006 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-19T13:30:58.973137 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-19T13:30:58.974422 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-19T13:30:58.975546 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-19T13:30:58.976621 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-19T13:30:58.979568 - Found Start (Window Exact) at block 3
2025-12-19T13:30:58.981522 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-19T13:30:58.982796 - MATCH FOUND on Page 81: 3-3
2025-12-19T13:30:58.992037 - Replacing blocks 3 to 3
2025-12-19T13:30:58.999581 - Detected Font Size: 9.0
2025-12-19T13:30:59.000525 - Using font name: helv
2025-12-19T13:30:59.025900 - Failed size 9.0 (Justified)
2025-12-19T13:30:59.030811 - Failed size 8.5 (Justified)
2025-12-19T13:30:59.034531 - Failed size 8.0 (Justified)
2025-12-19T13:30:59.040314 - Failed size 7.5 (Justified)
2025-12-19T13:30:59.046305 - Failed size 7.0 (Justified)
2025-12-19T13:30:59.051224 - Failed size 6.5 (Justified)
2025-12-19T13:30:59.075156 - Failed size 6.0 (Justified)
2025-12-19T13:30:59.076676 - Fallback to Left Align (safe font)
2025-12-19T13:30:59.278761 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpffi3xuuv.pdf
2025-12-19T13:56:44.764065 - --- START REPLACEMENT on Page 81 ---
2025-12-19T13:56:44.765428 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-19T13:56:44.784557 - Search Strategy: Checking pages [81, 80, 82]
2025-12-19T13:56:44.785577 - Scanning Page 81...
2025-12-19T13:56:44.813124 - Found 24 blocks on page.
2025-12-19T13:56:44.814299 - Block 0: ...
2025-12-19T13:56:44.815193 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-19T13:56:44.816101 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-19T13:56:44.816819 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-19T13:56:44.817798 - Block 4: ...
2025-12-19T13:56:44.818682 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-19T13:56:44.819594 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-19T13:56:44.821391 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-19T13:56:44.822285 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-19T13:56:44.823320 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-19T13:56:44.824198 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-19T13:56:44.824967 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-19T13:56:44.825864 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-19T13:56:44.826535 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-19T13:56:44.827128 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-19T13:56:44.827838 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-19T13:56:44.828449 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-19T13:56:44.829297 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-19T13:56:44.830071 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-19T13:56:44.830734 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-19T13:56:44.831410 - Block 20: parameters....
2025-12-19T13:56:44.832047 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-19T13:56:44.832738 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-19T13:56:44.833377 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-19T13:56:44.834065 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-19T13:56:44.834611 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-19T13:56:44.836519 - Found Start (Window Exact) at block 3
2025-12-19T13:56:44.839777 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-19T13:56:44.840988 - MATCH FOUND on Page 81: 3-3
2025-12-19T13:56:44.844710 - Replacing blocks 3 to 3
2025-12-19T13:56:44.852661 - Detected Font Size: 9.0
2025-12-19T13:56:44.853327 - Using font name: helv
2025-12-19T13:56:44.876617 - Failed size 9.0 (Justified)
2025-12-19T13:56:44.878998 - Failed size 8.5 (Justified)
2025-12-19T13:56:44.881192 - Failed size 8.0 (Justified)
2025-12-19T13:56:44.885232 - Failed size 7.5 (Justified)
2025-12-19T13:56:44.888226 - Failed size 7.0 (Justified)
2025-12-19T13:56:44.890520 - Failed size 6.5 (Justified)
2025-12-19T13:56:44.893257 - Failed size 6.0 (Justified)
2025-12-19T13:56:44.893969 - Fallback to Left Align (safe font)
2025-12-19T13:56:45.043341 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpxp6rotae.pdf
2025-12-19T14:07:17.563138 - --- START REPLACEMENT on Page 81 ---
2025-12-19T14:07:17.567818 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-19T14:07:17.696898 - Search Strategy: Checking pages [81, 80, 82]
2025-12-19T14:07:17.697799 - Scanning Page 81...
2025-12-19T14:07:17.722847 - Found 24 blocks on page.
2025-12-19T14:07:17.724068 - Block 0: ...
2025-12-19T14:07:17.725079 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-19T14:07:17.726379 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-19T14:07:17.728187 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-19T14:07:17.729672 - Block 4: ...
2025-12-19T14:07:17.731133 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-19T14:07:17.732309 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-19T14:07:17.733455 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-19T14:07:17.734536 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-19T14:07:17.735845 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-19T14:07:17.737061 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-19T14:07:17.738457 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-19T14:07:17.740059 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-19T14:07:17.741634 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-19T14:07:17.743011 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-19T14:07:17.744986 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-19T14:07:17.746223 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-19T14:07:17.747698 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-19T14:07:17.749030 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-19T14:07:17.750200 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-19T14:07:17.751205 - Block 20: parameters....
2025-12-19T14:07:17.752163 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-19T14:07:17.753507 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-19T14:07:17.754519 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-19T14:07:17.755716 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-19T14:07:17.756875 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-19T14:07:17.759464 - Found Start (Window Exact) at block 3
2025-12-19T14:07:17.761832 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-19T14:07:17.763470 - MATCH FOUND on Page 81: 3-3
2025-12-19T14:07:17.770059 - Replacing blocks 3 to 3
2025-12-19T14:07:17.777876 - Detected Font Size: 9.0
2025-12-19T14:07:17.779299 - Using font name: helv
2025-12-19T14:07:17.803218 - Failed size 9.0 (Justified)
2025-12-19T14:07:17.808236 - Failed size 8.5 (Justified)
2025-12-19T14:07:17.812586 - Failed size 8.0 (Justified)
2025-12-19T14:07:17.817270 - Failed size 7.5 (Justified)
2025-12-19T14:07:17.821854 - Failed size 7.0 (Justified)
2025-12-19T14:07:17.825879 - Failed size 6.5 (Justified)
2025-12-19T14:07:17.831688 - Failed size 6.0 (Justified)
2025-12-19T14:07:17.833713 - Fallback to Left Align (safe font)
2025-12-19T14:07:18.000335 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmpi6xizob7.pdf
2025-12-19T15:48:08.508737 - --- START REPLACEMENT on Page 81 ---
2025-12-19T15:48:08.510259 - Input Start Anchor (50 chars): 2.6.3. Discussion on clinical pharmacology 
The su...
2025-12-19T15:48:08.519564 - Search Strategy: Checking pages [81, 80, 82]
2025-12-19T15:48:08.521193 - Scanning Page 81...
2025-12-19T15:48:08.538570 - Found 24 blocks on page.
2025-12-19T15:48:08.539334 - Block 0: ...
2025-12-19T15:48:08.539860 - Block 1: assessment report ema/464842/2024 page 81/195...
2025-12-19T15:48:08.540352 - Block 2: figure 20: boxplot of tissue factor pathway inhibitor over time (150 mg) by ada status by age...
2025-12-19T15:48:08.540816 - Block 3: for study b7841005 – marstacimab dataset...
2025-12-19T15:48:08.541249 - Block 4: ...
2025-12-19T15:48:08.541717 - Block 5: 2.6.3. discussion on clinical pharmacology...
2025-12-19T15:48:08.542219 - Block 6: the submitted dossier includes pk/pd data from six clinical trials....
2025-12-19T15:48:08.542681 - Block 7: healthy male adults were recruited for the phase 1 first-in-human single ascending dose study b78410...
2025-12-19T15:48:08.543139 - Block 8: for the phase 1 bioequivalence study b7841009. study b7841001 investigated the pk/pd of marstacimab ...
2025-12-19T15:48:08.543671 - Block 9: different dose levels (30 to 440 mg) in 6 cohorts with either sc or iv administration (cohort 1: 30 ...
2025-12-19T15:48:08.544315 - Block 10: cohort 2: 100 mg sc, n=6; cohort 3: 300 mg sc, n=6; cohort 4: 150 mg iv, n=6; cohort 5: 440 mg iv, n...
2025-12-19T15:48:08.544784 - Block 11: cohort 6: 300 mg sc, 4 japanese participants). a total of 9 healthy individuals received placebo. st...
2025-12-19T15:48:08.545321 - Block 12: b7841009 was a phase 1, open-label, randomised, single dose, 4-period, 2-sequence, full replicate cr...
2025-12-19T15:48:08.545747 - Block 13: study in healthy adult male participants and compared the pk of a pre-filled syringe (used for the p...
2025-12-19T15:48:08.546175 - Block 14: with a pre-filled pen. both presentations are intended for marketing. only pk data were collected du...
2025-12-19T15:48:08.546667 - Block 15: bioequivalence study. while 38 participants (19 participants per sequence) were planned to be enroll...
2025-12-19T15:48:08.547066 - Block 16: approximately 34 evaluable participants, only 22 participants were actually enrolled due to the occu...
2025-12-19T15:48:08.547459 - Block 17: an event of deep vein thrombosis and pulmonary embolism leading to termination of the study. a total...
2025-12-19T15:48:08.547831 - Block 18: participants completed at least 1 period and contributed data for the calculation of pk parameters f...
2025-12-19T15:48:08.548273 - Block 19: pfp. a total of 11 participants completed all 4 periods and contributed data for the statistical ana...
2025-12-19T15:48:08.548715 - Block 20: parameters....
2025-12-19T15:48:08.549175 - Block 21: the phase 1b/2 study b7841002 was a first-in-patients safety, efficacy and pharmacology study and re...
2025-12-19T15:48:08.549615 - Block 22: patients with haemophilia a or b, with or without inhibitors. the study consisted of 4 dose cohorts ...
2025-12-19T15:48:08.550006 - Block 23: non-inhibitors, 300 mg sc qw, n=7; cohort 2: non-inhibitors, 150 mg sc qw with a 300 mg loading dose...
2025-12-19T15:48:08.550428 - Sanitized Start: 2.6.3. discussion on clinical pharmacology the su...
2025-12-19T15:48:08.550814 - Sanitized End: cipants completed all 4 periods and contributed da...
2025-12-19T15:48:08.553510 - Found Start (Window Exact) at block 3
2025-12-19T15:48:08.555373 - End anchor not found with simple scan. Trying fuzzy suffix match.
2025-12-19T15:48:08.556415 - MATCH FOUND on Page 81: 3-3
2025-12-19T15:48:08.558904 - Replacing blocks 3 to 3
2025-12-19T15:48:08.564748 - Detected Font Size: 9.0
2025-12-19T15:48:08.565263 - Using font name: helv
2025-12-19T15:48:08.584284 - Failed size 9.0 (Justified)
2025-12-19T15:48:08.586304 - Failed size 8.5 (Justified)
2025-12-19T15:48:08.588280 - Failed size 8.0 (Justified)
2025-12-19T15:48:08.590498 - Failed size 7.5 (Justified)
2025-12-19T15:48:08.592699 - Failed size 7.0 (Justified)
2025-12-19T15:48:08.595082 - Failed size 6.5 (Justified)
2025-12-19T15:48:08.597348 - Failed size 6.0 (Justified)
2025-12-19T15:48:08.598179 - Fallback to Left Align (safe font)
2025-12-19T15:48:08.673660 - Saved new PDF to C:\Intelli CMC Nexus_ Final V1\CMC_Review_P3_v_backup_last\CMC_Review_P3_v_backup\backend\tmptz3ytyo7.pdf
